<SEC-DOCUMENT>0001047469-17-004772.txt : 20170726
<SEC-HEADER>0001047469-17-004772.hdr.sgml : 20170726
<ACCEPTANCE-DATETIME>20170726122404
ACCESSION NUMBER:		0001047469-17-004772
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20170726
DATE AS OF CHANGE:		20170726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MADRIGAL PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001157601
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219304
		FILM NUMBER:		17982111

	BUSINESS ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428
		BUSINESS PHONE:		404-380-9263

	MAIL ADDRESS:	
		STREET 1:		200 BARR HARBOR DRIVE, SUITE 400
		CITY:			WEST CONSHOHOCKEN
		STATE:			PA
		ZIP:			19428

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SYNTA PHARMACEUTICALS CORP
		DATE OF NAME CHANGE:	20010815
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>a2232779z424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg40801_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-219304</B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>328,300 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g467069.jpg" ALT="LOGO" WIDTH="337" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>MADRIGAL PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the disposition of up to 328,300 shares of Madrigal Pharmaceuticals,&nbsp;Inc., or Madrigal, common stock by the
selling stockholders listed in this prospectus or their permitted transferees. The shares of common stock being offered by the selling stockholders were originally issued in a private placement to
selling stockholders completed on June&nbsp;23, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the shares offered hereby are being sold by the selling stockholders named in this prospectus, or their permitted transferees, and Madrigal will not receive any proceeds from
sales of these securities. Madrigal will bear the costs and fees of the registration of the shares, and the selling stockholders will bear all commissions and discounts, if any, attributable to the
sales of the shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prices at which the selling stockholders or their permitted transferees may dispose of their Madrigal shares will be determined by the selling stockholders at the time of sale and
may be at the prevailing market price for the shares, at prices related to such market price, at varying prices determined at the time of sale, or at negotiated prices. Information regarding the
selling stockholders and the times and manner in which they may offer and sell the shares or interests therein under this prospectus is provided under "Selling Stockholders" and "Plan of Distribution"
in this prospectus. The selling stockholders may resell the common stock to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or
commissions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should carefully read this prospectus and any prospectus supplement, as well as the documents incorporated by reference or deemed to be incorporated by reference into this prospectus
and any prospectus supplement, before you invest in our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the NASDAQ Global Market and traded under the symbol "MDGL." On July&nbsp;13, 2017, the last reported sale price for our common stock on the NASDAQ Global
Market was $15.35 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>INVESTING IN OUR SECURITIES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER THE SECTION&nbsp;OF THIS PROSPECTUS ENTITLED "RISK
FACTORS" BEGINNING ON PAGE&nbsp;25 OF THIS PROSPECTUS BEFORE YOU INVEST IN OUR SECURITIES.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>The
date of this prospectus is July&nbsp;25, 2017. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=254896,FOLIO='blank',FILE='DISK112:[17ZCE1.17ZCE40801]BC40801A.;19',USER='CHE108932',CD='25-JUL-2017;20:56' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A
NAME="BG40801A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg40801_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG40801_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca40801_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca40801_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca40801_special_note_regarding_forward-looking_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca40801_special_note_regarding_forward-looking_information"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#cb40801_prospectus_summary"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY.&nbsp;</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#cb40801_prospectus_summary"><FONT SIZE=2><BR>
3</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40801_risk_factors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40801_risk_factors"><FONT SIZE=2><BR>
25</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de40801_use_of_proceeds"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de40801_use_of_proceeds"><FONT SIZE=2><BR>
49</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de40801_selling_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING STOCKHOLDERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de40801_selling_stockholders"><FONT SIZE=2><BR>
50</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de40801_plan_of_distribution"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de40801_plan_of_distribution"><FONT SIZE=2><BR>
51</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#de40801_description_of_capital_stock"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#de40801_description_of_capital_stock"><FONT SIZE=2><BR>
53</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg40801_legal_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg40801_legal_matters"><FONT SIZE=2><BR>
57</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg40801_experts"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg40801_experts"><FONT SIZE=2><BR>
57</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg40801_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg40801_incorporation_of_certain_documents_by_reference"><FONT SIZE=2><BR>
58</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dg40801_where_you_can_find_more_information"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dg40801_where_you_can_find_more_information"><FONT SIZE=2><BR>
59</FONT></A></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=1008731,FOLIO='blank',FILE='DISK112:[17ZCE1.17ZCE40801]BG40801A.;4',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ca40801_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca40801_about_this_prospectus"> </A>
<A NAME="toc_ca40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a "shelf"
registration process. Under this shelf registration process, selling stockholders may from time to time sell the shares of common stock described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
references to "Madrigal," "Company," "we," "our" or "us" refer solely to Madrigal Pharmaceuticals,&nbsp;Inc. References to "selling stockholders" refer to those stockholders listed
under the "Selling Stockholders" section of this prospectus, who may sell shares from time to time as described in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may add, update or change any of the information contained in this prospectus or in any accompanying prospectus supplement we may authorize to be delivered to you. To the extent there
is a conflict between the information contained in this prospectus and any accompanying prospectus supplement, you should rely on the information in the prospectus supplement. This prospectus,
together with any accompanying prospectus supplement, includes all material information relating to this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
dealer, salesperson or other person has been authorized to give any information or to make any representations other than those contained or incorporated by reference in this
prospectus or any accompanying prospectus supplement in connection with the offer made by this prospectus or any accompanying prospectus supplement. You must not rely upon any information or
representation not contained or incorporated by reference in this prospectus or any accompanying prospectus supplement as if we had authorized it. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus and any accompanying prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities
to which they relate, nor does this prospectus and any accompanying prospectus supplement constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any
person to whom it is unlawful to make such offer or solicitation in such jurisdiction. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should not assume that the information contained in this prospectus and any accompanying prospectus supplement is correct on any date after their respective dates, even though this
prospectus or any prospectus supplement may be delivered or securities may be sold on a later date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing
in our securities involves a high degree of risk. You should carefully consider the section entitled "Risk Factors" in this prospectus and any accompanying prospectus
supplement before you invest in our securities. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should also carefully read the additional information described in the sections entitled "Incorporation of Certain Documents by Reference" and "Where You Can Find More Information"
before you invest in our securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=266699,FOLIO='1',FILE='DISK112:[17ZCE1.17ZCE40801]CA40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ca40801_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca40801_special_note_regarding_forward-looking_information"> </A>
<A NAME="toc_ca40801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, any accompanying prospectus supplement, and the documents we incorporate by reference in this prospectus and any accompanying
prospectus supplement contain forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. These forward-looking
statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are
forward-looking statements. We have attempted to identify forward-looking statements by using words such as "may," "believe," "will," "could," "project," "anticipate," "expect," "estimate," "should,"
"continue," "potential," "plan," "forecasts," "goal," "seek," "intend," other forms of these words or similar words or expressions or the negative thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
particular, this prospectus, any accompanying prospectus supplement, and the documents we incorporate by reference in this prospectus and any accompanying prospectus supplement,
contain forward-looking statements relating to, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Anticipated or estimated future results, including the risks and uncertainties associated with our future operating performance and financial
position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Market demand for and acceptance of our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Research, development and commercialization of new products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Obtaining and maintaining regulatory approvals, including, but not limited to, potential regulatory delays or rejections; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Risks associated with meeting the objectives of clinical studies, including, but not limited to, delays or failures in enrollment, and the
occurrence of adverse safety events; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Risks related to our ability to accomplish our business development objectives and realize the anticipated benefit of any such transactions;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Assumptions underlying any of the foregoing. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have based our forward-looking statements on our expectations and projections about trends affecting our business and industry and other future events. Although we do not make
forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties
that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking
statement. Some of the risks and uncertainties that may cause actual results to differ from those expressed or implied in the forward-looking statements are described in the section entitled "Risk
Factors" in this prospectus and in any accompanying prospectus supplement, as well as in our other filings with the SEC. In addition, actual results may differ as a result of additional risks and
uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, investors are cautioned not to place undue reliance on any
forward-looking statements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus in its entirety, together with any accompanying prospectus supplement, the documents that we file as exhibits to the registration statement of which this
prospectus is a part, and the documents that we incorporate by reference into this prospectus and any accompanying prospectus supplement, with the understanding that our future results may be
materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update
any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of
The NASDAQ Stock Market,&nbsp;LLC. If we do update or correct any forward-looking statements, investors should not conclude that we will make additional updates or corrections. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
qualify all of our forward-looking statements by these cautionary statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=180370,FOLIO='2',FILE='DISK112:[17ZCE1.17ZCE40801]CA40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cb40801_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cb40801_prospectus_summary"> </A>
<A NAME="toc_cb40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following is a summary of what we believe to be the most important aspects of our business and the offering of our
common stock under this prospectus. Please read the additional information in the sections entitled "Incorporation of Certain Documents by Reference" and "Where You Can Find More
Information."</I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>References to Madrigal, the Company, we, our and us refer to Madrigal Pharmaceuticals,&nbsp;Inc. "Madrigal" is a registered trademark of Madrigal
Pharmaceuticals,&nbsp;Inc. in the U.S. and/or other countries. Other trademarks or service marks appearing in this report may be trademarks or service marks of other owners.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Overview  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the
treatment of cardiovascular, metabolic and liver diseases. Our lead product candidate, MGL-3196, is a proprietary, liver-directed, selective thyroid hormone receptor-&szlig;, or
THR-&szlig;, agonist that can potentially be used to treat a number of disease states with high unmet medical need. THR-&szlig; is known to regulate cholesterol and triglyceride
metabolism, which we believe suggests potential therapeutic benefits for patients suffering from hypercholesterolemia, genetic dyslipidemias and diseases resulting from accumulation of fat in liver
tissue, such as non-alcoholic steatohepatitis, or NASH. Based on scientific publications in human and animal studies, we believe that human NASH livers have a deficiency in THR-&szlig; activity
that leads to features of NASH including fatty liver, inflammation and fibrosis, and that treatment with MGL-3196 may potentially replace this hormone deficiency and be an effective NASH treatment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 is a first-in-class, highly selective, liver-directed THR-&szlig; agonist. We are developing MGL-3196 for NASH and we have initiated a Phase&nbsp;2
clinical trial in this indication. We are also developing MGL-3196 for dyslipidemia, particularly genetic dyslipidemias such as familial hypercholesterolemia, or FH, including both homozygous and
heterozygous forms of the disease. We have initiated a Phase&nbsp;2 clinical trial in heterozygous FH, or HeFH, patients and we are planning to conduct a proof-of-concept clinical trial in
homozygous FH, or HoFH, patients. MGL-3196 is a once-daily oral pill that has been studied in four completed Phase&nbsp;1 trials in a total of 129 subjects. MGL-3196 appeared to be safe and
well-tolerated in these trials, which included a single ascending dose trial, a multiple ascending dose trial, and two drug interaction trials with statins. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the multiple ascending dose Phase&nbsp;1 clinical trial in healthy volunteers with mildly elevated low-density lipoprotein cholesterol, or LDL-C, the administration of MGL-3196 in
once daily doses of up to 200 mg per day for 14&nbsp;days demonstrated statistically significant reductions of LDL-C, apolipoprotein B, or apoB, and non-high density lipoprotein cholesterol, or
non-HDL-C, of up to 30%, and a reduction of triglycerides, or TG, of up to 60%. Increased levels of LDL-C, commonly known as "bad cholesterol", apoB and non-HDL-C are each strongly associated with
increased risk of heart disease. The lipid parameter reductions observed with MGL-3196 treatment occurred rapidly in the trial, becoming apparent within the first few days of dosing. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=5,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=894253,FOLIO='3',FILE='DISK112:[17ZCE1.17ZCE40801]CB40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cb40801_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following chart summarizes the status of our product candidate development programs for MGL-3196 and MGL-3745, a preclinical compound which has similar thyroid receptor selectivity
to MGL-3196 and is thus a potential backup compound for MGL-3196: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g81786.jpg" ALT="GRAPHIC" WIDTH="649" HEIGHT="258">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
July&nbsp;22, 2016, we completed the merger with Synta Pharmaceuticals Corp., or the Merger, which provided $42.6&nbsp;million in cash, cash equivalents and marketable securities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lead Product Candidate&#151;MGL-3196  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Active thyroid hormone, known as T3, interacts with two nuclear receptors, thyroid hormone receptor-alpha
(THR-<FONT FACE="SYMBOL">a</FONT>), which is the predominant receptor expressed in most human tissues, including heart and bone, and thyroid hormone receptor-beta (THR-&szlig;), which
has more restricted tissue expression, and is the predominant receptor responsible for metabolic actions in the liver, including both cholesterol- and TG-lowering. Selective activation of the
THR-&szlig; receptor in liver tissue is believed to favorably affect cholesterol and lipoprotein levels&nbsp;via multiple mechanisms, which may be complementary to those of other
lipid-lowering therapies such as statin drugs. We believe that these characteristics of THR-&szlig; activation by MGL-3196 will in turn lead to clinically meaningful reductions in LDL-C, plasma
and liver TGs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 is the first selective small molecule THR- &szlig; agonist compound. MGL-3196, along with other THR-&szlig;-selective small molecules, such as
MGL-3745, a potential backup compound to MGL-3196, was discovered at Hoffmann-La Roche, or Roche, in Nutley, New Jersey, by utilizing a novel functional assay that, unlike a simple receptor binding
assay, assessed the functional activity of compounds which interacted with thyroid hormone receptors. In a published study by us and Roche in the Journal of Medicinal Chemistry using this functional
assay, MGL-3196 was shown to be highly selective for the THR-&szlig; receptor, with almost no effect on THR-<FONT FACE="SYMBOL">a</FONT>, unlike other compounds purported in published
studies to be &szlig;-selective based on binding affinity, but which were shown to equally activate THR-<FONT FACE="SYMBOL">a</FONT> and THR-&szlig; in the novel functional
assay. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the &szlig;-selectivity and liver-targeting properties of MGL-3196 are critically important for MGL-3196's beneficial metabolic actions in the liver, and enable
avoidance of safety issues associated with THR-<FONT FACE="SYMBOL">a</FONT> activation by thyroid hormone and/or less selective THR agonists in tissues such as heart and bone. In a variety
of preclinical animal model studies, MGL-3196 showed enhanced safety relative to T3 or other thyroid agonists. In animal models, MGL-3196 demonstrated cholesterol lowering, liver triglyceride
lowering, and reduction of markers of NASH-related liver inflammation and fibrosis at drug levels similar to those that lowered LDL-C in human clinical trials, providing data to support the
advancement of MGL-3196 into NASH and FH clinical trials. In chronic </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=6,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=3488,FOLIO='4',FILE='DISK112:[17ZCE1.17ZCE40801]CB40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cb40801_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>animal
toxicology studies in dogs and rats, no effects on bone or cartilage histology were seen at any MGL-3196 dose in either species. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that MGL-3196 may be the first product candidate in development for NASH or FH that selectively targets the THR-&szlig; pathway and has shown a lack of liver enzyme
elevations in Phase&nbsp;1 clinical studies as well as an absence of bone and cartilage histologic findings in chronic animal toxicology studies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 Clinical and Non-Clinical Development Program  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have completed a series of Phase&nbsp;1 clinical studies, Phase&nbsp;2-enabling preclinical GLP toxicology studies, and drug
manufacturing studies to support further clinical development, including API manufacturing and drug product development studies, drug metabolism studies, acute, subchronic and chronic animal
toxicology studies, and other safety pharmacology and toxicology studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed Phase&nbsp;1 studies with MGL-3196 in a total of 129 subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effects of MGL-3196. Our
Phase&nbsp;1 studies included randomized, placebo-controlled, double-blind, single and 14-day multiple-dose escalation studies, as well as a drug-interaction study in healthy volunteers. In
Phase&nbsp;1 studies, MGL-3196 appeared safe and was well-tolerated at all doses tested. The results of these studies suggest that MGL-3196 has pharmacokinetic properties suitable for once-daily
oral dosing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the multiple ascending dose study, lipid parameters were assessed as initial markers of MGL-3196 pharmacodynamic activity (Atherosclerosis 230:373-380, 2013). As illustrated in the
figure below, daily doses of MGL-3196 ranging from 50 to 200 mg showed highly statistically significant reductions relative to placebo of up to 30% for LDL-C (range, p=.05-&#60;0.0001), 28%
for non-HDL-C (range, p =0.027-p&#60;0.0001) and 24% for apoB (range, p =0.008-0.0004), and statistical trends of up to 60% reduction in TG (range, p =0.13-0.016). The near maximal lipid
effects were observed at a MGL-3196 dose of 80 mg once-daily. MGL-3196 was well-tolerated at all doses,
with no dose-related adverse events or liver enzyme, electrocardiography or vital-sign changes. At the highest dose of MGL-3196 (200 mg), there was a reversible reduction of 20% in the level of a
precursor hormone to T3, free T4, which was significantly different from placebo (p &#60; 0.0001) that may be explained by increased liver metabolism of free T4. There was no change in
thyrotropin, a pituitary hormone that regulates the level and production of thyroid hormone by the thyroid gland or T3, or other evidence of central thyroid axis dysfunction at any dose of MGL-3196. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=7,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=39069,FOLIO='5',FILE='DISK112:[17ZCE1.17ZCE40801]CB40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cb40801_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cb40801_change_in_lipids_after_14_days"> </A>
<A NAME="toc_cb40801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Change in Lipids After 14 Days    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g809717.jpg" ALT="GRAPHIC" WIDTH="597" HEIGHT="310">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=2>Change
from Baseline (CFB) by mean % CFB calculated for each individual subject 24h after 14th&nbsp;dose; baseline value obtained just prior to first dose; ApoB, apolipoprotein B; Chol, total
cholesterol; LDL-C, LDL cholesterol directly measured; Non-HDL-C, non-HDL cholesterol; TG, triglycerides (median % CFB). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we are encouraged by these results, they are based on a small number of patients in early-stage clinical trials and are not necessarily predictive of results in later-stage
clinical trials with larger and more diverse patient populations. In addition, the FDA typically requires sponsors of lipid-lowering product candidates to conduct drug-drug interaction studies with
statins because statins may have increased safety risks when administered together with other drug therapies that affect their pharmacokinetic profile. We have completed two clinical drug interaction
studies of MGL-3196 and 3&nbsp;commonly used statins in 39 normal healthy volunteers, which showed MGL-3196 to have a favorable safety profile and to be well-tolerated. We have initiated a
Phase&nbsp;2 clinical study in NASH including patients taking low dose statins. We have also initiated a Phase&nbsp;2 clinical study in HeFH including patients taking high dose statins. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to become a leading biopharmaceutical company developing and commercializing innovative liver-directed, &szlig;-selective
thyroid hormone receptor agonists for the treatment of cardio-metabolic and liver disease, fibrosis and inflammation. A key element is building a multi-therapy NASH focused company. To achieve our
goal, we plan to: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Complete clinical development and seek regulatory approval of MGL-3196 in
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We plan to report data for the primary endpoint from our Phase&nbsp;2 study in NASH by the end of 2017. NASH is a disease driven by the
growing epidemic of obesity, with a significant unmet need for approved therapies that are effective and well tolerated. We believe MGL-3196 is an excellent candidate for the chronic treatment of NASH
due to its safety profile and first-in-class dual mechanism of action targeting fibrosis-generating cells. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=8,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=715975,FOLIO='6',FILE='DISK112:[17ZCE1.17ZCE40801]CB40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cc40801_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Establish commercial capabilities to market MGL-3196 as a leading treatment for
NASH.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;If approved, we may choose either to establish a sales and marketing organization with technical expertise and supporting distribution
capabilities to commercialize MGL-3196, or to collaborate with one or more third parties to accomplish these tasks. Patients with NASH are primarily managed by a concentrated group of liver
specialists in the United States and Europe. We believe this will enable us to launch MGL-3196 in NASH in a cost-effective, targeted manner.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I> Grow our pipeline through additional indications for MGL-3196 including orphan
indications.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe that MGL-3196 has the potential to be an effective treatment for other disease indications that are rare diseases or may
be designated rare diseases, including HoFH and severe HeFH, and we plan to pursue orphan drug designation where possible. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Target Indications  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview and Market Opportunity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASH is a serious inflammatory form of nonalcoholic fatty liver disease, or NAFLD. NAFLD has become the most common liver disease in the United
States and other developed countries and is characterized by an accumulation of fat in the liver with no other apparent causes. The rising worldwide prevalence of obesity-related disorders has
contributed to a rapid increase in the global prevalence of NASH and NAFLD. In the United States, NAFLD is estimated to affect approximately 27% to 34% of the population, or an estimated
86&nbsp;million to 108&nbsp;million people, and approximately 10% to 20% of those will progress from NAFLD to NASH. Current estimates place
NASH prevalence at approximately 9&nbsp;million to 15&nbsp;million people in the United States, or 3% to 5% of the population, with similar prevalence in Europe and Asia. The prevalence of NASH is
also increasing in developing regions due to the adoption of a more sedentary lifestyle and a diet consisting of processed foods with high fat and fructose content. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the accumulation of fat in the liver, NASH is characterized by inflammation and cellular damage with or without fibrosis, the first stage of liver scarring, which may
ultimately progress to cirrhosis. NASH is a severe condition that can lead to fibrosis and eventually progress to cirrhosis, portal hypertension, esophageal varices, ascites, liver cancer and liver
failure. NASH is strongly associated with cardiovascular disease, or CVD, and the most common cause of death in NASH patients is CVD. Progression to cirrhosis and other late-stage complications can
occur within 5 to 10&nbsp;years after an initial NASH diagnosis. NASH patients with type-2 diabetes have a heightened risk of NASH disease progression. Once the disease advances beyond NASH to such
life-threatening conditions as liver cancer and failure, then liver transplantation is the only treatment alternative. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Centers for Disease Control and Prevention projects the prevalence of obesity to increase from 34% of the United States population to 42% of the United States population by 2030.
Driven by this epidemic of obesity, NASH is projected to become the leading cause of liver transplants by 2020. Given the extremely limited availability of organ donors and high transplant costs, NASH
patients who require transplantation will place a significant economic burden on the healthcare system. As such, there is a significant unmet medical need for well-tolerated oral treatments for NASH.
Because there are currently no therapeutic products approved for the treatment of NASH, the market size is difficult to estimate. However, based on our analysis of multiple market assessments, we
estimate that the addressable NASH population is several million patients worldwide, and that NASH could become a multi-billion dollar market able to support multiple approved drug products. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=32443,FOLIO='7',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cc40801_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 in NASH  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing MGL-3196 for NASH. Based on the scientific literature in human and animal studies, we believe that NASH livers in humans
frequently have a deficiency in THR-&szlig; activity that leads to features of NASH, including fatty liver, inflammation and fibrosis, and that treatment with MGL-3196 will replace this hormone
deficiency and be an effective NASH treatment. We believe that MGL-3196 is an excellent candidate for the chronic treatment of NASH because of its safety and tolerability profile observed to date in
healthy subjects, its effects in reducing cardiovascular risk factors such as LDL-C and TGs in early-stage clinical trials, and its multiple beneficial effects in animal models of NASH. CVD is the
most common cause of death in patients with NASH. We have completed multiple studies in animal models of metabolic diseases, dyslipidemia and NASH in which MGL-3196 demonstrated a statistically
significant reduction in liver TGs, insulin resistance, liver enzymes (which may be elevated in NASH), and markers of inflammation and fibrosis (Figures). The figures below show the beneficial effects
of MGL-3196 to reduce these parameters in NASH animal models. We believe that MGL-3196 will treat the underlying lipotoxicity that drives the inflammation and liver cell damage observed in NASH
patients, and after the underlying lipotoxicity is treated, NASH-related liver fibrosis will resolve as the liver regenerates. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196: Preclinical NASH Animal Model Study  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc40801_upper_panels__24d_study_in_17___upp04720"> </A>
<A NAME="toc_cc40801_1"> </A></FONT> <FONT SIZE=2><B>  Upper panels: 24d study in 17 wk old DIO mice (po, qd) on high fat diet (HFD) 13 wks;<BR>  lower panels: 24d study in 40 wk old DIO mice on HFD 35 wks    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g823383.jpg" ALT="GRAPHIC" WIDTH="642" HEIGHT="337">
  </B></FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=273394,FOLIO='8',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cc40801_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 Preclinical NASH Animal Model Gene Expression Study  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cc40801_25_week_study_in_dio,_lean_con__25_03625"> </A>
<A NAME="toc_cc40801_2"> </A></FONT> <FONT SIZE=2><B>  25&nbsp;week study in DIO, lean control mice and HFD mice treated with 0.1 to 3 mg/kg<BR>  MGL-3196 or Rosiglitazone (3mg/kg)    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g777688.jpg" ALT="GRAPHIC" WIDTH="547" HEIGHT="301">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=2>"HFD",
lane 1 means HFD gene expression normalized to mean Lean; Lanes (2-7) mean gene expression normalized to mean of DIO; "Rosi" (rosiglitazone, 3 mg/kg, 24&nbsp;weeks) TIMP1 tissue inhibitor
metalloproteinase; CTGF connective tissue growth factor; SMA smooth muscle actin; SAA serum amyloid A; CRP C-reactive protein; Red, higher expression; blue decreased expression. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 NASH Phase&nbsp;2 Clinical Plan  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In October 2016, we initiated a Phase&nbsp;2 proof of concept clinical trial in approximately 117&nbsp;patients with liver biopsy documented
NASH, including those with type-2 diabetes, dyslipidemia and hypertension. In the study we are randomizing NASH patients 2:1, MGL-3196 or placebo QD in a double-blind, placebo-controlled, study of
once-daily MGL-3196 versus placebo in patients with NASH, including those with type-2 diabetes. Patients are to continue treatment through 36&nbsp;weeks. The study is being conducted in the United
States. The primary endpoint is to evaluate the efficacy of MGL-3196 as measured by the reduction of liver fat at 12&nbsp;weeks, and the secondary endpoint will be to evaluate the efficacy of
MGL-3196 as measured by a reduction of NASH, which will be assessed by liver biopsy, at 36&nbsp;weeks. Other secondary and exploratory endpoints include safety and tolerability, and effects on serum
biomarkers at 12 and 36&nbsp;weeks, lipid parameters, and biomarker measures of insulin sensitivity. We expect to reach our top-line analysis of the primary endpoint by late 2017 and our top-line
analysis of the secondary endpoint (NASH assessment on liver biopsy) by spring of 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2013, the American Association for the Study of Liver Disease and the FDA conducted a joint workshop focused on trial designs and endpoints in drug and diagnostic
development for liver disease secondary to NAFLD, including NASH. In December 2014, the journal Hepatology accepted for publication a manuscript summarizing the workshop output, including potentially
acceptable surrogate endpoints for clinical studies supporting the approval of agents for NASH and liver fibrosis. We believe that our Phase&nbsp;2 NASH study design incorporates surrogate endpoints
consistent with the current FDA requirements for demonstration of efficacy in registrational trials. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=105224,FOLIO='9',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cc40801_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Familial Hypercholesterolemia  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview and Market Opportunity  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FH is a genetic disorder characterized by aggressive and early onset of CVD. In people with FH, genetic mutations make the liver incapable of
metabolizing or removing excess LDL-C, causing very high LDL-C levels in the blood. There are two forms of FH: HoFH, a less common condition where mutation is inherited from both parents, and HeFH, a
more common condition where mutation is inherited from just one parent. The vast majority of the cholesterol circulating in a person's body is produced by the liver. Cholesterol is a necessary
component in the structure and function of human cells. Individuals with FH are unable to recycle this natural supply of cholesterol that their bodies are constantly producing. Therefore, the
cholesterol levels of an individual with FH are exceedingly high. Over time, the elevated blood cholesterol can lead to blockages in the arteries of the heart and/or brain. The longer a person
experiences high LDL-C, the more likely he or she will be to experience a cardiovascular event (i.e.,&nbsp;heart attack or stroke). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HoFH
has an estimated worldwide prevalence of 1 in 160,000 to 1 in 1,000,000 and is a life-threatening condition characterized by markedly elevated levels of LDL-C. This is predominantly
due to inactivating mutations in the LDL receptor, with onset of atherosclerotic CVD in childhood to early adulthood. HeFH, more common than HoFH, has an estimated worldwide prevalence of 1 in 200 to
1 in 500 and is characterized by early onset CVD in middle age, typically caused by an inactivating mutation in one of the two LDL receptor genes. While HeFH patients have a range of disease severity,
we believe approximately 10% of the HeFH population can be characterized as having severe FH, with higher baseline LDL-C levels (&gt;309 mg/dL; 8 mmol/L) than those of a majority of the HeFH population.
Despite multiple therapeutics currently available for the treatment of HoFH, including statins, ezetimibe, and newer agents such as lomitapide, mipomersen, and anti-PCSK9 antibodies, we believe that
the treatment target goal to reduce LDL-C to recommended levels is rarely achieved. In HeFH, with the recent addition of anti-PCSK9 antibodies to the treatment regimen, we believe that LDL-C target
treatment goals (&#60;100 mg/dL; &#60; 70 mg/dL in patients with CVD or diabetes) may be achieved in &gt; 50% of the patients; however, many HeFH patients, particularly those with
severe FH or who cannot tolerate treatment with high-dose statins, are not at goal and are in need of additional lipid-lowering therapies beyond current therapeutic approaches. In addition, elevation
of lipoprotein(a), or Lp(a), a severely atherogenic lipoprotein particle, which is frequently elevated in FH patients, is not effectively lowered by current therapeutic
approaches. In 2014, an estimated $16.6&nbsp;billion was spent on drug therapy in the United States, five major European Union markets, and Japan to treat dyslipidemias, according to Datamonitor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 in FH  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are developing MGL-3196 for FH and potentially other genetic dyslipidemias. We believe that experimental results from various sources,
including Madrigal, academic groups and other pharmaceutical companies, support targeting the THR-&szlig; pathway as a potential novel approach to lipid-lowering in FH. We believe that MGL-3196
has a unique and complementary lipid-lowering profile that will bring an added benefit to the standard of care treatment of FH patients, particularly those with severe HeFH (~10% of FH patients with
high baseline LDL-C, typically &gt;309 mg/dL) and those with HoFH who do not achieve LDL-C target levels with current therapies. Specifically, in preclinical animal studies MGL-3196 lowered LDL-C in a
variety of species as a monotherapy and also when dosed in combination with statins. MGL-3196 also showed the potential to lower Lp(a), a severely atherogenic particle that is frequently elevated in
patients with FH. A previous THR agonist, eprotirome, demonstrated clinical proof of concept for the THR target in Phase&nbsp;2 and Phase&nbsp;3 FH clinical trials by significantly lowering LDL-C
and Lp(a) in patients with HeFH who were on standard treatments such as statins and ezetimibe. The development of eprotirome ceased during the Phase&nbsp;3 FH trial due to liver toxicity observed in
the trial as well as eprotirome-induced cartilage damage seen </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=651770,FOLIO='10',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cc40801_1_11"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>in
chronic toxicology studies in dogs. Because of its high level of THR-&szlig; selectivity, its liver-targeting properties, and its absence of findings in chronic animal toxicology studies, we
believe that MGL-3196 will avoid the toxicity issues of previous THR agonist compounds and may be a beneficial treatment for FH patients. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MGL-3196 FH Phase&nbsp;2 Clinical Plan  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2017, we initiated a Phase&nbsp;2 clinical trial of MGL-3196 for the treatment of HeFH. In the study we are randomizing NASH
patients 2:1, MGL-3196 or placebo QD in double-blind, placebo-controlled fashion. Patients are to continue treatment through 12&nbsp;weeks. The study is being conducted in Europe. In this
12&nbsp;week clinical trial, the primary endpoint is to evaluate the efficacy of MGL-3196 as measured by the percent reduction in LDL-C as compared with placebo. Secondary endpoints include safety
and tolerability, and evaluate the efficacy of MGL-3196 to reduce a variety of lipid parameters, including non-HDL-C, apoB, TGs, Lp(a), apoA/B, and lipoprotein particles. Based on interim efficacy and
safety data obtained from this HeFH study, we plan to conduct a proof of concept open-label Phase&nbsp;2 study of 6-8 patients with HoFH at sites in the United States and Europe. We expect that
top-line results of the HeFH clinical trial will be available in late 2017 and top-line results of the HoFH trial will be available in 2018. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Collaborations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;VIA Pharmaceuticals,&nbsp;Inc., or VIA, entered into a research, development and commercialization agreement, or the Roche Agreement, with
Hoffmann-La Roche Pharmaceutical Company Limited, or Roche, on December&nbsp;18, 2008. We subsequently assumed all of VIA's rights in, to and under, and all of VIA's obligations under, the Roche
Agreement pursuant to an asset purchase agreement dated September&nbsp;14, 2011. Pursuant to the terms of the Roche Agreement, we, as successor-in-interest to VIA, assumed control of all development
and commercialization of MGL-3196 and will own exclusive worldwide rights for all potential indications. Roche assigned all patent rights relating to MGL-3196 to us and granted us an exclusive license
to use certain know-how relating to MGL-3196 in exchange for consideration consisting of an upfront payment, milestone payments, the remainder of which total $10&nbsp;million and are tied to future
commencement of Phase&nbsp;2 and Phase&nbsp;3 clinical trials and regulatory approval in the United States and Europe of a product developed from MGL-3196, and single-digit royalty payments based
on net sales of products developed from MGL-3196, subject to certain reductions. In 2011, we commenced Phase&nbsp;1 clinical trials and subsequently paid Roche a related milestone payment. In
October 2016, we commenced a Phase&nbsp;2 study in NASH and subsequently paid Roche a related milestone payment. Except as described above, we have not achieved any additional product development or
regulatory milestones under the Roche Agreement and have generated no net sales of products developed from MGL-3196. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Roche Agreement, we must use commercially reasonable efforts to conduct clinical and commercial development programs for products containing MGL-3196. If we determine
that it is not reasonable to continue clinical trials or other development of MGL-3196, we may elect to cease further development and Roche may terminate the license. If we determine not to pursue the
development or commercialization of MGL-3196 in certain jurisdictions, including the United States, Roche may terminate the license for such territories. The Roche Agreement will expire, unless
earlier terminated pursuant to other provisions of the agreement, on the last to occur of (i)&nbsp;the expiration of the last valid
claim of a licensed patent covering the manufacture, use or sale of products containing MGL-3196, or (ii)&nbsp;ten years after the first sale of a product containing MGL-3196. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The development and commercialization of new drugs is highly competitive. We will face competition with respect to all product candidates we may
develop or commercialize in the future from </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=13,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=480116,FOLIO='11',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_cc40801_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>pharmaceutical
and biotechnology companies worldwide. The key factors affecting the success of any approved product will be its efficacy, safety profile, drug interactions, method of administration,
pricing, reimbursement and level of promotional activity relative to those of competing drugs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
potential competitors may have substantially greater financial, technical, and personnel resources than us. In addition, many of these competitors have significantly greater
commercial infrastructures. Our ability to compete successfully will depend largely on our ability to leverage our collective experience in drug discovery, development and commercialization
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discover and develop medicines that are differentiated from other products in the market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain patent and/or proprietary protection for our products and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain required regulatory approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> obtain a commercial partner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commercialize our drugs, if approved; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attract and retain high-quality research, development and commercial personnel. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are currently no therapeutic products approved for the treatment of NASH. There are several commercially available products that are currently used off-label for NASH, such as
vitamin E, an antioxidant, insulin sensitizers, such as pioglitazone, anti-hyperlipidemic agents, such as gemfibrozil, pentoxifylline, ursodiol and others. In addition, there are numerous drugs in
development for the treatment of NASH. We are aware of several companies that have product candidates in clinical development for the treatment of NASH, including Intercept
Pharmaceuticals,&nbsp;Inc., Gilead Sciences,&nbsp;Inc., Galectin Therapeutics,&nbsp;Inc., Allergan&nbsp;plc / Tobira Pharmaceuticals,&nbsp;Inc., Galmed Medical Research&nbsp;Ltd., Genfit
Corp., Novartis AG, Novo Nordisk A/S, Takeda, Immuron&nbsp;Ltd., Shire&nbsp;plc, Boehringer Ingelheim&nbsp;GmbH, and Conatus Pharmaceuticals&nbsp;Inc., and there are other companies with
candidates in earlier stages of development. Given MGL-3196's actions on the underlying biological pathways across the spectrum of early to late stages of NASH, its CV beneficial effects, and its
complementary mechanism to other therapies, we believe that MGL-3196 has the potential to be used alone or in combination with some of these potential NASH products. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are several marketed products, both generic and proprietary, available for the treatment of HoFH and HeFH. We believe that MGL-3196 has the potential to be used in combination with
several of these products. Available marketed products include: various statins, Merck's ezetimibe, Aegerion's lomitapide, Ionis' mipomersen, Amgen's evolocumab and Sanofi/Regeneron's alirocumab. In
addition, there are multiple drugs in development for the treatment of FH, including Gemphire's gemcabene, Merck's anacetrapib, Esperion's ETC-1002, and drugs at an earlier stage of development. Given
MGL-3196's pleoitropic lipid-lowering actions, its complementary mechanism to statins and other
lipid-lowering drugs, and its potential for lowering Lp(a), we believe that MGL-3196 has the potential to be used in combination with the standard of care to treat patients with HoFH and HeFH. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Sales and Marketing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we are focused on discovery and development of our product candidates, we currently have no sales, marketing or distribution
capabilities in order to commercialize any approved product candidates. If our product candidates are approved, we intend either to establish a sales and marketing organization with technical
expertise and supporting distribution capabilities to commercialize our products, or to outsource this function to a third party. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to rely, on
third-party contract manufacturers, or CMOs, for the manufacture of any product candidates that we may develop for larger-scale preclinical and clinical testing, as well as for commercial quantities
of any drug candidates that are approved. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=14,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=239581,FOLIO='12',FILE='DISK112:[17ZCE1.17ZCE40801]CC40801A.;9',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ce40801_1_13"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses primarily consist of costs associated with our research activities, including the preclinical and clinical
development of our product candidates. Our research and development expenses were $15.9&nbsp;million for the year ended December&nbsp;31, 2016 compared to $2.4&nbsp;million for the same period
in 2015. The large increase in research and development expenses was primarily due to the advancement of clinical programs to Phase&nbsp;2 studies, further API manufacturing studies and the
continuation of preclinical studies. We expect research and development expenses to increase over time as we advance our clinical and preclinical development programs for MGL-3196. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will be able to protect our technology and products from unauthorized use by third parties only to the extent we are covered by valid and
enforceable patents or such knowledge is effectively maintained as trade secrets. Patents and other proprietary rights are thus an essential element of our business. We also rely on trade secrets,
know-how, continuing technological innovation and licensing opportunities to develop and maintain our competitive position. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
success will depend in part on our ability to obtain and maintain patent and other proprietary protection for our current and future product candidates, technology and know-how, to
operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We seek to protect our proprietary position by, among other methods,
filing United States and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
own or have exclusive rights to four United States and 69 foreign issued patents and allowed patent applications, and two United States and 25 foreign pending patent applications,
relating to composition-of-matter of MGL-3196 and its use in the treatment of key disease indications. Our current patent portfolio broadly covers the United States and other jurisdictions worldwide. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issued
United States patents which cover MGL-3196 will expire between 2026 and 2033, excluding any patent term extensions that might be available following the grant of marketing
authorizations. Issued patents outside of the United States directed to MGL-3196 will expire between 2026 and 2033. We have pending patent applications for MGL-3196 that, if issued, would expire in
the United States and in countries outside of the United States between 2026 and 2033, excluding any patent term adjustment
that might be available following the grant of the patent and any patent term extensions that might be available following the grant of marketing authorizations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, pursuant to the Roche Agreement, Roche granted us an exclusive license to certain patents and know-how relating to MGL-3196. The Roche Agreement imposes various diligence,
milestone payment, royalty payment, insurance, indemnification, and other obligations on us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
trademarks are protected under the common law and/or by registration in the United States and other countries. We seek to protect our proprietary processes, in part, by
confidentiality agreements and invention assignment agreements with our personnel, including consultants and commercial partners. These agreements are designed to protect our proprietary information. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some of MGL-3196's target disease indications are rare diseases or may be designated rare diseases, including HoFH and severe HeFH, and we plan
to pursue orphan drug designation where possible. If granted, each such designation might provide for regulatory exclusivity for seven years in the United States and ten years in the European Union
from the date of product approval for individual indications. </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=2741,FOLIO='13',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation and Product Approval  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import
of products such as those we are developing. A new drug must be approved by the FDA through the new drug application, or NDA, process and a new biologic must be approved by the FDA through the
biologics license application, or BLA, process before it may be legally marketed in the United States. The animal and other non-clinical data and the results of human clinical trials performed under
an Investigational New Drug application, or IND, and under similar foreign applications will become part of the NDA or BLA. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Drug Development Process  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and in the case of biologics, also under
the Public Health Service Act, or PHSA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign
statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product
development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA's refusal to approve pending
applications, withdrawal of an approval, a clinical hold, warning letters, requesting product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required
by the FDA before a drug or biologic may be marketed in the United States generally involves the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable
regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an IND which must become effective before human clinical trials may begin; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials according to Good Clinical Practices to establish the safety and efficacy of
the proposed drug for its intended use; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> submission to the FDA of an NDA or BLA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> satisfactory completion of a FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with
current good manufacturing practice, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> FDA review and approval of the NDA or BLA. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity
and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND.
The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective
30&nbsp;days after receipt by the FDA, unless </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=968861,FOLIO='14',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>the
FDA, within the 30-day time period, places the clinical trial on a clinical hold or a partial clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns
before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during studies due to safety concerns or non-compliance. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with Good Clinical Practice regulations. They must be conducted under
protocols detailing the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted
to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually. In addition, timely safety reports must be submitted to the FDA
and the investigators for serious and unexpected adverse events. An institutional review board, or IRB, at each institution participating in the clinical trial must review and approve each protocol
before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal
representative, monitor the study until completed and otherwise comply with IRB regulations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human
clinical trials are typically conducted in three sequential phases that may overlap or be combined: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Phase&nbsp;1:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;The product candidate is initially introduced into healthy
human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, such as cancer,
especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Phase&nbsp;2:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;This phase involves studies in a limited patient population
to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> Phase&nbsp;3:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage,
clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product
candidate and provide, if appropriate, an adequate basis for product labeling. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug
has been associated with unexpected serious harm to patients. Phase&nbsp;1, Phase&nbsp;2, and Phase&nbsp;3 testing may not be completed successfully within any specified period, if at all. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of
Phase&nbsp;2, and before an NDA or BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered
to date, for the FDA to provide advice, and for the sponsor and FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase&nbsp;2 meeting to discuss their
Phase&nbsp;2 clinical results and present their plans for the pivotal Phase&nbsp;3 clinical trial that they believe will support approval of the new drug. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the manufacturer must develop methods for testing the </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=69470,FOLIO='15',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>identity,
strength, quality and purity of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United States Review and Approval Processes  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical
tests conducted on the chemistry of the drug, proposed labeling, and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market the product. The
submission of an NDA or BLA is subject to the payment of user fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews all NDAs and BLAs submitted to ensure
that they are sufficiently complete for substantive review before it accepts them for filing. The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the
NDA or BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing,
the FDA begins an in-depth substantive review. The FDA may refer the NDA or BLA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and
under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The approval process is lengthy and often difficult, and the
FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. Even if such data and information is
submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data
differently than we interpret the same data. The FDA may issue a complete response letter, which may require additional clinical or other data or impose other conditions that must be met in order to
secure final approval of the NDA or BLA, or an approval letter following satisfactory completion of all aspects of the review process. The FDA reviews an NDA to determine, among other things, whether
a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product's identity, strength, quality and purity. The FDA reviews a BLA
to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product's
continued safety, purity and potency. Before approving an NDA or BLA, the FDA will inspect the facility or facilities where the product is manufactured. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NDAs
or BLAs receive either standard or priority review. A drug representing a significant improvement in treatment, prevention or diagnosis of disease may receive priority review.
Priority review for an NDA for a new molecular entity and original BLAs will be six months from the date that the NDA or BLA is filed. In addition, products studied for their safety and effectiveness
in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing
treatments may receive accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint
that is reasonably likely to predict clinical benefit or on the basis of an effect on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is
reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and
well-controlled post-marketing clinical trials. Priority review and accelerated approval do not change the standards for approval, but may expedite the approval process. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could
restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct Phase&nbsp;4 </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=18,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=662896,FOLIO='16',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>testing
which involves clinical trials designed to further assess a drug's safety and effectiveness after NDA or BLA approval, and may require testing and surveillance programs to monitor the safety
of approved products which have been commercialized. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Food and Drug Administration Safety and Innovation Act, or FDASIA, which was enacted in 2012, made permanent the Pediatric Research Equity Act, or PREA, which requires a sponsor to
conduct pediatric studies for most drugs and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original NDAs, BLAs
and supplements thereto, must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the product for
the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA
may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug or biologic is ready for
approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. After April 2013, the FDA
must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric formulation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Marketing Exclusivity  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA approval of our product candidates, some of our United States patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent
restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining
term of a patent beyond a total of 14&nbsp;years from the product's approval date. The patent term restoration period is generally one-half the time between the effective date of an IND, and the
submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application, except that the period is reduced by any time during which the
applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the extension must be applied for prior to expiration of the patent. The
United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is another type of marketing exclusivity available in the United States. The FDASIA made permanent the Best Pharmaceuticals for Children Act, or BPCA, which
provides for an additional six months of marketing exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA, or a Written Request. If the Written
Request does not include studies in neonates, the FDA is required to include its rationale for not requesting those studies. The FDA may request studies on approved or unapproved indications in
separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described studies. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Biologics Price Competition and Innovation Act of 2009  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act which included the Biologics Price
Competition and Innovation Act of 2009, or BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for two types of "generic" biologics&#151;biosimilars and interchangeable
biologic products, and provides for a twelve-year exclusivity period for the first approved biological product, or reference product, against which a biosimilar or interchangeable application is
evaluated; however if pediatric studies are performed and accepted by the FDA, the twelve-year exclusivity period will be extended for an additional six months. A biosimilar </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=19,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=588320,FOLIO='17',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>product
is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences
between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that may be substituted for the
reference product without the intervention of the healthcare provider who prescribed the reference product. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biosimilar applicant must demonstrate that the product is biosimilar based on data from (i)&nbsp;analytical studies showing that the biosimilar product is highly similar to the
reference product; (ii)&nbsp;animal studies (including toxicity); and (iii)&nbsp;one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use
for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label,
route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
application for a biosimilar product may not be submitted until four years after the date on which the reference product was first approved. The first approved interchangeable
biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed, but the exclusivity period may be shortened under certain circumstances. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA has issued a number of final and draft guidances in order to implement the law. On April&nbsp;28, 2015, the FDA issued the following three final guidances: "Scientific
Considerations in Demonstrating Biosimilarity to a Reference Product," "Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product," and
"Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry." The draft guidances include "Formal Meetings between
the FDA and Biosimilar Biological Product Sponsors or Applicants" issued March&nbsp;29, 2013, "Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product" issued
May&nbsp;13, 2014, "Reference Product Exclusivity for Biological Products Filed Under Section&nbsp;351(a) of the PHS Act" issued August&nbsp;4, 2014, and "Biosimilars: Additional Questions and
Answers Regarding Implementation of the Price Competition and Innovation Act of 2009," issued May&nbsp;12, 2015. The guidance documents provide FDA's current thinking on approaches to demonstrating
that a proposed biological product is biosimilar to a reference product. The FDA intends to issue additional guidance documents in the future.
Nevertheless, the absence of final guidance documents covering all biosimilars issues does not prevent a sponsor from seeking licensure of a biosimilar under the BPCIA, and the FDA recently approved
the first biosimilar application in the United States. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally
a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the
cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must
be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan
drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives the first
FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the
same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity, however, also could block the approval of one </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=20,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=968486,FOLIO='18',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>of
our product candidates for seven years if a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within the competitor's
product for the same indication or disease. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA also administers a clinical research grants program, whereby researchers may compete for funding to conduct clinical trials to support the approval of drugs, biologics, medical
devices, and medical foods for rare diseases and conditions. A product does not have to be designated as an orphan
drug to be eligible for the grant program. An application for an orphan grant should propose one discrete clinical study to facilitate FDA approval of the product for a rare disease or condition. The
study may address an unapproved new product or an unapproved new use for a product already on the market. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fast Track Designation and Accelerated Approval  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or
life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the
sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as a fast track drug concurrent with, or after, the filing of the IND for the drug
candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60&nbsp;days of receipt of the sponsor's request. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the fast track program, the FDA may designate a drug for fast-track status if it is intended to treat a serious or life-threatening illness and nonclinical or clinical data
demonstrate the potential to address an unmet medical need. Similarly, the agency may designate a drug for accelerated approval if it treats a serious condition and generally provides meaningful
therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier
than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or
prevalence of the condition and the availability or lack of alternative treatments. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels,
functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A drug candidate approved on this basis is subject to rigorous post-marketing
compliance requirements, including the completion of Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies,
or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under
accelerated regulations are subject to prior review by the FDA. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a fast
track drug's BLA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and
the applicant pays applicable user fees. However, the FDA's time period goal for reviewing an application does not begin until the last section of the BLA is submitted. Additionally, the fast track
designation may be
withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
FDASIA, Congress encouraged the FDA to utilize innovative and flexible approaches to the assessment of products under accelerated approval. The law required the FDA to issue related
draft guidance within a year after the law's enactment and also promulgate confirming regulatory changes. In </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=21,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=309087,FOLIO='19',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;"><FONT SIZE=2>May
2014, the FDA published a Guidance for Industry entitled, "Expedited Programs for Serious Conditions-Drugs and Biologics" which provides guidance on FDA programs that are intended to facilitate
and expedite development and review of new drugs as well as threshold criteria generally applicable to concluding that a drug is a candidate for these expedited development and review programs. In
addition to the Fast Track, accelerated approval and priority review programs discussed above, the FDA also provided guidance on a new program for Breakthrough Therapy designation. A request for
Breakthrough Therapy designation should be submitted concurrently with, or as an amendment to an IND. The FDA has already granted this designation to over 30 new drugs and has approved several. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur
after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the
market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and
approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies,
and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws and
regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our product candidates. Future inspections by the FDA and other
regulatory agencies may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
drug products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying with certain electronic records
and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that
are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing
of products regulated by the FDA. It is impossible to predict whether further legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such
changes, if any, may be. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Regulation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial
sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas,
such as the 28-member European Union, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical
trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=22,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=539198,FOLIO='20',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which
is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of AIDS, cancer,
neurodegenerative disorders, diabetes, viral diseases and designated orphan medicines, and optional for other medicines which are highly innovative. Under the centralized procedure, a marketing
application is submitted to the European Medicines Agency where it will be evaluated by the Committee for Medicinal Products for Human Use and a favorable opinion typically results in the grant by the
European Commission of a single marketing authorization that is valid for all European Union member states within 67&nbsp;days of receipt of the opinion. The initial marketing authorization is valid
for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure provides for approval by one or more "concerned" member states based on an assessment of an
application performed by one member state, known as the "reference" member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to
the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120&nbsp;days after receipt of a valid
application. Within 90&nbsp;days of receiving the reference member state's assessment report, each concerned member state must decide whether to approve the assessment report and related materials.
If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
conducting clinical trials in the EU, we must adhere to the provisions of the EU Clinical Trials Directive and the laws and regulations of the EU Member States implementing them.
These provisions require, among other things, that the prior authorization of an Ethics Committee and the submission and approval of a clinical trial authorization application be obtained in each
Member State be obtained before commencing a clinical trial in that Member State. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
in the United States, it may be possible in foreign countries to obtain a period of market and/or data exclusivity that would have the effect of postponing the entry into the
marketplace of a competitor's generic product. For example, in the EU, if any of our products receive marketing approval in the European Economic Area, or EEA which is comprised of the 28 member
states of the EU plus Norway, Iceland and Liechtenstein, we expect that we will benefit from eight years of data exclusivity and an additional two years of marketing exclusivity. An additional
one-year extension of marketing exclusivity is possible if during the data exclusivity period we obtain an authorization for one or more new therapeutic indications that is deemed to bring a
significant clinical benefit compared to existing therapies. The data exclusivity period begins on the date of the product's first marketing authorization in the EU and prevents biosimilars from
relying on the holder of the marketing authorization for the reference biological medicine's pharmacological, toxicological and clinical data for a period of eight years. After eight years, a
biosimilar product application may be submitted and the sponsoring companies may rely on the marketing authorization holder's data. However, a biosimilar medicine cannot launch until 2&nbsp;years
later (or a total of ten years after the first marketing authorization in the EU of the innovator product), or 3&nbsp;years later (or a total of eleven years after the first marketing authorization
in the EU of the innovator product) if the marketing authorization holder obtains
marketing authorization for a new indication with significant clinical benefit within the eight year data exclusivity period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
in the United States, a sponsor may apply for designation of a product as an orphan drug for the treatment of a specific indication in the EU before the application for marketing
authorization is made. Orphan drugs in Europe enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that
its product is safer, more effective or otherwise clinically superior to the orphan-designated product. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=23,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=293880,FOLIO='21',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reimbursement  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of pharmaceutical products depend in significant part on the availability of third-party reimbursement. Third-party payors include
government healthcare programs, managed care providers, private health insurers and other organizations. These third-party payors are increasingly challenging the price and examining the
cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the reimbursement status of newly approved healthcare products. We may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. Our product candidates may not be considered cost-effective. It is time consuming and expensive to seek
reimbursement from third-party payors. Reimbursement may not be available or sufficient to allow us to sell our products on a competitive and profitable basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from
country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or
indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance
that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically,
products launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;24, 2017, we had eight full-time employees, including five engaged in research, development, and regulatory activities, and
three in executive, general and administrative functions, and multiple part-time consultants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in Delaware in September 2011. Our principal executive offices are located at 200 Barr Harbor Drive, Suite&nbsp;400, West
Conshohocken, PA 19428. Our telephone number is (484)&nbsp;380-9263. Our Internet website address is www.madrigalpharma.com. The contents of our website are not incorporated into, and do not
form&nbsp;a part of, this prospectus or the registration statement of which it forms&nbsp;a part. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Reverse Merger  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On July&nbsp;22, 2016, Synta Pharmaceuticals Corp., or Synta, completed its business combination with Private Madrigal (Madrigal
Pharmaceuticals,&nbsp;Inc. prior to the consummation of the Merger described herein) in accordance with the terms of an Agreement and Plan of Merger and Reorganization, dated as of April&nbsp;13,
2016, or the Merger Agreement. Pursuant to the Merger Agreement, Synta formed a wholly-owned subsidiary that merged with and into Private Madrigal, with Private Madrigal surviving the merger and
becoming a wholly-owned subsidiary of Synta, or the Merger. In connection with, and prior to the consummation of, the Merger, Synta effected a 1-for-35 reverse stock split of its common stock, or the
Reverse Stock Split, and, following the Merger, changed its name to "Madrigal Pharmaceuticals,&nbsp;Inc." All shares and per share amounts have been retrospectively adjusted to give effect to the
Reverse Stock Split, except as otherwise disclosed. Following the consummation of the Merger, our business became the business conducted by Private Madrigal prior to the consummation of the Merger. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=24,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=112632,FOLIO='22',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_ce40801_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Securities Purchase Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;20, 2017, we entered into a Securities Purchase Agreement, or the Securities Purchase Agreement, with a group of institutional
accredited investors, or the Investors, which were existing, non-controlling stockholders of ours, and are named on the Schedule of Investors to the Securities Purchase Agreement. Under the terms of
the Securities Purchase Agreement, we sold 328,300 shares of our common stock at a price of $15.23 per share, and 1.97&nbsp;million shares of our Series&nbsp;A Convertible Preferred Stock, or the
Series&nbsp;A Preferred Stock, at a price of $15.23 per share. The Series&nbsp;A Preferred Stock is convertible into shares of our common stock at a one-to-one ratio, subject to adjustment as
provided in the Securities Purchase Agreement. We consummated the sale under the Securities Purchase Agreement on June&nbsp;23, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offer and sale of the shares were not registered under the Securities Act in reliance on the exemption afforded by Section&nbsp;4(a)(2) of the Securities Act and Rule&nbsp;506(b)
of Regulation&nbsp;D promulgated thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Securities Purchase Agreement, we agreed to file&nbsp;a registration statement registering the resale of the common stock issued to the Investors under the Securities
Purchase Agreement within 30&nbsp;days after the closing of the sale. We also agreed to use our best efforts to have the registration statement declared effective within 90&nbsp;days after the
closing of the sale. The registration statement of which this prospectus is a part has been filed by us in fulfillment of our obligations under the Securities Purchase Agreement. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=25,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=763763,FOLIO='23',FILE='DISK112:[17ZCE1.17ZCE40801]CE40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_cg40801_1_24"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cg40801_the_offering"> </A>
<A NAME="toc_cg40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Offering    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="248pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock offered by us</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>None</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock offered by the selling stockholders</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Up to 328,300 shares issued pursuant to the Securities Purchase Agreement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Use of Proceeds</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We will not receive any proceeds from the resale by the selling stockholders of the common stock offered by this
prospectus.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Risk Factors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully
consider all of the information in this prospectus and, in particular, you should evaluate the risk factors identified in this prospectus under "Risk Factors" beginning on page&nbsp;25.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>NASDAQ Global Market Symbol</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MDGL</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=26,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=843037,FOLIO='24',FILE='DISK112:[17ZCE1.17ZCE40801]CG40801A.;10',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_da40801_1_25"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da40801_risk_factors"> </A>
<A NAME="toc_da40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You should carefully consider the risks described below, together with all of the other information included in or incorporated by reference
into this report, before making an investment decision. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that
we do not currently believe are important to an investor may also harm our business. If any of the events, contingencies, circumstances or conditions described in the following risks actually occur,
our business, financial condition or our results of operations could be seriously harmed. If that happens, the trading price of our common stock could decline and you may lose part or all of the value
of any of our shares held by you. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus and the documents we incorporate by reference in this prospectus contain forward-looking statements that involve risks and uncertainties. Our actual results could differ
materially from those anticipated in these forward-looking statements as a result of certain factors,
including the risks described in this prospectus and in the documents incorporated by reference in this prospectus. For more information, see "Special Note Regarding Forward-Looking Information." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Business  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have limited operating history, we have incurred significant operating losses since inception and we
expect to incur significant operating losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future as we
continue our clinical trial and development programs for MGL-3196 and other future product candidates. As of December&nbsp;31, 2016, we had an accumulated deficit of $75.3&nbsp;million. Losses
have principally resulted from costs incurred in our preclinical and clinical trials, research and development programs and from our general and administrative expenses. As of December&nbsp;31,
2016, we had cash, cash equivalents and marketable securities of $40.5&nbsp;million. In the future, we intend to continue to conduct research and development, clinical testing, regulatory compliance
and, if MGL-3196 or other future product candidates are approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring
further significant losses for the foreseeable future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently generate no revenue from product sales, and we may never be able to commercialize MGL-3196 or other future product candidates. We do not currently have the required
approvals to market MGL-3196 or any other future product candidates, and we may never receive them. We may not be profitable even if we or any of our future development partners succeed in
commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the
extent of any future losses or when we will become profitable, if at all. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our business depends on the success of MGL-3196, which is still in clinical development. If we are unable to
obtain regulatory approval for or successfully commercialize MGL-3196, our business will be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, the sole focus of our product development has been MGL-3196, a liver-directed selective thyroid hormone receptor beta agonist for
potential use in non-alcoholic steatohepatitis, or NASH, and FH. Successful continued development and ultimate regulatory approval of MGL-3196 for NASH or genetic dyslipidemias, such as FH, is
critical to the future success of our business. We have invested, and will continue to invest, a significant portion of our time and financial resources in the clinical development of MGL-3196. We
will need to raise sufficient funds to successfully complete our clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=143566,FOLIO='25',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>development
program for MGL-3196 in NASH and FH. The future regulatory and commercial success of MGL-3196 is subject to a number of risks, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not have sufficient financial and other resources to complete the necessary clinical trials for MGL-3196, including but not limited to
Phase&nbsp;2 clinical trials and, later, registrational clinical trials to obtain drug approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the mechanism of action of MGL-3196 is complex and we do not know the degree to which it will translate into a therapeutic benefit, if any, in
NASH, FH or any other indication, and we do not know the degree to which the complex mechanism of action may contribute to long term safety issues or adverse events, if any, when MGL-3196 is taken for
prolonged periods such as in the treatment of NASH, FH or any other indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to obtain adequate evidence from clinical trials of efficacy and safety for MGL-3196 in NASH, FH or any other indication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we do not know the degree to which MGL-3196 will be accepted as a therapy by physicians, patients and payors, even if approved; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in our clinical programs for MGL-3196, we may experience variability in patients, adjustments to clinical trial procedures and the need for
additional clinical trial sites, which could delay our clinical trial progress; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the results of our clinical trials may not meet the level of statistical or clinical significance required by the FDA or comparable foreign
regulatory bodies for marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patients in our clinical trials may die or suffer other adverse effects for reasons that may or may not be related to MGL-3196, which could
delay or prevent further clinical development; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the standards implemented by clinical or regulatory agencies may change at any time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the FDA or foreign clinical or regulatory agencies may require efficacy endpoints for a Phase&nbsp;3 clinical trial for the treatment of NASH
or FH that differ from the endpoints of our current or future trials, which may require us to conduct additional clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if approved for NASH, MGL-3196 will likely compete with the off-label use of currently marketed products and other therapies in development
that may reach approval for NASH prior to MGL-3196; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if approved for FH, MGL-3196 will likely compete with currently approved and marketed products and other therapies in development that may
reach approval for FH prior to MGL-3196; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we may not be able to obtain, maintain or enforce our patents and other intellectual property rights. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
the large number of drugs in development in the pharmaceutical industry, only a small percentage results in the submission of a new drug application, or NDA, to the FDA and even fewer
are approved for commercialization. Furthermore, even if we do receive regulatory approval to market MGL-3196, any such approval may be subject to limitations on the indicated uses or patient
populations for which we may market the products. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we may be unable to successfully
develop or commercialize MGL-3196. If we or any of our future development partners are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize MGL-3196, we
may not be able to generate sufficient revenue to continue our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=675560,FOLIO='26',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The results of preclinical studies and early clinical trials are not always predictive of future results. Any
product candidate that we advance into clinical trials, including MGL-3196, may not have favorable results in later clinical trials or receive regulatory approval.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drug development has inherent risk. We will be required to demonstrate through adequate and well-controlled clinical trials that our product
candidates are safe and effective, with a favorable benefit-risk profile, for use in our target indications before we can seek regulatory approvals for its commercial sale. Clinical studies are
expensive, difficult to design and implement, can take many years to complete and are uncertain as to outcome. Delay or failure can occur at any stage of development, including after commencement of
any of our clinical trials. In addition, success in early clinical trials does not mean that later clinical trials will be successful, because later-stage clinical trials may be conducted in broader
patient populations and involve different study designs. For instance, our Phase&nbsp;1 results may not be predictive of any future Phase&nbsp;2 results. Furthermore, our future trials will need
to demonstrate sufficient safety and efficacy in larger patient populations for approval by
regulatory authorities. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small
percentage of drugs under development result in the submission of an NDA to the FDA and even fewer are approved for commercialization. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications
could limit the prospects for regulatory approval of our product candidates in those and other indications. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because MGL-3196 has not yet received regulatory approval for any indication, it is difficult to predict the
time and cost of development and our ability to successfully complete clinical development and obtain the necessary regulatory approvals for commercialization.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MGL-3196 has not yet received regulatory approval for the treatment of NASH, FH or any other indication, and unexpected problems may arise that
could cause us to delay, suspend or terminate our development efforts in any or all indications. Further, MGL-3196 has not yet demonstrated efficacy in patients with NASH or FH, and the long-term
safety consequences of a liver-directed thyroid hormone receptor beta agonist are not known. Regulatory approval of new product candidates such as MGL-3196 can be more expensive and take longer than
approval for candidates for the treatment of more well-understood diseases with previously approved products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If clinical trials or regulatory approval processes for our product candidates are prolonged, delayed or
suspended, we may be unable to commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product
sales.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot predict whether we will encounter problems with any of our completed, ongoing or planned clinical trials that will cause us or any
regulatory authority to delay or suspend those clinical trials or delay the analysis of data derived from them. A number of events, including any of the following, could delay the completion of our
ongoing and planned clinical trials and negatively affect our ability to obtain regulatory approval for, and to market and sell, a particular product
candidate:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> conditions imposed on us by the FDA or other regulatory authorities regarding the scope or design of our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> insufficient supply of our product candidates or other materials necessary to conduct and complete our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> slow enrollment and retention rate of subjects in our clinical trials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> serious and unexpected drug-related side effects related to the product candidate being tested. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=523539,FOLIO='27',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercialization
of our product candidates may be delayed by the imposition of additional conditions on our clinical trials by the FDA or any other applicable foreign regulatory
authority or the requirement of additional supportive studies by the FDA or such foreign regulatory authority. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not know whether our clinical trials will begin as planned, will need to be restructured, or will be completed on schedule, if at all. Delays in the initiation, enrollment or
completion of our clinical trials will result in increased development costs for our product candidates, and our financial resources may be insufficient to fund any incremental costs. In addition, if
our clinical trials are delayed, our competitors may be able to bring products to market before we do and the commercial viability of our product candidates could be limited. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we inadvertently fail to comply with foreign regulatory requirements governing human clinical trials and
marketing approval for drugs, we could be prevented from selling our drug candidates in foreign markets, which may adversely affect our operating results and financial
condition</I></B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement for marketing our drug candidates outside the United States
vary greatly
from country to country and may require additional testing. We expect that our future clinical development of our drug candidates will involve a number of clinical trials in foreign jurisdictions,
particularly in Europe. We have no experience in obtaining foreign regulatory approvals. The time required to obtain approvals outside the United States may differ from that required to obtain FDA
approval. We may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not guarantee approval by regulatory authorities in other countries, and approval by one
foreign regulatory authority does not ensure approval by regulatory authorities in other countries or by the FDA. Failure to comply with these regulatory requirements or obtain required approvals
could impair our ability to develop foreign markets for our drug candidates and may have a material adverse effect on our results of operations and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities
could be delayed or otherwise adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may not be able to initiate, continue, or complete clinical trials required by the FDA or foreign regulatory agencies for MGL-3196 if we are
unable to locate and enroll a sufficient number of eligible patients to participate in these clinical trials. Patient enrollment, a significant factor in the timing to conduct and complete clinical
trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the
clinical trial, competing clinical trials, and clinicians' and patients' perceptions as to the potential advantages and disadvantages of the product candidate being studied in relation to other
available therapies, including any new drugs that may be approved for the indications we are investigating. In the proposed clinical trials, patient willingness to undergo a liver biopsy in our NASH
trials, and identification of patients willing to participate in our FH trials due to the rarity of the disease, are also risk factors. Potential patients for MGL-3196 may not be adequately diagnosed
or identified with the diseases which we are targeting or may not meet the entry criteria for our studies. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA typically requires sponsors of lipid-lowering product candidates to conduct drug-drug interaction studies with statins because statins may have increased safety risks when
administered together with other drug therapies that affect their pharmacokinetic profile. We have completed one clinical drug interaction study of MGL-3196 and two statins in 25 normal healthy
volunteers, which showed MGL-3196 to have a favorable safety profile and to be well-tolerated. We are currently conducting a second drug-interaction study of MGL-3196 with a third statin. We have
initiated a Phase&nbsp;2 clinical study in NASH including patients taking low dose statins. We have also initiated a Phase&nbsp;2 clinical study in HeFH including patients taking high dose
statins. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=960026,FOLIO='28',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_29"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will be required to identify and enroll a sufficient number of patients for each of our ongoing and planned clinical trials of MGL-3196 for NASH and FH indications, respectively. We
also may encounter difficulties in identifying and enrolling NASH patients and FH patients with a stage of disease appropriate for our ongoing or future clinical trials. We may not be able to initiate
or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other foreign regulatory agencies. In
addition, the process of finding and diagnosing patients may prove costly. Our inability to enroll a sufficient number of patients for any of our clinical trials would result in significant delays or
may require us to abandon one or more clinical trials. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any product candidate in our current or future clinical trials may cause unacceptable adverse events or have
other properties that may delay or prevent its regulatory approval or commercialization or limit its commercial potential.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unacceptable adverse events caused by any of our product candidates in current or future clinical trials could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications and
markets. This in turn could prevent us from completing development of or commercializing the affected product candidate and generating revenue from its sale. If any of our product candidates cause
unacceptable adverse events in clinical trials, we may not be able to obtain regulatory approval or commercialize such product candidate. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our product candidates will remain subject to ongoing regulatory review even if they receive marketing
approval, and if we fail to comply with continuing regulations, we could lose these approvals and the sale of any approved commercial products could be suspended.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we receive regulatory approval to market a particular product candidate, the manufacturing, labeling, packaging, adverse event
reporting, storage, advertising, promotion, and record keeping related to the product will remain subject to extensive regulatory requirements. If we fail to comply with the regulatory requirements of
the FDA and other applicable domestic and foreign regulatory authorities, or previously unknown problems with any approved product, manufacturer, or manufacturing process are discovered, we could be
subject to administrative or judicially imposed sanctions, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on the products, manufacturers, or manufacturing processes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warning letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> civil or criminal penalties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injunctions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product seizures or detentions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> pressure to initiate voluntary product recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> suspension or withdrawal of regulatory approvals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> refusal to approve pending applications for marketing approval of new products or supplements to approved applications. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our industry is highly competitive, and our product candidates may become obsolete.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are engaged in a rapidly evolving field. Competition from other pharmaceutical companies, biotechnology companies and research and academic
institutions is intense and likely to increase. Many </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=397335,FOLIO='29',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>of
those companies and institutions have substantially greater financial, technical and human resources than us. Those companies and institutions also have substantially greater experience in
developing products, conducting clinical trials, obtaining regulatory approval and in manufacturing and marketing pharmaceutical products. Our competitors may succeed in obtaining regulatory approval
for their products more rapidly than we do. Competitors have developed or are in the process of developing technologies that are, or in the future may be, the basis for competitive products. Some of
these competitive products may have an entirely different approach or means of accomplishing the desired therapeutic effect than products being developed by us. Our competitors may succeed in
developing products that are more effective and/or cost competitive than those we are developing, or that would render our product candidates less competitive or even obsolete. In addition, one or
more of our competitors may achieve product commercialization or patent protection earlier than us, which could materially adversely affect our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the FDA or other applicable regulatory authorities approve generic products that compete with any of our
or any of our partners' product candidates, the sales of our product candidates would be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a "listed drug"
that can, in turn, be cited by potential competitors in support of approval of an abbreviated new drug application in the United States. Agency regulations and other applicable regulations and
policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an abbreviated new drug application or other application for generic
substitutes in the United States and in nearly every pharmaceutical market around the world. These manufacturers might only be required to conduct a relatively inexpensive study to show that their
product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use, or labeling, as our product and that the generic product is bioequivalent to our
product, meaning it is absorbed in the body at the same rate and to the same extent as our product. These generic equivalents, which must meet the same quality standards as branded pharmaceuticals,
would be significantly less costly than our product to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the
introduction of a generic competitor, a significant percentage of the sales of any
branded product are typically lost to the generic product. Accordingly, competition from generic equivalents to our product or any of our partners' future products, if any, would materially adversely
affect our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made and expect to make in our or any of our partners' product
candidates, including MGL-3196. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If physicians and patients do not accept our future products or if the market for indications for which any
product candidate is approved is smaller than expected, we may be unable to generate significant revenue, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if any of our product candidates obtain regulatory approval, they may not gain market acceptance among physicians, patients, and
third-party payers. Physicians may decide not to recommend its treatments for a variety of reasons including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> timing of market introduction of competitive products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstration of clinical safety and efficacy compared to other products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cost-effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limited or no coverage by third-party payers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> convenience and ease of administration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prevalence and severity of adverse side effects; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=32,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=658856,FOLIO='30',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions in the label of the drug; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> other potential advantages of alternative treatment methods; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ineffective marketing and distribution support of its products. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are approved, but fail to achieve market acceptance or such market is smaller than anticipated, we may not be able to generate significant revenue and
our business would suffer. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


As we evolve from a company that is primarily involved in clinical development to a company that is also
involved in commercialization, we may encounter difficulties in expanding our operations successfully.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As we advance our product candidates through clinical trials, we will need to expand our development, regulatory, manufacturing, and marketing
and sales capabilities and may need to further contract with third parties to provide these capabilities. As our operations expand, we likely will need to manage additional relationships with such
third parties, as well as additional collaborators, distributors, marketers and suppliers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintaining
third party relationships for these purposes will impose significant added responsibilities on members of our management and other personnel. We must be able to effectively
manage our development efforts; recruit and train sales and marketing personnel, effectively manage our participation in the clinical trials in which our product candidates are involved and improve
our managerial, development, operational and finance systems, all of which may impose a strain on our administrative and operational infrastructure. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we enter into arrangements with third parties to perform sales, marketing or distribution services, any product revenues that we receive, or the profitability of these product
revenues to us, are likely to be lower than if we were to market and sell any products that we develop without the involvement of these third parties. In addition, we may not be successful in entering
into arrangements with third parties to sell and market our products or in doing so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may
fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in
collaboration with third parties, we will not be successful in commercializing our products. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The uncertainty associated with pharmaceutical reimbursement and related matters may adversely affect our
business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market acceptance and sales of any one or more of our product candidates will depend on reimbursement policies and may be affected by future
healthcare reform measures in the United States and in foreign jurisdictions. Government authorities and third-party payers, such as private health insurers and health maintenance organizations,
decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for any of our product candidates. Also, we cannot be certain that
reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully
commercialize any product candidates that we develop. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and
pays for pharmaceutical products. The legislation established Medicare Part&nbsp;D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority
for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs.
The United States and several foreign jurisdictions are considering, or have already enacted, a number of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=33,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=873033,FOLIO='31',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>legislative
and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payers in the United States and
elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In
the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing
pressures in connection with the sale of any products that we develop due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional
legislative proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, ACA, became law in the
United States. The goal of ACA is to reduce the cost of healthcare and substantially change the way healthcare is financed by both government and private insurers. While we cannot predict what impact
on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively
affect market acceptance of, and the price we may charge for, any products we develop that receives regulatory approval. We also cannot predict the impact of ACA on us as many of the ACA reforms
require the promulgation of detailed regulations implementing the statutory provisions, which have not yet been fully implemented. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If any product liability lawsuits are successfully brought against us or any of our collaborative partners,
we may incur substantial liabilities and may be required to limit commercialization of our product candidates.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients and will face
an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our partners by participants
enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any
such claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> decreased demand for any of our future approved products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> injury to our reputation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> withdrawal of clinical trial participants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> termination of clinical trial sites or entire trial programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> significant litigation costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> substantial monetary awards to or costly settlements with patients or other claimants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> product recalls or a change in the indications for which products may be used; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> loss of revenue; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversion of management and scientific resources from our business operations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the inability to commercialize our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be
adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are
asserted to be, harmful to patients. Also, because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients' use or
misuse of our products or </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=34,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=64224,FOLIO='32',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>any
similar products distributed by other companies could have a material adverse impact on our results of operations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not currently hold product liability insurance coverage. Prior to commercialization of our product candidates, we will need to purchase insurance coverage. As a result, we may be
unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. These liabilities could prevent or
interfere with our product development and commercialization efforts. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance
coverage, could decrease our cash resources and adversely affect our business, financial condition and results of operations. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees, contractors, vendors and partners may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements and insider trading.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of fraud or other misconduct by our employees, contractors, vendors or partners. Misconduct by these parties could
include failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state healthcare fraud and abuse laws and regulations, to report financial
information or data timely, completely or accurately, or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to
extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Third-party misconduct could also involve the improper use of information obtained
in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to
identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from
governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are
instituted against us resulting from this misconduct and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including
the imposition of significant fines or other sanctions. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We enter into various contracts in the normal course of our business in which we indemnify the other party to
the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other
agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from
claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our potential
sublicensees' exercise of rights under the agreement. With respect to our commercial agreements, we indemnify our vendors from any third-party product liability claims that could result from the
production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
our obligation under an indemnification provision exceed applicable insurance coverage or if we are denied insurance coverage, our business, financial condition and results of
operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the
applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition and results of operations could be adversely affected. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=35,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=254349,FOLIO='33',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to develop and commercialize other product candidates, we may be unable to grow our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although the development and commercialization of MGL-3196 is our primary focus, as part of our longer-term growth strategy, we plan to evaluate
the development and commercialization of other therapies related to thyroid hormone, orphan and other diseases. We will evaluate internal opportunities from our compound libraries, and also may choose
to in-license or acquire other product candidates as well as commercial products to treat patients suffering from
thyroid hormone, orphan or other disorders with high unmet medical needs and limited treatment options. These other product candidates may require additional, time-consuming development efforts prior
to commercial sale, including preclinical studies, clinical trials and approval by the FDA and/or applicable foreign regulatory authorities. All product candidates are prone to the risks of failure
that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory
authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, be successfully commercialized, be widely accepted in the
marketplace, or be more effective than other commercially available alternatives. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our
ability to identify, develop and commercialize products will be impaired.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on principal members of our management team, including our Chief Executive Officer, Paul A. Friedman, M.D., and our
Chief Medical Officer, Rebecca Taub, M.D. These executives each have significant pharmaceutical industry experience. The loss of any member of our management team or scientific staff, including Drs.
Friedman and Taub, would impair our ability to identify, develop and market new products. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of
the services of these or other key personnel, or the inability to attract and retain additional qualified personnel, could result in delays to development or approval, loss of sales and diversion of
management resources. In addition, we depend on our ability to attract and retain other highly skilled personnel. Competition for qualified personnel is intense, and the process of hiring and
integrating such qualified personnel is often lengthy. We may be unable to recruit such personnel on a timely basis, if at all, which would negatively impact our development and commercialization
programs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
we do not currently maintain "key person" life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not receive
adequate compensation for the loss of the services of these individuals. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have no marketing, sales or distribution infrastructure with respect to our product candidates.
If we are unable to develop our sales, marketing and distribution capabilities on our own or through collaborations with marketing partners, we will not be successful in commercializing our product
candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have no marketing, sales or distribution capabilities and have limited sales or marketing experience within our organization. If
our product candidate, MGL-3196, is approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize
MGL-3196, or to outsource this function to a third party. Either of these options would be expensive and time consuming. Some or all of these costs may be incurred in advance of any approval of
MGL-3196. In addition, we may not be able to hire a sales
force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales,
marketing and distribution capabilities would adversely affect the commercialization of MGL-3196 and other future product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=36,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=79873,FOLIO='34',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_35"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to
augment our own sales force and distribution systems or as an alternative to our own sales force and distribution systems. To the extent that we enter into co-promotion or other licensing
arrangements, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these
third parties, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully
commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product
revenue will suffer and we may incur significant additional losses. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain FDA approval of MGL-3196 or any other future product candidate, we or our partners may
never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of
other countries regarding clinical trial design, safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval
in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and
additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or
clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those
countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any
country may delay or have negative effects on the process for regulatory approval in other countries. We and our partners do not have any product candidates approved for sale in any jurisdiction,
including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we or our partners fail to comply with regulatory requirements in
international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation by extending
the term of patents covering each of our product candidates, our business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents
may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments
permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review
process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable
requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the
period during which we can enforce our patent rights for that product may not extend beyond the current patent expiration dates and our competitors may obtain approval to market competing products
sooner. As a result, our revenue could be potentially materially reduced. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=37,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=860969,FOLIO='35',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we or our partners market products in a manner that violates fraud and abuse and other healthcare laws, or
if we or our partners violate government price reporting laws, we or our partners may be subject to administrative civil and/or criminal penalties.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws, including
those commonly referred to as "fraud and abuse" laws, have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include, among others, false
claims and anti-kickback statutes. At such time, if ever, as we or any of our partners market any of our future approved products, it is possible that some of our business activities and/or our
partners could be subject to challenge under one or more of these laws. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal
false claims, false statements and civil monetary penalties laws prohibit, among others, any person from knowingly presenting, or causing to be presented, a false claim for
payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other
things, knowingly and
willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or
service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the
one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from
prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they
do not qualify for an exception or safe harbor. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we and/or our partners may be subject to data privacy and security regulation, including the Health Insurance Portability and Accountability Act of 1996, as amended by the
Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, which impose specified requirements relating to the privacy, security and
transmission of individually identifiable health information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most
states also have statutes or regulations similar to these federal laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. We
and/or our partners may be subject to administrative, civil and criminal sanctions for violations of any of these federal and state laws. Pharmaceutical and other healthcare companies have been
prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to
prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting
inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the third parties on which we rely for the conduct of our clinical trials and results do not perform our
clinical trial activities in accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize our product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We use third-party service providers to conduct and/or oversee the clinical trials of our product candidates and expect to continue to do so for
the foreseeable future. We rely heavily on these parties for successful execution of our clinical trials. Nonetheless, we are responsible for confirming that each of our clinical trials is conducted
in accordance with FDA requirements and our general investigational plan and protocol. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA requires us and our third-party service providers to comply with regulations and standards, commonly referred to as good clinical practices, or GCP, for conducting, recording and
reporting the results of clinical trials to assure that data and reported results are credible and accurate, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=38,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=840284,FOLIO='36',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_da40801_1_37"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
that the trial participants are adequately protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Third parties may not
complete activities on schedule or may not conduct our clinical trials in accordance with regulatory or GCP requirements or the respective trial plans and protocols. In addition, third parties may not
be able to repeat their past successes in clinical trials. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of
our product candidates or result in enforcement action against us. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have relied on, and expect to continue to rely on, third-party manufacturers to produce our product
candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack
the resources and the capabilities to do so. As a result, we currently rely, and expect to rely for the foreseeable future, on third-party manufacturers to supply our product candidates. Reliance on
third-party manufacturers entail risks to which we would not be subject if we manufactured our product candidates or products ourselves, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reliance on third-parties for manufacturing process development, regulatory compliance and quality assurance; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> limitations on supply availability resulting from capacity and scheduling constraints of third-parties; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible breach of manufacturing agreements by third-parties because of factors beyond our control; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the possible termination or non-renewal of manufacturing agreements by third-parties, at a time that is costly or inconvenient to us. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our
ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers, we may not be able to enter into
agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA and other foreign regulatory
authorities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA and other foreign regulatory authorities require manufacturers to register manufacturing facilities. The FDA and corresponding foreign regulators also inspect these facilities to
confirm compliance with current good manufacturing practices, or cGMPs. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays
or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, European Medicines Agency,
or EMA, and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products following
approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop our
product candidates and commercialize any products that receive regulatory approval on a timely basis. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=39,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=365523,FOLIO='37',FILE='DISK112:[17ZCE1.17ZCE40801]DA40801A.;7',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc40801_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We previously identified a material weakness in our internal control over financial reporting and may
identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, which may result in material misstatements of our financial statements or
cause us to fail to meet our reporting obligations or fail to prevent fraud; and in that case, our stockholders could lose confidence in our financial reporting, which would harm our business and
could negatively impact the price of our stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective internal controls are necessary for us to provide reliable financial reports and prevent fraud. If we fail to maintain an effective
system of internal controls, we may be unable to report our financial results accurately or prevent fraud; and in that case, our stockholders could lose confidence in our financial reporting, which
would harm our business and could negatively impact the price of our stock. On March&nbsp;31, 2017, we filed with the SEC an amendment to our Quarterly Report on Form&nbsp;10-Q for the quarter
ended September&nbsp;30, 2016 to correct certain errors therein. Management reported a material weakness in our system of internal control over financial reporting as of September&nbsp;30, 2016. A
material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual
or interim financial statements will not be prevented or detected on a timely basis. We remediated this material weakness. We cannot assure you that the measures we have taken to date will
be sufficient to avoid future material weaknesses. Even when we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or
detect fraud or misstatements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
reporting obligations as a public company will require significant managerial, operational and financial resources for the foreseeable future. If we fail to maintain the adequacy of
our internal control over financial reporting, we may not be able to produce reliable financial reports or help prevent fraud. Our failure to maintain effective internal control over financial
reporting could prevent us from filing our periodic reports on a timely basis which could result in the loss of investor confidence in the reliability of our financial statements, harm our business
and negatively impact the trading price of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Relating to Our Intellectual Property  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our rights to develop and commercialize our product candidates are subject in part to the terms and
conditions of a license to MGL-3196 granted to us by Roche.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We entered into a research, development and commercialization agreement, or the Roche Agreement, with Hoffmann-La Roche Pharmaceutical Company
Limited, or Roche, on December&nbsp;18, 2008. Pursuant to the terms of the Roche Agreement, we assumed control of all development and commercialization of MGL-3196 and will own exclusive worldwide
rights for all potential indications. Roche assigned all patent rights relating to MGL-3196 to us and granted us an exclusive license to use certain know-how relating to MGL-3196 in exchange for
consideration consisting of an upfront payment, milestone payments tied to the achievement of product development and regulatory milestones, and royalty payments based on net sales of products
containing MGL-3196, subject to certain reductions. We must use commercially reasonable efforts to conduct clinical and commercial development programs for products containing MGL-3196. If we
determine that it is not reasonable to continue clinical trials or other development of MGL-3196, we may elect to cease further development and Roche may terminate the license. If we determine not to
pursue the development or commercialization of MGL-3196 in certain jurisdictions, including the United States, Roche may terminate the license for such territories. The Roche Agreement will expire,
unless earlier terminated pursuant to other provisions of the agreement, on the last to occur of (i)&nbsp;the expiration of the last valid claim of a licensed patent covering the manufacture, use or
sale of products containing MGL-3196, or (ii)&nbsp;ten years after the first sale of a product containing MGL-3196. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=399288,FOLIO='38',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_39"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have, nor have we had, any material disputes with Roche regarding the Roche Agreement. However, if there is any future dispute between us and Roche regarding the parties'
rights under the Roche Agreement, our ability to develop and commercialize MGL-3196 may be materially harmed. Any uncured, material breach under the Roche Agreement could result in our loss of
exclusive rights to MGL-3196 and may lead to a complete termination of the Roche Agreement and force us to cease product development efforts for MGL-3196. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may fail to comply with any of our obligations under agreements pursuant to which we license rights or
technology, which could result in the loss of rights or technology that are material to our business.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may enter into license agreements from time to time. Licensing of intellectual property is important to our business and involves complex
legal, business and scientific issues. Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the scope of rights granted under the license agreement and other interpretation-related issues; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing
agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the sublicensing of patent and other rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our licensors and
collaborators; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the priority of invention of patented technology. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our success depends on our ability to protect our intellectual property and our proprietary technologies.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success depends on our ability to protect our intellectual property and our proprietary technologies. Our commercial success depends in part
on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses, as well as our ability to operate without
infringing upon the proprietary rights of others. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
can provide no assurance that our patent applications or those of our licensors will result in additional patents being issued or that issued patents will afford sufficient protection
against competitors with similar technologies, nor can we provide any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may
later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary
rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the
intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations. Composition-of-matter patents on the
biological or chemical active pharmaceutical ingredients are generally considered to offer the strongest protection of intellectual property and provide the broadest scope of patent protection for
pharmaceutical products, as such patents provide protection without regard to any method of use or any method of manufacturing. While we own and have licensed rights to issue composition-of-matter
patents in the United States and other jurisdictions
for MGL-3196, we cannot be certain that the claims in issued composition-of-matter patents will not be found invalid or unenforceable if challenged. We cannot be certain that the claims in owned and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=712175,FOLIO='39',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_40"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>licensed
patent applications covering our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, and valid by courts in the United States or by
the patent offices and courts in foreign jurisdictions. Even if we owned and licensed patent applications covering our product candidates, the patents may not be enforced against competitors. For
example, a formulation patent will not be enforced against those making and marketing a product that has the same active pharmaceutical ingredient in a different formulation that is not claimed in the
formulation patent. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. This type of patent may not be enforced against competitors
making and marketing a product that has the same active pharmaceutical ingredient but is used for a method not claimed in the patent. Moreover, even if competitors do not actively promote their
product for our targeted indications, physicians may prescribe these products "off-label." Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the
practice is common and such infringement is difficult to prevent or prosecute. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
licensed composition-of-matter patent from Roche for MGL-3196 is expected to expire in the United States in 2026. Our owned patents and pending patent applications that cover solid
form, method of manufacturing, and use of MGL-3196 to treat various indications are expected to expire in 2033. While patent term adjustments or patent term extensions could result in later expiration
dates for each of these patents, there can be no assurances that we will receive any patent adjustments or patent term extensions. The patent application process and patent maintenance and enforcement
are subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining
and defending patents. These risks and uncertainties include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
provisions during the patent process and after a patent has issued. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in
partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patent applications may not result in any patents being issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive
advantage; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> us and our licensor(s) may not have been the first to make the inventions covered by pending patent applications or issued patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> us and our licensor(s) may not have been the first to file patent applications for our product candidates or the compositions developed, or for
their uses; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may independently develop identical, similar or alternative products or compositions and uses thereof; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> us and our licensor(s)' disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may design around our owned and licensed patent claims to produce competitive products which fall outside of the scope of the patents; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> others may identify prior art or other bases which could invalidate our or licensor(s)' patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where us and our licensor(s) do not have </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=905079,FOLIO='40',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_41"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>patent
rights, and then use the information learned from such activities to develop competitive products for sale in major commercial markets; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> there may be significant pressure on the United States government and international governmental bodies to limit the scope of patent protection
both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing
foreign competitors a better opportunity to create, develop and market competing product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we rely on the protection of our trade secrets and proprietary know-how. Although we have taken steps to protect our trade secrets and unpatented know-how, including
entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that any
of these parties would not breach the agreements to disclose any proprietary information, including trade secrets, and we may not be able to obtain adequate remedies for such breaches. Further, third
parties may still obtain this information by other means, such as breaches of our physical or computer security systems. Enforcing a claim that a party illegally disclosed or misappropriated a trade
secret is difficult, expensive and time-consuming, and the outcome is unpredictable. Moreover, third parties may come upon this or similar information lawfully and independently. We would have no
right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Further, intellectual property rights have limitations and do not necessarily
address all potential threats to our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, our business may be harmed. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a
number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. In particular, under the
Leahy-Smith Act, the United States transitioned in March 2013 to a "first inventor to file" system in which the first inventor to file&nbsp;a patent application will be entitled to the patent. Third
parties are allowed to submit prior art before the issuance of a patent by the USPTO, in which case a patent may become subject to post-grant proceedings including opposition, derivation,
reexamination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in
any such submission, proceeding or litigation could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Claims by third parties that we infringe their proprietary rights may result in liability for damages or
prevent or delay our developmental and commercialization efforts.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S.
and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands
and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained
in secrecy until the application is published, we may be unaware of third party patents that may be infringed by commercialization of MGL-3196 or our other product candidates. Moreover, because patent
applications can take many years to issue, there may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=141360,FOLIO='41',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_42"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>currently-pending
patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third party patent rights that may be relevant to
our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims.
Any claims of patent infringement asserted by third parties would be time consuming and could likely:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> result in costly litigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> divert the time and attention of our technical personnel and management; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> cause development delays; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prevent us from commercializing MGL-3916 for NASH or FH or our other product candidates until the asserted patent expires or is held finally
invalid or not infringed in a court of law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> require us to enter into royalty or licensing agreements. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
no third party has asserted a claim of patent infringement against us as of the filing date of this report, others may hold proprietary rights that could prevent MGL-3196 or our
other product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes
could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market MGL-3196 or our other product candidates. We cannot predict whether we would
prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could
redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary
licenses,
could prevent us from developing and commercializing MGL-3196 or our other product candidates, which could harm our business, financial condition and operating results. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
we may be subject to a third party preissuance submission of prior art to the USPTO or in addition to interference proceedings, may become involved in opposition, derivation,
reexamination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, post-grant review or other post-grant proceedings challenging our patent rights or the patent rights of others. An
adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and
compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or
strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future
product candidates. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or any of our future development partners were to initiate legal proceedings against a third party to enforce a patent directed at one of
our product candidates, or one of our future product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=637732,FOLIO='42',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_43"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>with
prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even
outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability,
we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interference
proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or
patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our
business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful,
may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise
the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring
our product candidates to market. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be successful in obtaining or maintaining necessary rights to our product candidates through
acquisitions and in-licenses.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have the intellectual property rights, through licenses from third parties and under patents that we own, to develop our product
candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these
proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be
unable to acquire or in-license any compositions, methods of use, processes, or other third party intellectual property rights from third parties that we identify as necessary for our product
candidates. The licensing and acquisition of third party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or
acquire third party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater
clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license
or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may collaborate with U.S. and foreign academic institutions and industry collaborators to accelerate our preclinical or clinical research. Typically, these institutions provide us
with an option to negotiate a license to any of the institution's rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the
specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability
to pursue our program. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=45,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=144773,FOLIO='43',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon
development of that program and our business and financial condition could suffer. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a
competitor will discover them or that our trade secrets will be misappropriated or disclosed.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we rely on third parties to research and develop and to manufacture our product candidates, we must, at times, share trade secrets with
them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar
agreements with our advisors, employees, third party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the
third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets
and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in
violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor's discovery of our trade secrets or other unauthorized use or
disclosure would impair our competitive position and may have a material adverse effect on our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, these agreements typically restrict the ability of our advisors, employees, third party contractors and consultants to publish data potentially relating to our trade
secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will usually expect to be granted
rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure
patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. In the
future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts
to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any
of our third party collaborators. A competitor's discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be
infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of
interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there
could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks
or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be
adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could
result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=46,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=160041,FOLIO='44',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_45"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to protect our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we have licensed from Roche issued composition-of-matter patents directed at MGL-3196 in the United States and other countries, filing,
prosecuting and defending patents on MGL-3196 in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States
can be less extensive than those in the United States. In addition, the laws of some foreign countries may not protect intellectual property rights to the same extent as federal and state laws in the
United States. Consequently, we may not be able to prevent third parties from practicing their inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products
and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with
MGL-3196, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain
developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to
stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result
in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at
risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be
commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Capital  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully develop
and commercialize MGL-3196 and other future product candidates.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we believe that our existing cash and cash equivalents will be sufficient to fund our current operations through at least the next
12&nbsp;months, we will require substantial future working capital in order to complete the remaining clinical development for MGL-3196 and our other product candidates through potential regulatory
approval and through potential commercialization of these product candidates. In particular, in order to initiate our Phase&nbsp;3 clinical program for MGL-3196 in NASH, we will need to collaborate
with a strategic partner or raise significant financing. We expect our spending levels to increase in connection with our clinical trials of MGL-3196 as well as other corporate activities. The amount
and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the type, number, scope, progress, expansion costs, results of and timing of our ongoing or future clinical trials or the need for additional
clinical trials of MGL-3196 for NASH and FH or any of our other product candidates which we are pursuing or may choose to pursue in the future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=47,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=691521,FOLIO='45',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_46"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of obtaining regulatory approval for MGL-3196 for NASH and FH and any of our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of obtaining or maintaining manufacturing for MGL-3196 for NASH and FH and any of our other product candidates, including
commercial manufacturing if any product candidate is approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs and timing of establishing sales, marketing and reimbursement capabilities and enhanced internal controls over financial reporting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms and timing of establishing and maintaining collaborations, license agreements and other partnerships; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs associated with any new product candidates that we may develop, in-license or acquire; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the effect of competing technological and market developments; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the costs associated with operating as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some
of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and
commercialization of our product candidates. We expect that we will need to raise substantial additional funds in the future. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through future debt and
equity financings, as well as potential additional collaborations or strategic partnerships with other companies or through non-dilutive financings. Additional funding may not be available to us on
acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. In addition, the issuance of additional shares by us, or the
possibility of such issuance, may cause the market price of our shares to decline. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to obtain additional funding on a timely basis, we may be unable to complete ongoing and planned clinical trials for MGL-3196 for NASH and FH and any of our other
product candidates, and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise
that may require us to relinquish rights to our product candidates or otherwise agree to terms unfavorable to us. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce
future tax payments may be limited by provisions of the Internal Revenue Code.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our net operating losses have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax
benefits. Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change" (generally defined as a greater than 50% change (by value) in its
equity ownership over a three year period), the corporation's ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be
limited. Similar rules may apply under state tax laws. We have not performed a detailed analysis to determine whether an ownership change under Section&nbsp;382 of the Code, or similar state
provisions, has previously occurred. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may become
subject to limitations, which could potentially result in increased future tax liability to us and may be substantial. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=48,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=216953,FOLIO='46',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_47"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Relating to Ownership of Our Common Stock  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock has been, and may continue to be, volatile.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, the market price of our common stock has fluctuated over a wide range, and it is likely that the price of our common stock will
continue to be volatile in the future. The market price of our common stock could be impacted due to a variety of factors, including, in addition to global and industry-wide
events:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the losses we may incur; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developments in patent or other proprietary rights owned or licensed by us, our collaborative partners or our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> public concern as to the safety and efficacy of products developed by us or others; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> litigation. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors.
In that event, the market price of our common stock could materially decline. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A small number of our stockholders beneficially own a substantial amount of our common stock and have
substantial control over us; therefore, your ability to influence corporate matters may be limited.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain stockholders affiliated with our officers and directors collectively beneficially own or control approximately 52.4% of our outstanding
common stock as of December&nbsp;31, 2016 and acting together, may have the ability to affect matters submitted to our stockholders for approval. This concentration of ownership may have the effect
of delaying, deferring or preventing a strategic transaction, even if such a transaction would benefit other stockholders. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our
company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions in our charter and bylaws may delay or prevent a merger, acquisition or other change of control that stockholders may consider
favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include a classified board of directors. In addition, we are governed by the
provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or
combining with us. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would
apply even if the offer may be considered beneficial by some stockholders. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future sales and issuances of our common stock or rights to purchase common stock could result in additional
dilution of the percentage ownership of our stockholders and could cause our share price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional
capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities
or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than
one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to
our existing stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=49,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=724115,FOLIO='47',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dc40801_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a substantial number of shares of our common stock by our existing stockholders in the public market
could cause our stock price to fall.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could
significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not anticipate paying cash dividends on our common stock, and accordingly, stockholders must rely on
stock appreciation for any return on their investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividend on our common stock and do not anticipate paying cash dividends on our common stock in the
future. As a result, the only return to stockholders will be appreciation in the price of our common stock, which may never occur. Investors seeking cash dividends should not invest in our common
stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Stockholders' Sales of Shares, Including Those Issued under the Securities Purchase
Agreement  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a significant number of shares of our common stock in the public markets or significant short sales
of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital.  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock or other equity-related securities in the public markets, could depress the market
price of our common stock. If there are significant short sales of our stock, the price decline that could result from this activity may cause the share price to decline further, which, in turn, may
cause long holders of the common stock to sell their shares, thereby contributing to sales of common stock in the market. Such sales also may impair our ability to raise capital through the sale of
additional shares in the future at a time and price that our management deems acceptable, if at all. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to maintain effectiveness of the registration statement of which this prospectus
forms&nbsp;a part, which could impact the liquidity of our common stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Securities Purchase Agreement with the initial Investors, we are obligated to include the shares of common stock issued
under the Securities Purchase Agreement in an effective registration statement. The registration statement of which this prospectus forms&nbsp;a part is intended to satisfy that obligation. We
cannot assure you that we will not be required to suspend or cease sales under the registration statement, that the SEC will not issue any stop order to suspend the effectiveness of the registration
statement or that, if such a stop order is issued, we will be able to amend the registration statement to respond to the stop order to permit sales to be made under the registration statement in a
timely manner or at all. To the extent the registration statement is not effective, the selling stockholders' ability to sell the shares of common stock may be limited, which could (depending on the
extent of the selling stockholders' selling activity) have a material adverse effect on the liquidity of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=50,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=54535,FOLIO='48',FILE='DISK112:[17ZCE1.17ZCE40801]DC40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de40801_1_49"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de40801_use_of_proceeds"> </A>
<A NAME="toc_de40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All proceeds from the disposition of the common shares covered by this prospectus will go to the selling stockholders. We will not receive any
proceeds from the disposition of the common stock by the selling stockholders. See "Plan of Distribution." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders will pay any underwriting discounts and commissions and expenses incurred by the selling stockholders for brokerage, accounting, tax or legal services or any
other expenses incurred by the selling stockholders in disposing of the shares. We will bear the costs, fees and expenses incurred to effect the registration of the shares covered by this prospectus,
including all registration and filing fees, Nasdaq listing fees and fees and expenses of counsel and our independent registered public accounting firm. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=51,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=824170,FOLIO='49',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_50"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de40801_selling_stockholders"> </A>
<A NAME="toc_de40801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to the offering by the selling stockholders of up to 328,300 shares of common stock, comprised of: (i)&nbsp;an
aggregate of 98,490 shares of our common stock held by Adage Capital Partners,&nbsp;L.P., which were issued by us on June&nbsp;23, 2017 pursuant to the Securities Purchase Agreement;
(ii)&nbsp;an aggregate of 131,320 shares of our common stock held by Armistice Capital Master Fund&nbsp;Ltd., which were issued by us on June&nbsp;23, 2017 pursuant to the Securities Purchase
Agreement; and (iii)&nbsp;an aggregate of 98,490 shares of our common stock held by Rock Springs Capital Master Fund&nbsp;LP, which were issued by us on June&nbsp;23, 2017 pursuant to the
Securities Purchase Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth, based on information provided to us by the selling stockholders or known to us, the name of the selling stockholders and the number of shares of our
common stock beneficially owned by the selling stockholders before this offering. The number of shares owned are those beneficially owned, as determined under the rules of the SEC, and the information
is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares of common stock as to which a person has sole or shared voting
power or investment power and any shares of common stock which the person has the right to acquire within 60&nbsp;days through the exercise of any option, warrant or right, through conversion of any
security or pursuant to the automatic termination of a power of attorney or revocation of a trust, discretionary account or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the selling stockholders has held any position or office or had any other material relationship with us or any of our predecessors or affiliates within the past three years other
than as a result of the ownership of our securities. None of the selling stockholders is a broker-dealer or affiliate of a broker-dealer. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration of such shares does not necessarily mean, however, that any of these shares will be offered or sold by the selling stockholders. The selling stockholders may from time
to time offer and sell all or a portion of their shares in the over-the-counter market, in negotiated transactions, or otherwise, at market prices prevailing at the time of sale or at negotiated
prices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have assumed all shares of common stock reflected on the table will be sold from time to time in the offering covered by this prospectus. Because the selling stockholders may offer
all or any portions
of the shares of common stock listed in the table below, no estimate can be given as to the amount of those shares of common stock covered by this prospectus that will be held by the selling
stockholders upon the termination of the offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de40801_selling_stockholders__table_1"> </A>
<A NAME="toc_de40801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  <U>SELLING STOCKHOLDERS' TABLE</U>  <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned Prior<BR>
to Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares<BR>
Offered </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Beneficially<BR>
Owned After Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adage Capital Partners,&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>600,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,490</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>501,510</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Armistice Capital Master Fund&nbsp;Ltd.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>251,320</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>131,320</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rock Springs Capital Master Fund&nbsp;L.P.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>538,790</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98,490</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>440,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Total</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,390,110</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>328,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,061,810</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
on 12,495,705 shares of our common stock outstanding on June&nbsp;30, 2017 (including the outstanding shares of common stock offered by this prospectus). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=52,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=90783,FOLIO='50',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_51"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de40801_plan_of_distribution"> </A>
<A NAME="toc_de40801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are registering the shares of common stock to permit the resale of these shares of common stock by the selling stockholders from time to time
after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock. We will bear all fees and expenses incident to our
obligation to register the shares of common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may sell all or a portion of the shares of common stock beneficially owned by them and offered hereby from time to time directly or through one or more
underwriters, broker-dealers or agents. If the shares of common stock are sold through underwriters or broker-dealers, then the selling stockholders will be responsible for underwriting discounts or
commissions or agents' commissions. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices
determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, by one or more of the following methods: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the over-the-counter market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in transactions otherwise than on these exchanges or systems or in the over-the-counter market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through the writing of options, whether such options are listed on an options exchange or otherwise; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
principal to facilitate the transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an exchange distribution in accordance with the rules of the applicable exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> privately negotiated transactions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> short sales as permitted by applicable law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sales pursuant to Rule&nbsp;144; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a combination of any such methods of sale; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other method permitted pursuant to applicable law. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the selling stockholders effect such transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents
may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of common stock for whom they may act as agent
or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of
transactions involved). In connection with sales of the shares of common stock or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers as permitted by applicable
law, which may in turn engage in short sales of the shares of common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of common stock short as
permitted by applicable law and deliver shares of common stock covered by this prospectus to close out short positions and to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=53,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=426944,FOLIO='51',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>return
borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of common stock to broker-dealers that in turn may sell such shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders may pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or any amendment to this prospectus under Rule&nbsp;424(b)(3)
or other applicable provision of the Securities Act, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders
under this prospectus. The selling stockholders also may transfer and donate the shares of common stock in other circumstances in which case the transferees, donees, pledgees or other successors in
interest will be the selling beneficial owners for purposes of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders and any broker-dealer participating in the distribution of the shares of common stock may be deemed to be "underwriters" within the meaning of the Securities
Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a
particular offering of the shares of common stock is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of shares of common stock being offered
and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any
discounts, commissions or concessions allowed or reallowed or paid to broker-dealers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the
shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
can be no assurance that any selling stockholder will sell any or all of the shares of common stock registered pursuant to the registration statement, of which this prospectus
forms&nbsp;a part. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
selling stockholders and any other person participating in such distribution will be subject to applicable provisions of the Securities Exchange Act of 1934, as amended, or the
Exchange Act and the rules and regulations thereunder, including, without limitation, Regulation&nbsp;M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of
common stock by the selling stockholders and any other participating person. Regulation&nbsp;M may also restrict the ability of any person engaged in the distribution of the shares of common stock
to engage in market-making activities with respect to the shares of common stock. All of the foregoing may affect the marketability of the shares
of common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay all expenses of the registration of the shares of common stock pursuant to the registration rights agreement, including, without limitation, SEC filing fees and expenses of
compliance with state securities or "blue sky" laws; provided, however, that a selling stockholder will pay all underwriting discounts and selling commissions, if any. We will indemnify the initial
selling stockholders against liabilities, in accordance with the Securities Purchase Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
sold under the registration statement, of which this prospectus forms&nbsp;a part, the shares of common stock will be freely tradable in the hands of persons other than our
affiliates. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=54,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=603122,FOLIO='52',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_53"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de40801_description_of_capital_stock"> </A>
<A NAME="toc_de40801_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of all material characteristics of our capital stock as set forth in our restated certificate of incorporation, our
restated bylaws and our Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;A Convertible Preferred Stock. The summary does not purport to be complete and is qualified
in its entirety by reference to our certificate of incorporation and bylaws, copies of which have been filed as exhibits to our previous SEC filings. For more information, see the sections entitled
"Incorporation of Certain Documents by Reference" and "Where You Can Find More Information." </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of Common Stock  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share. The following summary of certain provisions of our
common stock does not purport to be complete. You should refer to our restated certificate of incorporation and our restated bylaws, both of
which have been filed with the SEC. The summary below is also qualified by provisions of applicable law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, and do
not have cumulative voting rights. Subject to preferences that may be applicable to any outstanding shares of preferred stock, holders of common stock are entitled to receive ratably such dividends,
if any, as may be declared from time to time by our board of directors out of funds legally available for dividend payments. The holders of common stock have no preferences or rights of conversion,
exchange, pre-emption or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock. In the event of any liquidation, dissolution or winding-up of our
affairs, holders of common stock will be entitled to share ratably in our assets that are remaining after payment or provision for payment of all of our debts and obligations and after liquidation
payments to holders of outstanding shares of preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


NASDAQ Global Market  </B></FONT></P>

</UL>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed for quotation on The NASDAQ Global Market under the symbol "MDGL." </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of Preferred Stock  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are authorized to issue 5,000,000 shares of preferred stock, par value $0.0001 per share. As of July&nbsp;23, 2017, we had 1,969,797 shares
of preferred stock, designated Series&nbsp;A Convertible Preferred Stock, outstanding held by two stockholders of record. No other shares of our preferred stock were outstanding or designated. The
following summary of certain provisions of our preferred stock does not purport to be complete. You should refer to our restated certificate of incorporation, our restated bylaws and our Certificate
of Designation of Preferences, Rights and Limitations of Series&nbsp;A Convertible Preferred Stock, each of which have been filed with the SEC. The summary below is also qualified by provisions of
applicable law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, without further action by our stockholders, from time to time, direct the issuance of shares of preferred stock in
series and may, at the time of issuance, determine the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=55,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=244625,FOLIO='53',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>rights,
preferences and limitations of each series, including voting rights, dividend rights and redemption and liquidation preferences. Satisfaction of any dividend preferences of outstanding shares
of preferred stock would reduce the amount of funds available for the payment of dividends on shares of our common stock. Holders of shares of preferred stock may be entitled to receive a preference
payment in the event of any liquidation, dissolution or winding-up of our company before any payment is made to the holders of shares of our common stock. In some circumstances, the issuance of shares
of preferred stock may render more difficult or tend to discourage a merger, tender offer or proxy contest, the assumption of control by a holder of a large block of our securities or the removal of
incumbent management. Upon the affirmative vote of our board of directors, without stockholder approval, we may issue shares of preferred stock with voting and conversion rights which could adversely
affect the holders of shares of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Convertible Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of the Series&nbsp;A Convertible Preferred Stock is convertible into shares of the common stock at any time at the holder's option
at a one-to-one ratio, subject to adjustment. The holder, however, will be prohibited from converting shares of the Series&nbsp;A Convertible Preferred Stock into shares of our common stock if, as a
result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of our common stock or any other class of any equity security of ours (other than an
exempted security) that is registered pursuant to Section&nbsp;12 of the Securities Exchange Act of 1934, which may be increased or decreased to any other percentage at the holder's election on
61&nbsp;days' notice delivered to the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
our liquidation, dissolution or winding-up, whether voluntary or involuntary, after the satisfaction in full of our debts and the payment of any liquidation preference owed to the
holders of shares of our capital stock ranking prior to the Series&nbsp;A Convertible Preferred Stock upon liquidation, the holders of the Series&nbsp;A Convertible Preferred Stock shall
participate </FONT><FONT SIZE=2><I>pari passu</I></FONT><FONT SIZE=2> with the holders of our common stock (on an as-if-converted-to-common-stock basis) in our net assets. Shares of the
Series&nbsp;A Convertible Preferred Stock will generally have no voting rights, except as required by law. Shares of the Series&nbsp;A Convertible Preferred Stock will be entitled to receive
dividends before shares of any other class or series of our capital stock (other than dividends in the form of our common stock) equal to the dividend payable on each share of our common stock, on an
as-converted basis. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Provisions of our Certificate of Incorporation and Bylaws  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to the board of directors' ability to issue shares of preferred stock, our restated certificate of incorporation and restated bylaws
contain other provisions that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors and which may have the effect of delaying, deferring or
preventing a future takeover or change in control of our company unless such takeover or change in control is approved by our board of directors. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking
to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly
or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Classified board of directors; removal of directors for cause.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws provide
for our board of
directors to be divided into three classes serving staggered terms. At each annual meeting of stockholders, directors elected to succeed those directors whose terms have expired are elected for a
three-year term of office. All directors elected to our classified board of directors will serve until the election and qualification of their respective </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=56,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=48175,FOLIO='54',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>successors
or their earlier resignation or removal. The board of directors is authorized to create new directorships and to fill such positions so created and is permitted to specify the class to
which any such new position is assigned. The person filling such position would serve for the term applicable to that class. The board of directors (or its remaining members, even if less than a
quorum) is also empowered to fill vacancies on the board of directors occurring for any reason for the remainder of the term of the class of directors in which the vacancy occurred. Members of the
board of directors may only be removed for cause and only by the affirmative vote of 80% of our outstanding voting stock. These provisions are likely to increase the time required for stockholders to
change the composition of the board of directors. For example, in general, at least two annual meetings will be necessary for stockholders to effect a change in a majority of the members of the board
of directors. The provision for a classified board could prevent a party who acquires control of a majority of our outstanding common stock from obtaining control of our board of directors until our
second annual stockholders meeting following the date the acquirer obtains the controlling stock interest. The classified board provision could have the effect of discouraging a potential acquirer
from making a tender offer or otherwise attempting to obtain control of us and could increase the likelihood that incumbent directors will retain their positions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advance notice provisions for stockholder proposals.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated bylaws establish an advance notice procedure for stockholder
proposals to be
brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors, as well as procedures for including proposed nominations at
special meetings at which directors are to be elected. Stockholders at our annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by
or at the direction of our board or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given to our secretary
timely written notice, in proper form, of the stockholder's intention to bring that business before the meeting, and who has complied with the procedures and requirements set forth in the bylaws.
Although our bylaws do not give our board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or
annual meeting, our bylaws may have the effect of precluding the conduct of some business at a meeting if the proper procedures are not followed or may discourage or defer a potential acquirer from
conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Special meetings of the stockholders may be called only by our board of directors pursuant to a
resolution adopted
by a majority of the total number of authorized directors. Stockholders are not permitted to call a special meeting or to require our board of directors to call a special meeting. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No stockholder action by written consent.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our restated certificate of incorporation and restated bylaws do not permit our stockholders
to act by
written consent. As a result, any action to be effected by our stockholders must be effected at a duly called annual or special meeting of the stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-majority stockholder vote required for certain actions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law, or DGCL, provides generally that
the affirmative
vote of a majority of the shares entitled to vote on any matter is required to amend a corporation's certificate of incorporation or bylaws, unless the corporation's certificate of incorporation or
bylaws, as the case may be, requires a greater percentage. Our restated certificate of incorporation requires the affirmative vote of the holders of at least 80% of our outstanding voting stock to
amend or repeal certain provisions of our restated certificate of incorporation. This 80% stockholder vote would be in addition to any separate class vote that might in the future be required pursuant
to the terms of any preferred stock that might then be outstanding. In addition, an 80% vote is also required for any amendment to, or repeal of, our restated bylaws by the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=57,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=800911,FOLIO='55',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_de40801_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>stockholders.
Our restated bylaws may be amended or repealed by a vote of a majority of the total number of authorized directors. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Delaware Law Governing Business Combinations  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to the "business combination" provisions of Section&nbsp;203 of the DGCL. In general, such provisions prohibit a publicly held
Delaware corporation from engaging in any
"business combination" transactions with any "interested stockholder" for a period of three years after the date on which the person became an "interested stockholder,"
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> prior to such date, the board of directors approved either the "business combination" or the transaction which resulted in the "interested
stockholder" obtaining such status; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> upon consummation of the transaction which resulted in the stockholder becoming an "interested stockholder," the "interested stockholder" owned
at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding
voting stock owned by the "interested stockholder") those shares owned by (a)&nbsp;persons who are directors and also officers and (b)&nbsp;employee stock plans in which employee participants do
not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at or subsequent to such time the "business combination" is approved by the board of directors and authorized at an annual or special meeting
of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the outstanding voting stock which is not owned by the "interested stockholder." </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
"business combination" is defined to include mergers, asset sales and other transactions resulting in financial benefit to a stockholder. In general, an "interested stockholder" is a
person who, together with affiliates and associates, owns 15% or more of a corporation's voting stock or within three years did own 15% or more of a corporation's voting stock. The statute could
prohibit or delay mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=58,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=769304,FOLIO='56',FILE='DISK112:[17ZCE1.17ZCE40801]DE40801A.;8',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg40801_1_57"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg40801_legal_matters"> </A>
<A NAME="toc_dg40801_1"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain legal matters, including the validity of the issuance of the shares of common stock offered by this prospectus will be passed upon for
us by Stradling Yocca Carlson&nbsp;&amp; Rauth, P.C. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg40801_experts"> </A>
<A NAME="toc_dg40801_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements as of December&nbsp;31, 2016 and for the year ended December&nbsp;31, 2016 incorporated in this Prospectus by
reference to the Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 have been so incorporated in reliance on the report of
PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements as of December&nbsp;31, 2015 and for the year ended December&nbsp;31, 2015 incorporated in this Prospectus by reference to the Annual Report on
Form&nbsp;10-K for the year ended December&nbsp;31, 2016 have been so incorporated in reliance on the report of Friedman&nbsp;LLP, an independent registered public accounting firm, given on the
authority of said firm as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=59,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=583850,FOLIO='57',FILE='DISK112:[17ZCE1.17ZCE40801]DG40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dg40801_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg40801_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_dg40801_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate" into this prospectus information that we file with the SEC in other documents. This means that we can
disclose important information to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus is considered part of this
prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
contained in this prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies and supersedes
previously filed information, including information in previously filed documents or reports that have been incorporated by reference in this prospectus, to the extent the new information differs from
or is inconsistent with the old information. Any information so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following documents previously filed by us with the SEC are incorporated in this prospectus by reference:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;31, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2017, filed with the SEC on May&nbsp;11, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Definitive Proxy Statement on Schedule&nbsp;14A, filed with the SEC on April&nbsp;28, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K filed with the SEC on March, 31, 2017, June&nbsp;1, 2017, June&nbsp;21, 2017, and July&nbsp;5,
2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our common stock set forth in the Registration Statement on Form&nbsp;8-A filed with the SEC on January&nbsp;1, 2007
(the "Form&nbsp;8-A"), as well as the description of our common stock set forth on pages&nbsp;123 through 125 of the Registration Statement on Form&nbsp;S-1, as amended (Registration
No.&nbsp;333-138894), which was originally filed with the SEC on November&nbsp;22, 2006 (which description is incorporated by reference into the description of our common stock set forth in the
Form&nbsp;8-A), and any other amendment or report filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents filed by us pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date the initial registration statement is
initially filed and prior to the termination of this offering, provided that nothing in this prospectus shall be deemed to incorporate portions of documents or information "furnished" and not "filed"
with the SEC. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus or any accompanying prospectus supplement. We have not authorized anyone to provide you
with different information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should not assume that the information contained in this prospectus and any accompanying prospectus supplement is correct on any date after their respective dates, even though this
prospectus or any prospectus supplement is delivered or securities are sold on a later date. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will provide to each person, including any beneficial owner, to whom a prospectus is delivered, upon oral or written request, a copy of any document incorporated by reference at no
cost. Requests should be made to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Marc
R. Schneebaum<BR>
Chief Financial Officer<BR>
Madrigal Pharmaceuticals,&nbsp;Inc.<BR>
Four Tower Bridge<BR>
200 Barr Harbor Drive, Suite&nbsp;400<BR>
West Conshohocken, Pennsylvania 19428<BR>
(484)&nbsp;380-9263 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=60,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=28698,FOLIO='58',FILE='DISK112:[17ZCE1.17ZCE40801]DG40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<A NAME="page_dg40801_1_59"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg40801_where_you_can_find_more_information"> </A>
<A NAME="toc_dg40801_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read, without charge, and copy the
documents we file at the SEC's public reference rooms in Washington, D.C. at 100&nbsp;F Street, NE, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public
reference rooms. Our SEC filings are also available to the public at no cost from the SEC's website at http://www.sec.gov. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus constitutes a part of a registration statement on Form&nbsp;S-3 filed under the Securities Act. As permitted by the SEC's rules, this prospectus and any accompanying
prospectus supplement, which form&nbsp;a part of the registration statement, do not contain all the information that is included in the registration statement. You will find additional information
about us in the registration statement. Any statements made in this prospectus or any prospectus supplement concerning legal documents are not necessarily complete and you should read the documents
that are filed as exhibits to the registration statement or otherwise filed with the SEC for a more complete understanding of the document or matter. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=61,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=506704,FOLIO='59',FILE='DISK112:[17ZCE1.17ZCE40801]DG40801A.;6',USER='CHE105137',CD='13-JUL-2017;20:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bG40801a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>328,300 Shares  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>
<IMG SRC="g467069.jpg" ALT="LOGO" WIDTH="337" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Madrigal Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>July&nbsp;25, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=62,EFW="2232779",CP="MADRIGAL PHARMACEUTICALS, INC",DN="1",CHK=825932,FOLIO='blank',FILE='DISK112:[17ZCE1.17ZCE40801]HO40801A.;8',USER='CHE109859',CD='25-JUL-2017;20:36' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g467069.jpg
<DESCRIPTION>G467069.JPG
<TEXT>
begin 644 g467069.jpg
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M>*&V&#8W87)V@;&UMR21L[C'T1DG*#,U0D-'4F7P_\0 '0$  @(" P$
M        !@<%"  $ @,) ?_$ #X1  (# 0 !! $" P0&!PD   ,$ 0(%!@<
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M%V"I([JOR 4N$>>%A6V6L9REGZCCWYTK"?NLV5(4O.<^/">\T=Z;B.8K3-)
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M[CT.+=P18XTY$?,C,MI]:/43M"U3XCBVD8]Q@-E2_5[?JS7+P+R13>5O;5%
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MJW+-SBN!L<*LA,=JM[' =9BP)^1-3QCY,[:W=:GB[R:JA'0JIV?S=;.'00-
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M#CGSSV62$'(6OWDD)SGIC<#V3/BRO9YSV"?6OOX.8&Y5&X$'.%H9Y'%#GO\
MBL5O]@-0,R.;!^-Z7'\YM^\+CR'Q2GE>>)?2W@Y%,#H-%H06U?L/I%0T *L@
M /\ )#:OP+F%]KU^WW'>E_A$>\>I*9QG*?M_^6,_[,+\Y_5_FQG^?KG9[@)Y
M4]M3GW?=GRT @?9,-LW9=BIUXVA34VRI["AKG,RA+%UAI*20(!*E2\++,K=E
M(*4$GJW(D&1;KD68R0'CHG__ -_+_NZK'LO=+X&L<E;MQ*V3L2#KMMHQT9%F
M62^QT>UJ4^XNM^[)T\6ZFN%PL9:*NZL<.738D0@'U5UR'CI,V5CY$,75\/\
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36>L]'1T='6>L]'1T='6>L]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g81786.jpg
<DESCRIPTION>G81786.JPG
<TEXT>
begin 644 g81786.jpg
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M%)4B<E%ON)OJDD.*W8VR\R\RC3.1TXU.-2K\HPAM:4N.S*&4NM,M%3B%*71
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M00>0E\,?!6:?:X.(!XE>T?L'R%\A4[7!Q /$KVC]@^0OD*O6"W+#  %LV50
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MJJJ&*6K;?N97/[[GQ6<@ Y[\8JF#R#P4E/+"/[*FRC<V5$NU[Y!VNL=27VX
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MEA"$+;=4M+A;;6X%+0E0ZK5J92LE12E\WG5OT<D4.)#RW Z7$I6RH)7?J0H
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M[7MEC>W<O;*U^5[7M?N7M>UKVOW+VI2$*4I2$*4I2$*4I2$*4I2$58'S$/\
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M 8,G$T/! DB.1420$IU$%%-2DU2,9%%-J*Q- 7R0UL)N*-,--*"HKB: TK4
MDC$BF(A?34BN@T.!I4"I%:4J :D5J(D!I5B)SG$M"#HUX;)QKGG$)L#L4@:]
MDCI92 2PVJ=76B^G9@ZCH)DD:R5R14-D#$<T@J(2-"B*01C$[A@5$"&OMC?I
M8XY>5TK6OR^[;G44( .HZ/HPB:@DC6,#T5^XQ^TI2HB84I2D(4I2D(4I2D(4
MI2D([4TOLX7_ %;_ &ZE5?ZK -/N'1K^=9-_MU*K3;XU/&:WUUWWQG76"()%
M;#-B^-CT7J#8NG,W$)WVS<41M)RJI94=199*FU(@,L.-2,8%!"X88>.)$/\
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M)AR 4YXJD6M2%)1@B0VP93$0H[#(R9 F&15O- R$IJ:5;$!33K%RAU<ZN,;
MR N9P)F,QLL,;!:1<Q!H34W*4%$TU8$$$85KB:U,5*%'.8%-0FE%8D@DD\(@
M@U^-VL0 8C(XBLH(^/$+5HFVOV1G[5S5U+U5,OC6T]![P>\>8R9L<9=1M.6P
M\U5@I9Y0?3Y;8>(:<SXV/Y7)J0Y=-(AE0[+>0A_ 5#W@V>VW:'#@@]QVVID\
MV\X>V'=DOM/5E\)$0SAL8\(DDAW1HQAW)(V:@@EV0WD-&:MW4_3=SX0"HO\
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MTYL:LF,>+4':QY&2<6LB0X <"S*)=@:D*YA!U@54-\G)+:)B./)(^6@H20D
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M J1<Y=/!4"MS&%R>47%5 IBHT&(.N[7"II70=>JL3?30FN@5XL"*BE:5-/\
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M[>]_*M;S[U^\LK7Z-\<K9<K7Z-\;VRY7MSM>V-[<[VO;NVORY7^U4=&Z^U:
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M3&^L7:J"\IL8#->"Q9/=28L-\6Y-I+JT-813338!6^'774^F#CE;/X'S$/\
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MW[9QQ8>Y:]_X4496\JWG_6Y=RO?4^'.ZBI\P7MQ.N+!GU*X5NE;9Z, [7Z8
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M(#^^A^;)O_QX_P P)?TU&7VNYU^B<<6'VT,9?1RKWLN'.ZK)@1KMG7%A_?*
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M4J(M"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A"E*4A%63OL1;^]H7]J)U4FJXC
M"&@U4L#;&XQ@D7 "MEET<;B"JR;AA;++E?HVOEE:U[\K\K=VJMY G)W@GZ\Q
M^+JX0M0!2DD 8T&TQCOH2I04H E0.)I\5,=-I7<O($Y.\$_7F/Q=/($Y.\$_
M7F/Q=3FG>0KHAG6N6GICIM*[EY G)W@GZ\Q^+IY G)W@GZ\Q^+IFG>0KHAG6
MN6GICIM*[EY G)W@GZ\Q^+IY G)W@GZ\Q^+IFG>0KHAG6N6GICIM*[EY G)W
M@GZ\Q^+IY G)W@GZ\Q^+IFG>0KHAG6N6GICIM*[EY G)W@GZ\Q^+IY G)W@G
MZ\Q^+IFG>0KHAG6N6GICI>?^)E_FY?[KU6%WS7/?YQ?W&6K@LHI]$R#!4, L
M!!P1!0[!"V%M?#"_0RZ5[8X\K\[VY6[O.W=KFN^:Y[_.+^XRU004I4"""%(J
M#IQ"S]T2"%*20:@I50CMHBDTI2J1>%*4I"%*4I"%*4I"*L@^;27_ %P+_G5(
MQ\JWW+?[JJZ#YM)?]<"_YU2,?*M]RW^ZIU#MG[DQ4<-7<I^]<?M*4J(M"E*4
MA"E*4A"E*4A"JKGYA ??DW[@)52JJN?F$!]^3?N E4C0KM>4157Q>Z'EBE4I
M2HBT*4I2$*4I2$*4I2$6%VK_ (*^TGX,>QGZ$WY6G36XMM7_  5]I/P8]C/T
M)ORM.FMZ5X"NZ\@C1FN&GN?*8V.N!O\ Q0?#U^W_ -7DM^D*0//J\,Q[SJ,*
M/E 9#BTZVS6\7S*N$-Q>ZVRGP28:\I/4TF+2VE%F@*JS>E+(!-:1FZMJB<9=
M2.V^19/%P/8$S.8)<6SW W_B@^'I^#R5_2%(%7,WJZ%I*X:?2Z%KY\1N,\;=
M*^-KYWO"L[WZ.//E?+*]K<^C;G>]K7OR[EZUC3.J!%14ZR-5=7M3;C&R"0VD
M@TX(T"F*@,=FF+Y1_LTF.][HL;NZ+91A1\*T0.B;3#?EG!@D!$!EM>3TR*\L
MU]3:;Y=B&4/K2PKD5A&#!5#)3- $ZJH&T]4Z*7EDOSQZ71Z6/3N'B);'I8].
MX6?=P%MASZ=PA+<KABVMU/.U[7PRO4:4J0E$DY\2*+6W,3";DEME%T1>RV59
MKQ*W6F>=4S.T#*1,3R\T3 MT)S7($E$YV(#<*>IE$=1,75DX NKA%CH$>:3(
MM],M>]6]T$)"6W"U(,E[??3YU--*'4%D42(GU/,R%M<6D!B9'.FA$9C3E&$7
MLYOX#C#XM]%=AHH%G@5M<*HN!5 DF\0,*8$D$@ UV4QUD0OE-Z]B 3C7&@*
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M741,^5^7$,Z2&.&DX$Z2&42 8(Q].".E15$@$8Y=;BGT\,;(Z1",<[=;BFP
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M.404DR9'.FBY"6&R?/YX!#DPL,PRY$L8''MEET;!!Y6O:][VQRULN%KQ3'C
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M!$:+3@V/6W6@+GU5HV<F*8*,OPCY!EURJ"5&[@!2GXA*[/*9&&NH&E47!FU
MDI.C '1Q XX@4KQUUIK0D,XA0 .-14C548TH:'5HIQ Z0#-6(  *9P."@ "G
M0\3& 9T4 $0X%@;RPS-AA&\@[F 0S>8069H((3 ,SD$%<? 2X0?0H(K.9XSE
M >@S0:0SS*EK$RKR&:S?%>!4GB (5Q*%G6(FY.$N5Q*BBE<2X*D&#B5%$+8X
M6 SS#O&5/VR^T.F[%-!S*YX;?WU1YAAJ)X%GXK&#L;B<G#OU/=JS+2C+&O\
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MC"!(&9R"7#;N&.:RXD=;W,Y4<T==@1K%\ FI2S((J<5CXYDU!#3A,8 Y6S=
M<<17BU)2HZ2"10D5 .&-*&*AV\1O<-[QZU71C=H*4)H3B:"L3M^5;N6[EK7O
MW/*MCC:^65[_ &K8XXVOEEE?ECCC:^65[8VO>U-*K*,>(W5"*RC'DO$3,')5
M(K"8=2L1@Q P1 <E,J;&(8C!C"A B!7,V$P&%""RQL(*'CE$[NQLE'\WZN.=
MJ1X8D@--4=D=.H<E,N\XCF6(0EU@2SLHS6B]6PGGG\U&0,YT9U-\DLH3B\B1
MP_AFA'Q29T8(FNEKFO8@V)&)?:[<G7AW0FUM94+8.!6>1:^OT>9M]0CJ18O:
MSD?$8.78U.7F,"D,U)E#(=[M-FN%F);71'$S4Q"9*XI+KN/&@U-)K<P)-003
MA3'"[7 D'0JOT:16+9P7@!0C#&N%36F.C2*::DG &F,ME[7M>]KVO:]KWM>U
M[7M>U[7Y7M>U^5[7M?N7M>UKVOW+VYTK%G2.2W'+FIT%OEYG<E1ZCLXPU7LK
M9]+I+;RC%S."+'0OY99_OL\W"LLDXNC"WY=5'4A1+6QME;&V4U5(H2#I!(Z(
MN"" 1H(!':.,58'S$/\ WR3/<ZI6&&\K]=K"UN=(4?*9I"?\H.Z*=?F2Y"/1
ML<:;@V"DQKQ-9X%,\\P\ C[51G.LKR2/EGAU!:()@N.5L\<:S/!\Q#_WR3/<
MZI6(FYL8.B5M>W2EL(N(>D9CN2-IOC9+"'P+9+K\@>0VW+" U[#B9AA!9N^S
M6.-(N(-G8$(ZN%1A+VQ"Z6,BE45T5%>U>,5-:.4TUPU'@)T;>+;&%.W,-&$V
M<V"=DK5J=-N-*F; K?CQ@1]##E47&=B64D!TJA-Q2#(4.!2"QG-, [BCL-G)
M*"\"ZDZU1J&$9;!Q1<5-?,*8WN0W,J%&FK[I5]3)$3) 9!/9)898 &Z;O<D-
M)&BC94DXH?<,>S09DY6+3,LHL>+!40>/V09'L]ED&0VZ@HZEY#T?-P!9,/>$
M)4>$F![,:T3L/!RS*L;,E#D./9?A@:4V0Y4A #4EF/5LXPSSRCET1K++,3W2
MJ--?,)ZWB65$W+)'<:(*HHI$\'9-:X<ZXHIY-\6G9)<.S)K9P#:I[2I)4%MA
MZ18]GP6B52A)(:QJ P7.CIJ2QF(P#X8$:6+/(VZVVX2(3H/N%95S9@8.X4DA
M(4K 4PHKCQJ*4KB<4G'6#4TH4J!44ITUH:IQ!I2Z=-!Q*%!3 Z(ZPD\0Z0CN
MNNP$B(C:U_F"1H*V)@V 4Q5B.1G7> I?'FY8AXHDN-N.=83E!S-6R27E7),6
MRQG-U$$]PH1C,JH+"7?(/+QOK:K?AAJ6TK*-1?IVLNW52(439!RN4@\YP),U
M\QDXD)^+*;&K90#R?Y)T&3 LHL?0!Q]+ZJ98_6@;;'";-CJP<+)5RB&AKW/)
M<[I4@[&6>EIZE[6.>EU1(PPW68<;\C:].".5 VDMQ/1G6*C%HS<K<BMI-1NM
MHR6,.-FAX*:XINYZ*)VX6-_WWK"GOEW;9NP9Y*":)M7KJV->U$B"ADS0;')-
ME"F1$#=:<.(H@YKQTYA,!HR(D'0TXJ!F@%@L#PF*B/F55;&H'&N(/S,-5 -_
M3 [012%'"!4J&%" 4_.QKC7XH/TD"I-,190XD9 K)I>+H_>^HT2*:)#D-3$[
M5G<J9#T<D5H[-[<S>+1B:/4IM#EE,XKD6MB54GO)JCD<:[1$6V^2 ;2^9.&.
MMLY=:9[1-F=?(PG]K)!@F0DAI"+V+:+JJ:NF$Y<35!50' V"*^3R+HK@Q)NE
M"54='<1/,NCKQ7$BM 9%R1VU@L8G!HX]D!WAOW7V;F;&[G<4+Q%#,IX2?KJT
MIW;[NRA%JBLY@2@V$M8=;6.L:1DY!-&TH\'V5<#06TT%%!5D(P.BA&C&7[3B
M8FV(23(2,.]Z.<F4C<]'2D_7 I%,I!7^RZ"?15EX**HG$B) !U'QE,ZL!#)Z
M>53TT]D6 (% B9, *T*N4%WCXC6F-:UP-32F. ';B4!RIOZ*#12E<-%,? *Q
M@)$6]<H.#86"X=D[/3[(Y/R\\VV8BR#YM59*G'6Q9:[!<\@EB,SG20ZM'#LZ
M9-KF&VYC+2$;(**[CQ8FB^2%++&C]_/J[O!+FQ,II1' CJN692JZ9&;;OA%-
ME9?2-S]>2+0'<!1NN66H[>F26F.NZZ=0BQ9T-UB-TF.U '*E+"0K.U%)*!W+
M]BOA_P OQSEJH5,;,,(ZVM0'4F&XZ9S0U6:L<HCL:0D>+T3NW*2SB+(1U96I
M16V&OG2R,^40V@H"&XS2DYE1EN@V<+@)_;4K1R2522X"=,P[%(TO-S6F1!Y'
MCI>5(,1T79ER'4XBY$QF-^5=C@'LH'7.W4--<PI%T%T)FML>2BZ*B!NC+'')
M5Q/6.:QT<&@H%:16A -,3@#4[>.L .X5K6]4@E-"-[A4<6^- /)&1.S,3+4N
M-IL$!WQ)#8BMIK*Z]IE9\.G'<@2?,;>1&>LB-6,VV\6*L(KJ02AQXY$%I;26
M^H$5E^X)2<SB:FG@*!W,?#W2Q8EF2HJV>9<)R@^XIR9>S%F/"1#;]H.29)P@
MAE8,B/%9P-:5V(\GDAN\0)<<*BY7-#!)[/A?.)C$640\?.KB?8%( S(GZ%'O
M)AV+GI%$NFH;E6'W XE5KKI]L"2$P'(B/5M"--Y,V2HU\DK1!=J(H)UB*JA'
M %Y+5VHZ4=-6$LU</-0)FO)KK!J]#IZ37S(,C7ER8IK>C<>DEO4JT",=MG/R
M$M-+8K$:+)8:<JK^#9:;2:J5@3*]D%]?7U=2/JBLL*PXA@N6*4"@$Z172!30
M;P-=%#4#$DD_%I2+%)*ZT-,0372"!0"AJ*&N%*&MZM:1'@UY!F47@^0N^\)"
MD@P\5-'CBTVS U+*BK+21$JAL491]@Y-:=R "LM@NM&C2[B54\PADU!5:Z7@
M9.-PG<9"3\ <<W)N+'^MRMMJ%IC,CZEZ%DC0=_3PVUUZOZ2)QCB/=AF7*#5C
M@NJ1K(4HCKJ\Y4_-!D]!<4J,Y,7%Y"3W*WT,N7*D%]56$3*6]G:NJT>ZC-76
M!AS:^F2X6,W@$YH3@U$]/276E+J:^3K]2E<PV\SAQ'4T4<\:L@.MGG#^::[&
MF.K(QHV3NI]<%+>E=)#TB%I[4MK98 FIY3U"(NMY@XPHZ)0NRXPAH<^IN$VC
M1DSK.5^&"+I67PI!/Q>>"XO*AHXO(#7*%B11(1<"HUPI&^KH*R:4.()33"E,
M #3$$8BF,4*7-[32$IQ)&! -0#77A7 @X8X88W:K-UO)LI-N-7L<WYC_  GJ
M#GXD'$_;*0R;Z0-ONMTE",NN6V[@#(SS7]<9N9J M'G/>.$PA&QDRQ'*'85K
MYF67>R+G!I6_W/(.NC0S?2D(MO\ CIPR5 [^71\\1##B=T R,YXD4'.;%PM8
M,50=9)JI;G5! N>&:HL';VOSZ5K6Z94!2XR'BSYUV8GT39 76N/Y "BIKQ_
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M,Q]D9X#7<+_$F*32E*UXSPI2E(0I2E(0I2E(15D'S:2_ZX%_SJD8^5;[EO\
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M0#R^_@B<S;:L/<ESB%5-#P,D9-CQ8CA:1D-#S%0!@R[(,FHP0<%)..AGED8
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MR"#7!V\:\GPD\]>U4JZAT&,Y1836UQCF.)\A<^U#"HHIT:,R;58F^6P745X
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M?DME)]A6I^5VCIAU9L?LK9O?TKZV))Z5&QVXKA:^/9 'Y:<WS5IVXKA:^/9
M'Y:<WS5I[T,K?DME)]A6I^5VCIAU9L?LK9O?TKZV))Z5&QVXKA:^/9 'Y:<W
MS5IVXKA:^/9 'Y:<WS5I[T,K?DME)]A6I^5VCIAU9L?LK9O?TKZV)/4'S:2_
MZX%_SJD8^5;[EO\ =6"L7<5?APR+(S*8C%W-A%TO%V. HBMMN)*LXA%-:5C.
M(N9=/(X#MH '(P-B$)?"PHX6%^A?GG:_*U^@X<8SA:98898[VP!?'/#'/&]E
MES<LL<L;98WMS:EK\KXWM>W.W/NU7WJ94E1:&3.4)=2E+BFQ8MI%Q+;A4EM:
MD;EO)0XIMQ*%$!*U-K"22A0#JO90)6;3L\(("0K=LM=*DWBI(5G:$@*22 :@
M*!.D1)32HV.W%<+7Q[( _+3F^:M.W%<+7Q[( _+3F^:M6]Z&5OR6RD^PK4_*
M[1TPZLV/V5LWOZ5];$D]*C8[<5PM?'L@#\M.;YJT[<5PM?'L@#\M.;YJT]Z&
M5OR6RD^PK4_*[1TPZLV/V5LWOZ5];$D]*C8[<5PM?'L@#\M.;YJT[<5PM?'L
M@#\M.;YJT]Z&5OR6RD^PK4_*[1TPZLV/V5LWOZ5];$D]*C8[<5PM?'L@#\M.
M;YJT[<5PM?'L@#\M.;YJT]Z&5OR6RD^PK4_*[1TPZLV/V5LWOZ5];$D]57/S
M" ^_)OW 2J,/MQ7"U\>R /RTYOFK7>C'%8X;X$8I,A"[FP@&QU.0W QD]T9*
MSB[%&W>AM5M.17;H(EFS<:ZBG(+@1%4SCD!B!B44RM\!\Q<LPL*G)3*E% O)
MG*%!<(0V%V+:22M?""$7I87EE*5*"4U44I)I0$PZKV4K@VG9RKN^52=EC=2,
M"I5'<$@D"IPJ0-)$9VTJ-CMQ7"U\>R /RTYOFK3MQ7"U\>R /RTYOFK5O>AE
M;\ELI/L*U/RNT=,.K-C]E;-[^E?6Q)/2HV.W%<+7Q[( _+3F^:M.W%<+7Q[(
M _+3F^:M/>AE;\ELI/L*U/RNT=,.K-C]E;-[^E?6Q)/2HV.W%<+7Q[( _+3F
M^:M.W%<+7Q[( _+3F^:M/>AE;\ELI/L*U/RNT=,.K-C]E;-[^E?6Q)/2HV.W
M%<+7Q[( _+3F^:M.W%<+7Q[( _+3F^:M/>AE;\ELI/L*U/RNT=,.K-C]E;-[
M^E?6QE;M7_!7VD_!CV,_0F_*TZ:V MD.+APS7+KEL0VF[NS!:TX'+K_.3;04
M<@L.+,ZJKCAB=X(J.FE,!FT"'F9/*1XJ5 #R%PZ8HV&&-[Y96M>"_P"IZ]/_
M (;5/4@_CJR)R>M^32-UV%;,IG%'-[ILN>E\Y=";US.L(OW;Z+UVMV\FM+PK
MK/VG9SJ@6I^2= 30EN:86 230$I6:5U5VG48U/R__8A_YO\ SO7FI2OZA1^.
MH4I2D(4I2D(4I2D(4I2D(4I2D(4I2D(4I2D(4I2D(4I2D(S48G\7ILY^%UIE
M^BK<>L*Z4KDV9_:;=_SA/_TUC1N37Z&S_P#LU?[V<A2E*ZT:<*4I2$*4I2$*
M4I2$*4I2$*4I2$*4I2$*4I2$9IZM_P#<AQ$OP0FC_P"<W5:L+<O+O]V_^^E*
MY-G_ -OM_P#S*5_^CLB-R9_06?\ ]JY_OIR/RE*5UHTX4I2D(4I2D(4I2D(4
MI2D(]8[]@*/WN4/<8]9X<2O^'!/?WQCC]"$6TI7'>_Z@LW_);=_W^3<=9G]2
MSW_?27^E,Q@Q2E*[$<F%*4I"%*4I"%*4I",W.&S_  ^=1?\ YX-?W*JU@X5^
MQ"G]4*^YPZ4KBL?]16G_ )+8?^^RACHN_JJ3_P"]GO\ 1DH\]*4KM1SH4I2D
M(4I2D(4I2D(5FLN?Q<D8?AX3K_Y8]=Z4KBVQ^FL3_.F?]E/QT;/X%H_Y<[_K
MR\84TI2NU'.A2E*0A2E*0A2E*0CU%#S-5/O4J>X#%;R=*5\?]U?^X/\ ^K__
1 )T>\R-_13__ .QC\+L?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g809717.jpg
<DESCRIPTION>G809717.JPG
<TEXT>
begin 644 g809717.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@ ]1$E32S$Q,CI;,3=:0T4Q+C$W6D-%
M-# X,#$N3U544%5473$W.3 X7S%?3$E024137S1#7T)!4BY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" $V E4# 2(  A$! Q$!_\0 '@ !  ,! 0 # 0$           <("08* 00%
M P+_Q !M$   !0,! 0<+# L*"@@$!P " P0%!@ !!P@1"1(3%!=6EQ46&"$Q
M45>2EM76-E)56'%UE;31TM37(C(W07)T=[&RL[8*(S,T-3AA=H&1&20E)B='
M<X6UQ45&4V63H;?P0F*4IU1C9X:FP>'_Q  > 0$  00# 0$
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MLO>VWM=K;W^YM[VV_:MM[M^Y7S7G1U>9%RD7--T"U(H,\9@B,TT':H-$F+<
MXMBF0YG&<5*81/HSI;F,]:\F8E8UR&$9C.U"N^H";0<Q^G[#*72*H&")AQZM
MC#I'E2MP]!\@=U[(R+'1MC;Q+EJ49828^P',B=V7V,6%IA\5.DCPPLP;IB1B
M5G76NR2PB"#;$W-4"*(,8R"M-DB;%[+.8^G2/)3FQ9<S88X*E<:?F]G4A<,S
M3TY-9JDBUL3L4@&47L"L*97)P,;3+6(7A3&W""]E*I7@S)LS0PMX)38#RH[%
MCRIFQ2)2@=L0%DE'+,OS96H0#"X920J+JVL\\QM7# 0-&8L2GC;U:Y$(A6=^
MQ,LL:F>J9'6!IP?KL_$B^,]=CWC$+CU1X8_A>!LUY<NGXGQ?BV\N._"\+PV^
MM8.\K@[\%Y<7?QVV0<F_=N/#Y<Y(O-N/)5_*YXK^_+>4JBW*QK2]K>F^'(']
M;=0Y(IMNFBI[<E,<Q/'&YC.46&W(59F,E"A*1<HJPB3#C,BGF&[TZQMPC&<8
M.X!!L(5[V[76)]_^3./SQ@>O;UM^7]V^=W<?+/7']X3_ (*?]C\V^IE*R9O,
M=U++_?#<:12Q1?[X;>P,7W%P0/LC-[:V0-MQ;RPM[:VV][[+6M>_:JW0-4*C
M> W^"<PW'O [^]CL36M<6]MOMEKY2VVMMV[-O;V=VU=,VH4ZW'TNQ#3+[]V+
M4T4!DX[<N =QRX<EY;>7)=_,9W0Z=<LAC3KS70FW>&G#-8[OEOP[SNXSQY[-
MQW\^#;> RUE*J,YZLR&= I<W'!^8DZ)( (U!V_Q4;O C, 4&_!E9/&8+:,P
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M*!7,WYH;[!!"'>V%??;;6M>%^P:U9^!I7Y;XX]+:M[QVYV,LE=HV.VZCQ
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M54_J#*H8'N6]RWYJUE?_ .5_>?\ IDQ^S?W/5_TZ/^%O+U;FO_/3PU[L\_\
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M-3YBO(2AEMKGC9:9Z.Q!?$A#F!<X*-XS*F0>4#A)&XX:L;FK++NWF=BUZ<\
MY(:-U2S/EB- 99CCK6%JT5,6H!L>9'%L@XE;L=8FQM)HR^Q&=M#RV'1L4(=1
M'O#40$\+8:>8H0KTBQ$XJDBC4?4G34:VO2+-]D1'>BJU:T5N1FBMUH4=E6Y'
MPYF]R>,DRQB, *YD''?W0O6,GH#4JVFQR2R%]0=[=YZ42(:4LCQJQHS\RHH;
M*_M48R^W:/NSSU-RV&_^;PM[>P1=4[6%LO8(KVXEMM86S8*]K7#MM:][VVVV
M]VU0Y:U[WL$-KB$*]@A"&UQ"$(5]@0A#:U[B$*][6M:UKWO>]K6M>]ZH/I?F
MF2LEYWD$SR62ZWGDNW.W<S)O.&X:!4C CGDQCN>GB7G78P!X!E6KW0PPY:C+
M(($4.P4HPV E+**_%UDYE>#\?NN/DS#FO$L:<\^Z?L/Y0S&YQE7"(\'$N3,N
M-$+R ZXVR&D>C%(>JK:H*C1LI((9U+"T2@UW2GI5@"#"=6W^GK#=1MI"RH['
M^3.^L*NZ1"[6J2$I'RYS]VT_!%C]O.5!5$+[+*+ISJ^E#T#6U^2"1%"ZX:U0
MMM).VGWM251+,$,543)5,LLLQ[FLK,7DD6,LTRY;[<S4BMVPV;FPFXK7L((3
M2BC+&DB%:][!.*O>UC2A7L87>]K&!#?9:HN/_@#_ /8'?JAU%$LPW@+3[J3B
MT<Q<W$8>?)MC.1)!8AAC6M31&=M,+ZAJU,YDS9<A8E;Y+"#EQ#6CG"E4W.TH
MM)%3"\+Y$H"D*12N?_ '_P"P._5#K!-6K0UYPU:6S-6LPF>&2U3-*5E$TU>3
M\&)K,4B+-!*JRP69HVV*LT<Z30Q3 Z#U&S?T*FEV"A6NZ>:U&U#IVJ)JT",:
M-&] 6F]&I6()I*EVM))4N4JMB,N)(UGIRU+EGVLX ^X3A7\DN-_V,9:E0I(E
M(.4J"4Q!1ZTPLU8<4246<J,)) F*,4F@ $P\9:<HL@L9HAB 26 H-[%@"&T5
MX ^X3A7\DN-_V,9:ERO2'2_>W3OF-3[O'GY[>H??_7/IC4_OL^*4I5=EGS"+
M=//N]1/\E31^U4MK.4/=M[MOSUMWK1TBY8SWE%BF$%.B!;0W0=OCR@+^^+6Q
M9=P3/C\X&W+(3LSB :;B[DFL$VYP!W,L:&Y5K L(50[;FQJ,M>U[J<:[+=N_
M^=CI][_]K59+%>9II&6-R"Y(('@1F05;-=*\2M*BLJ@$$^(._K_?_O8Y9731
M:]\%XWM:U[WNSK+6M:VV][W?G>UK6M;MWO>_:M:W;O?M6J>!IE(0&7$E4A"$
ML=Q"$F."$-K!OVQ7$7:P;6[][VM;N[:B^!8O7P?&#9B>>)FAR5-K*[QF3HD9
MYK@RN"5V/<^/(@G&IT1RE&L;'2Z518:=.,033B][;985\8,.:2-.N-];^Z-N
MN+M,^-5$DTU8ET;9&TUQA"Q.!J>'Y.<<&9SE-[PUO"Y#LA<9G,(W&;.UDP!G
M.BM.CL/?&A!>M1RU([%S5^\E>)Z\\SJJQ(ZN6NK7V9VFCX;/,A)V8!0Q]0!W
M#'>EJ4=%$<"S1V*E=6;O&5D"4Q,2B+&YD)C1N*C8EB!^>]8MMC1%7M>Q@BS%
M5BK]HVZ6Q@@W56*O^^72V%]C=38%R+"^QN9M[5<C._4B^?BQ/QQ-6"ZN 8HB
MFY_8?UP+\0R#,637S#D;U.YMUOQ[-L6Q9J+Q_DT*!@DDA<(K*9^CD0W )$M6
M/^-&K!S8EO 6YL9^3=RABD+D!-;>6;&\/#'<_><'PZ%*?P>]L'><.H2'6!O0
M_8AWEC+!WH=@0[-Z&V]M:M,ZYI2:=79HYWL(TFHTW9XHH2MB@(TF C2U8E52
M9E*"S'6F*<)#"%D4Y*3H_6WU;4ZB2UHZSQMH5Y%CL2V0U;4W:2N6D>G6A9P(
M&5S5DM0"0/&)BT;#*SU#>:_4^S^_0OB"BIDJ&\U^I]G]^A?$%%:UL^X2?F'U
MADL^E?A#I?S@_9296NO25N.W\VV;_EJD/['PBO-K7I*W'?\ FVS?\M4B_8^$
M5LOL(^,"O]$ZG]2',#]F_P#$1>_:CIO[:SFJZYJ;'+@NJ+<A7\#O^!XZC3*N
M"X3><)P?&"C.#X3@R]_O-F^W@-]MWH=BOOTJ;F>,>>''=Q,I:68_N@D[C['N
M>^I-5JH3PO&H9#KI@V7]3&,\?')E<!:5$0;3HU@["&I=!D<B),RA&R.:!UQH
MW7$L;E:,Q<;8@(S]@OW/=)LBR/ N:[9+U!(L^/J#)<?)3JD^C>1:454+;3HB
M Q)&G)YE>$,!O^<EF]#QDR?NL( M2=MM,4EE'D(4E[]T?W0IFT X]A+LV88R
M'J.S'EI\F3#B/"&.7)JCSE*C,;8VD^7\COSY+Y"*['$HC!L<0]]DC^[#1O+E
M<H@DEN8E^^5'(OMZ!=T/@FNPK*K6Q0"88RFN(D&!)%)(S*5:-X1N<+U*8.BN
M=\2S6+2)O 0G=F"01J1+FLP"A$VNJ!YC;H2O;DY9B01C&8N_NEJ?XW81:=FU
M+@MOF&HG'V+=3NI>$9S.U(9!TR23$&'L+(\<\M,?QU(,5/;%,\D9!R0ED+$D
M8L=%K MP ,RJ1'W %(H.(T4W$"V$H[I[U'8:PGAQLQ,1ITUQ:A,)Y%=VC*+Y
MFM/FW(K$&'291G-=E*2K7)_E4CG$/ED/(EA+JXJC8M)F9UB"*R5J9$*%+0O=
ME,7:O]2&JK".!IWI4W-3-FCR4GS=GP.3JJSZ^XMF\ZSBJBN,W9O8F]\CS$GR
MW%,C\(@R0FB<(P>O?H_D>#-[PZY9.:1L$83&:3[BOCF18TT6D-"])HZ:(0Y9
M:R8\8:B^A>1)9S@:'8LLN;&5MC*7)(&=I=\F39%*F67J)Y-9:)TF*^0*SV^2
M.9C@UB1HF,UMI2]]EKW[W;[5KWO_ '6[=_<MVZI'K.U<272J1@HQAP//,KH<
MPZ@L'88D$U9UT99\?8=:LM9KQMB8R5Y$<71^3RJYYEY_OX8S1&(2D3^_(+-S
M\JBS.8<]E,9=RE9/9[W1/(V*LJYA-BF"X[+=,ND_*&!,0:J,GO>1WR-Y';95
MGY/C9W+7X6QTW8[DD>GK!B")YBQI+,E*)7/H,L7HWI\:XLF.<(O<;SJNI6I$
M2<Q6M5)T24H5@FJ59Y2<@N]S;$AWYQPP%AL(RX0 WPK;X0@AM;?"M:F,KOIM
M9W!*QS=W/E#XXM[KES-H$,86$, &6.B1YGGI2@UH/0LB-^.&YC_?UMGMZ>"P
M&]I !$5OBKV2JING&T 96><28M]1)WN398S/U4$LF2L]&:G0YBG86TQ"R+WH
MYF:0F)3 &#.9VY#=QL,"A6-2,03;V/Z\(GSGCWPVU_2Z8SHZ5SG7A$^<\>^&
MVOZ73KPB?.>/?#;7]+IC/VEO\35_BQ_ZH=8QYDT*Z2M0<S,R%F#"<>F$M<&%
MHBTE<NKDXC2?($485=US)$LK,<,E<;CN7HHTGC. W1O*+1+V9*B5+&HI'9H6
M*D!VO:J714:52 ,ECXA"3G!"&STV7N(5RQ6L&UK*KWO>][VM:UN[>]4XMW+>
MY:M<==S303:6\,LD3\;HYQNR-Q/H>XW4@[;@>'EN!ZQFS.SVO#8CU=)XHYD#
MT6"R(KJ& M@'9@0#L2-_D)'D3E=,N81Q&[0'-!+ACR,*",MX[BV,LDIK(1IT
MLPQ]$2'9CB\.=$B,],F*8&%EE<B:FM"VE(+)$+NJ3@'O I[$9^OND;3?)<K)
M<VO>*65?DI*\Q&2B>A.TM3M+G*8 C W0272*#(I$FQ[*YA#$)*1+%I9*8H\R
M)C+;FF[>YDC9VH:/57)?J%D?XH1\>253BM#=27KL%Z$PV[,1>D8W[N>5.4;R
M%71N+CDC+#$K*=U811@@A%VE)T'INGSZ18$U&G,$U0R():T,@22*O$T;J'0\
M7C,\Q1AL4,LG$CFV\%2V(1B$1-(S1)D0L#6LFDKE2I"WA-"0?(IL[O,NECP9
M8XTX=UK_ "9Y=7MQ'8=BS%R\\9191=PEABRIVRO_ ".U^^@OB9]036K]49GN
M2.[,[N$9F8EF9F4%F9B222222222<E!T<B1Z%7CC541))T1$ 5459"%55  5
M5      &PRLF:/52@]XDWQQ;42 ^W#^$'\]JEO-'JI0>\2;XXMJ) ?;!_"M^
M>U8M/[N_Z?\ _F2KZ9]X-*^:)_BV>O#0-_,[T^?D[;?CCA5OJI-H1DL=0Z0L
M )EK\RI%)6/6X)J=2ZH$YY8K+7"UPF%&J & %;[X1!M>W<O:U]MJMMUX1/G/
M'OAMK^EUZ-=*?!?IKZ T?^'5L_/]VH?&7VA_MQU9_P"->O@_^<Z.E<YUX1/G
M/'OAMK^ETZ\(GSGCWPVU_2ZO^8+G1U])R;D+NWKFIR3%+&YR1JF]<D.M<1*I
M&M3F)52<T-KAN(L].<849:U[7N =[6O:_;K\GKPB?.>/?#;7]+IUX1/G/'OA
MMK^ETQF1,AW+S03C16\Q"&Z;HHU1618K<\6/,:')\G.$;6XYE**[0^PRT<<Y
MXM84C$L;$:9"4G0-J4]N3$E@;%**]M]?[F&=&6EW3U(WJ98<PM%(7,'^/=:3
MI+0*Y3)I0;%+K N)L822&<2*4.[/'53B62X.#*R+&UN=%R5$K<TRQ0@1&)[Q
M90<$#E)[*6Y:D7I^IB,OAT2DA63P@#%-QE\*G,,+WX;"#<0-]OK6$&][;!6O
M>.1=R_N7_-6C^H+5K^5M3A](F[HV74Q=XX0J-ME*;\=AL/#;;PS?735*H=&T
MF<UXC,*J.)"@+AVWW8$^O_#QVVW.9$1_1'I4P!E!7(,,X88L>.<7,=66/"8Y
M%D$UN9FES;[(5S<WQ]XF3I'$Z,Y(H.(+("T;Q($RXD5DQE@"!]_,^G[#N>&U
MB3Y6A"63'PI:XO<,>TCS)XA+8@Z+V\:!S51:;P5\C$RC]GA#8")\2-3\E0/B
M0HA.[I5I:9-8FS.0/5M*??@_]417$J?XLI_%S_U0ZTG>OWFU.Q:-RT;,<\Z1
MV#8F,\:=Y*.$<I?O$79W'%6 V=AMLQWE)H^F::NC4*:T*8J3U*,DU;T:$P32
M&"NQDEB*&.1RT:'DREMT4[[J-J%8^Q[",50]F@6.8NT0Z',!1Y;4P,A R$2<
M:Q2:N<%9IAQAZQP<W5P4*7)X>'-4M=WES4J7)U7+%R@Y0/ZF4/4*^?[O_P")
M):[T/<M[EOS5P64/4*^?[O\ ^)):UU9DDF$\LLCRRREY))9&9Y))')9W=V)9
MW=B69F)9B2223DJ^G(8:VJZ'7KQ10007].A@@AC6*&&*.Q"D<442!4CCC0!4
M1%"JH"J  !E1:V2W&7[K.:OR<Q7]JUU8VUL)N.CFVM>5<SFN3@B;RC,=Q<!9
MBY6G2%C&&5++B" :@PL(A!L(-Q6#>][6O:]]FVVW)^R3XQ>F/G5O^&W3_AE;
M[*G^K]VE?1ND?YGT//192N<Z\(GSGCWPVU_2Z=>$3YSQ[X;:_I=3ZSPISHME
MN];^ZU0QJ#Q2HS9B.68S1O*>.J))9FL6[J4!CD2DZE/S8\BN-$2J1&'<,!O$
MG#O5)7!B-L;??6!< I%Z\(GSGCWPVU_2Z=>$3YSQ[X;:_I=<64.K*PW5@01Y
M>!\#XCQSDK%&5U.S*P93Y[%2"#L? ^(]>9$_X*Z2^&=B\AG+THK]?'>@1FTY
MY/49J=7R.3*;/6/5F)$3ZGC+@TO+7$3Y,W3A<S$JE3\Y);-*][;$JY8G(1)U
M*I:F1&*%9Q",@@K5_KPB?.>/?#;7]+J(\LO3.ZH6<#8[-CB,E<I&:!"O2+!E
M $DWH1F!3'&W  0OL;"%:UKB[5K[>U6-=2UH8M#U!XU*L(HQN'?R:>%6!!;8
M@@G<?E_-F5=+6YYM?TR.5PR&9R1P0>*P2LIW"@@AE!&Q'C^3PS(7-&YO:>\V
M9R@>69%#F1&V,[MG*=Y 9X^NG<+E4WS#EF&89Q\S97;9] )C%9##99&8=B,$
M:='"/+6U3)F)WNWKC# 7<KKXPU&:#=(4F!BV"N&"8HBB6*\6GXW@S)%G*805
M,U8Y>'90O>\?N!T%D\;72N$R!R("[R.+3)7(660O1JU[>D:YW<G):KU8JK^;
M/54W^\*;XZNK0W4.IZA'ID9BNV8C6DB6%H9I(FC!:3?9HV5MRLCH23N4/#?B
M ,DAT5H^ERZ^PFH59ULU[#S)8A2>-V18BOM)5= %9%<   . WF 1G[D715I6
MRQ(02N?84B[W( 1)@@07%(Y3&+WO"HH2O3QF*C10R41ML,8H^F='%,T-YJ$9
M*!*M4)4]@$&<';GCXZP0\X<2BC*UQN+Q<),>CD=8T*=L96)B9TY2!J:&EN2
M+2H6YN1$$I4B5.6 HDDH  A[5[WN'5595ZII![[+/UE:CUJY;GK5XI[5B:**
M3\%%+/+)'%^#*_@T=F5/:@#VH'@ /+)3] 4*-74]3GK4ZM>:Q3!GFAKQ12S?
MSF-OPCHBL_MB6/(G=CN?'QSFU/\ %E7XJI_4&50P/<M[EOS5?-3_ !95^*J?
MU!E4,#W+>Y;\U87?_P"5_>?^F2H[-_<]7_3H_5M9>K<UOYZ>&O=GG_IU*:]8
MP>Y;W+?FKR8[G"K2(=9>'52U2G1I2KSJQBE4>4G(+W^/9.6#?G'# 6#?C$$
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M?IGQID24L>/$D@Q;@*.Y7C\7F"N QU*U-3BHD"MD1%O,M?)(.X1K$ZTP=?\
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M.*1ZE>1%W)V5;4JJ-R23L !N23\IST-Z>=I-$T"1SR>32-)D=O <G>C79CL
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MG]O(_>693+*>\D9^)<@>T3EPC4 <450=SNQ4I2J3._%*4IC%*4IC%*4IC%?
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M_P#-MF_Y:I%^Q\(K9?81\8%?Z)U3ZD.8'[-_XB+W[4=-_;6<UFI2E3<SQCS
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M0#R]\,L3&85?NDG)NHW!<0QQ),.NF6L-XE<\<:@I/,LPZ=<,MDTETCU-19-
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MQD \O8_ QGSHWOY[IR]C\#&?.C>_GNI^W@/6A\6WR4W@/6A\6WR4QD \O8_
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MTSO3S#D68LG13,L3<6F?SX&0I49,)UFC$&9,R-0Y@XHX\RRIW@TM9'57%(+
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MQ=P;S(#Y23'TCIV+N#>9 ?*28^D=,9/V^MWA>(/YM-];O"\0?S:@'L7<&\R
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MR]MEZX2>YR?H-]4YV0^ZQ?K$^L,R:+_@R_P _HVKE9WZD7S\6)^.)JZL%[W
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M9Y1%R]+<"#,8V'"^:G9^&&28OC8C<O(I=@QKQ7%U*S(@51J<MY@+[G5_8W1
MWFQUKF40C8YX)>R*$T:?ZA;L]MY.\&[?"')_[NM S9_Y;*TML@U.[+?YTX([
MEO\ J#D3ZR:R1W6I/E4B!8:OD5XQ\Y)A3N16;2X7')*QGE*;145S1KC7Z52
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M7V/2AWB$8=)+$@J Q60N,?:%SY&@JR[$J@Q]W5(S7!ELI*M8I19L4I;'EVL
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MFDB4-6,D$IDV+R2W!7-&A(06VB=?W(/NL>/)UF7&, ;].VI%'B;/6?L@::<
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@DI2F,4I2F,4I2F,4I2F,4I2F,4I2F,4I2F,4I2F,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g823383.jpg
<DESCRIPTION>G823383.JPG
<TEXT>
begin 644 g823383.jpg
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MB%@LA&8W!:>ERG6XB'TQVW9#[B&L+>=4O/*:4L6Z#7U <4&?LT:YO"52>O\
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MO*-C7+18A58'RWX J[RB4B*T3,0OBTPHTB2B-EUUF.^MO#2V,<!PX8^?]_\
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MH-W7<:05I [-\(AH4%5=73&7)#'W531@Y Y898!)%^#"3"R/RRQB/SK.O^E
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MW1+\8^7X,Y\8SCZLXSXS\LYY5!N,R@H]375_WMNZLBZ#+-O[K78=0G-B=_\
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MR&V%MQ6WWO#>?BL>VO\ Z2O_ (L__=Y8[_(HRE9]:_K=Y5G/_F'V.^O.<_\
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MC+A_1%<_R_!Y#SSG_56H7ZNH0QU;URM&:D;E*]J>%"QFF!8I'(JEB%4%B-R
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MBIK[8\B[[,=<LW-6O @D>IUH"AS12N%2H M ''@C :47$394%]F//'1K",,
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MS$-,N>]-(ORYTE9N1&H:91,D'3.@:-HFDB60T*B4%OM7IEV]4@$NLI;EC%>
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M1P2;AMUD9,4N5F.QEM"'5/-?/W7^12_6X4M2L=7Z=XRI6<?^L;U]^K.<Y_\
M:'QD<KE<GQ_(T7Z+?H[^E]V!_@7M_%"_\E*];G]*_3O[H[K[_K#Y*#Z/'H(^
MK%T,[WZU[)[KZIXG:]J54VJ%*QZ)O3KE8+(J9<]=GJL'S$&3MLA8[S*29..J
M:M4]O+$3#KR$NK0EES&ZS%)/I&IPPHTDLM"W''&HW9W>!U15'O+,0 /I.9;0
M9HJVMZ18GD6*&'4J<LLCG9(XTL1L[L?<JJ"2?<!OETSAS3__ %B/TFV]O[->
MJW^T;P_]8C])MO;^S7JM_M&\X/\ %?J'_FB[_P#Q_P#G]8^_GH_XW],?\^:?
M[O\ VI]^W^#_ (0_#B2]K/SC+A_1%<_R_!Y#SR8?>%'[0[&UH?J-?Z<[G;+$
MW1"XRR=]ZM186$P2D:8_[U]KL-)6C/N6E8;PEE?M+\)S[.,^UA@?Y2KO1^E"
MOO\ ;5ZR_P"N_F@]4]"]7W-0BDJ]/:E/&M2-"\<&ZAQ+,Q7?EY@,I^TP^G/4
M7H5]+WHRT'I6[3UGK;0--M2:Y9LI!:N=N1H'H:9$LH7B?99X9%!^E#C=.)OM
MC^8Q_P#]Z"_\8]QZ?Y2KO1^E"OO]M7K+_KOYJ%YZ&]];'7G18_J)=4R5S84A
M.9.V>L[37L1UKRYY6G=CF<*\*Q[./8SYSY\YQS5Y/1UUR8W Z8U8DJ0 *_GO
MM_A?6/OYW#2/3[Z&(-3H2R^DGI:...W7=W:^ J*LJ,S,>'@  =S]61=\./<_
MX,SU$_TI-D_MP];?]<O#_@S/43_2DV3^W#UM_P!<O,?^9KU[^Y36/]6/_>SK
M']<MZ _[['1O\*+]7^!]?Y;C>&7N[^<HW^WBM?\ 4SW(A>6F.R'I >IMMC7*
M*I5^IA)!--E#%LJ*[LZX0HOPD".4:?Q[YO;DE67<JF,^[1[OPK'MYRK'LXPI
MA7_D]/J]?I4QG]T%UW_UF<^O_P!A3U)H707H3@T#K+5:?3FM+U3K]QM-U23U
M>T*MGU+U><QD'Y.7@_ [^/$Y^?O^J0,OI4^R2M=5>CMTZOZ<?HGI73UUC172
MS2:[3CNBU6$NZ_*P&1.XNWAR'B=\A<Y:/_(I'_/4["_U+DK^%:A<8G_Y/3ZO
M7Z5,9_=!==_]9G)I/1!]//U!O3E[$[6VMOOJ!<BE9NVEG]>AV=;;>ZR68LV=
M<N]8L:79T,KNZM,,#O@ TI&9+<M]W$E3+?PV4.*=;[MZ5/2-T-K'H_ZGTW2^
MJ-(O7[=**.M4KV0\TSK<JR%8UV&Y"*S?:!SQYZ/>B.K-+ZQT2]J&@WZM.O8E
M:>Q+&HCB4UIE!8AR0"S*O@#XD9<AXA78[\Z][]O>G/X9M?<TO\L)MG])%V9_
MLIZC?[4?$[VAM7;5[K4"KYZ?=B*RT1OVIE2K"8,=;BPD' @[8I!(B7*P*5V"
MM=K?&C1\.3,G*!ULS,8C,N250_A69$ACP5GKC'V8^K]U7[^><\XQ_P#YS^_G
MG/&,XSGQC.<_@QG/XN5I^W(OLK;/5%J&QM/ZM[&&=6Q7.O6IKJ>H5^[=ZDIT
M25K+<=U(VPM9\]7;*!UQMNO($7;WV0_8#-DA!QD:= DC M8/FH!"RNM/MH6G
MSX]I*D^?L]K&<>?W//(1;-TRT)H;L+-VGMKO[VOUA9.Q/:\_MNC:FH79S8^I
M=(E"D^RT-MJG%=5 9!&JD@+YIZL5F_&S2@X&V&KL,!&'HI.UBQ\QC))>T.F[
MKO&B!Z93+BW1'D6Z 5,V)DA<!=AAAHL0BPZNGDJH;%MC+4V_*CO!R]@@V4.'
M=;R2C 5'(P<H+3[3G6:ZZWJUC'W+;]CLQ I1;54<%PQ2RPIH]9A K+UO&2K.
M9M$J';C) 81N163[Y\:+M5D*1ZZ/A 6&(BWK>?&/S/E7YK'U_/Y97^:_^'&<
M_+\'CQ^#C#]0;?[6;!L5NCW+3<"L5T52+_@-&,"+70U']B0U:Y57ZZHZ<19$
MQ@ ]XQ>*_)NT(3.%W-(EFVU8.H9"D1'V,VKT]*TJJ='>IPQ5BM-GR[U^U(5^
MDK@72;+MX,4, 1P.1-1$A8P+%8D8@!XN6/,(:Q'BY=>RU[U3R.18=/[=WJJ?
M5+K;4[!U(UV.-U31VKZP3A6+LJ0JE@CRZ]31 =Q!RL2NO,N172V?@\*G@WI<
MMT6_E<-V2\ZTMS+C?OF]T?TJFH_[K23_ +./&,>%PXSW[YO=']*IJ/\ NM)/
M^SCP^^;W1_2J:C_NM)/^SCQC'A<.,VE;4[I1HLJ2GJ;JJ4J-&D2$Q8O;%]R5
M*4PRMY,6*A77-M"Y,E2,,1TN.--*><1AQUIO*G$^81MSNF5$BRB^HNLQ*R8P
M>16*+=K78Q46Y.ALRUC"D=KKM(98)#UO*AD&F)$EAN8P\AB3(9PAYQC'I<.,
M]^^;W1_2J:C_ +K23_LX\/OF]T?TJFH_[K23_LX\8QX7#C/?OF]T?TJFH_[K
M23_LX\_&3M#NHW'D+;ZIZERXB.^XWA';"2ZO*VVEK3A+>.N6/;5E6,82GSC"
ME9QC*DXSG.&,>1PY'KIS<_?:R:BU78KGU-UI%N!_7%(-6N,7[)3*>6CV0G6A
MDTXP3J3G7J:Y5R#11Z4W-KJYLQ822ET8N4^N+EU2D??-[H_I5-1_W6DG_9QX
MQCPN'&>_?-[H_I5-1_W6DG_9QX??-[H_I5-1_P!UI)_V<>,8\+AQF!+;/=,<
M.($$]2-7D%0($Z<@>.[7/R")!<.(]*0/'L+ZZ--NSYRFL1(3;KS#*Y3S*7GV
M&LK>1T$[<[IE10LHOJ+K,4LD,'D5BRW:UZ,5%N3X3$MP84CM]=GVF"0Y;RH1
M!IB1)CMS6'T1Y,EE+;[C&/2X<9[]\WNC^E4U'_=:2?\ 9QX??-[H_I5-1_W6
MDG_9QXQCPN'&>_?-[H_I5-1_W6DG_9QXG.XMR]]Z[J/:=@I?4[6<FX@]<7DQ
M4HXCLA.N1619Q=7*3@$<94&.O4)ZU$7BK$-J#6VID1PY*6R,3)CYE8=0QDA'
M#C-8FT>ZKL2*Z[U3U*EUR-'6ZESM?*8<2\MAM;J'&<]<E9:<0O*DN-^UG"%8
M4G&<XQC.?1]\WNC^E4U'_=:2?]G'C&/"X<9[]\WNC^E4U'_=:2?]G'A]\WNC
M^E4U'_=:2?\ 9QXQCE[W_,3</VK6'_(\WF;$_P#)@_\ H&'_ -5:XRNW['[H
M2*G9V,]3=9RL/5TXUF,)[4O3RLG#@N6C,<7!<Z]0FII)["O=CXCTR&S)F*88
M>EQ6G%OMO4%87@8.PXTZPYB##PME].$O-+Q&:PIIU*5+2EUO/E#B4K7C"TJQ
MA6<?/C&9#APX<8PX<.'&,.'#AQC-4NE%I>QZ_*J=_J=<NM8G/0Y$ROVH*//A
MI4@=+9GP'WQI2/)B.O0IL=B7%<6UE;$AIMUM25IQGFL;CU%5]W:FN^F;3,LP
M6HWZMR:H9DT2R$Z19X@>6EMM]L!90+L8H DJ8;^&;F#'F)#+"W$,K1[6,X5+
MAQC&8V'H[K*RDK\3G; W_&?V1=]#W^Q-BMUW(7&:-]>HXV-3V C$.2VD$$L#
M881]\4&.RR.O2Q[2S+*U/S<RF=]IMX=LQ_>3&GNOQ;:Y)D'J'JA>ZY0*QK;7
M!_2)8UL3L5M^J[BE=C=AGJQ/O=#JOWFJ"_,K,VL6JK+8, I3X+%GM;D"GG9D
MN>!L4,:)2C+0Z V7G0X0Z:4;AQD$98\:]-D#H,F<EK$J1#@2"1!^%%>>6Q%>
MG3'8[;:Y4A3C&0L;O=[4[6&L0NSVB;8:UG3-VZML6V^NVFJ4O:&O;]HR&C:H
MR9-K5[''\V[LG\-=I6H[G=]6V#6&ICL,* DL#M0W!J*HQ.T&S:]VF2ZF]4J+
MN_1>\MJ5/3I"R0MWZ9343E]N!E%UT]?)76UN.J,0E)V.K29FQ4&IVZPB;$5B
M4#8T"/9YY-+-)(6@'/GG&,^?.,9\^//G&/GX^KS]OC\'V<,I3G'C*4YQ]F<8
M\?+'C'XL?+];Y<8R ;KOUY[%CNRNM8NZ:9MN1N-AZ<K>G9X0:+C*C9.MI7H]
M7-:!M7AMI!CXYR39@79Y.+"Q30L9FQ!+E63^ZF$Q8]AAVFPO<ZR=;R%W]-?5
MO67>:]LU.88TO"H%[=Q<K35]PP&F2$I+KDJ]9EN6^':941B,LB?>G.&9JY4B
M3)DKD2G'<R.^,>?/C'G[?&//X_KYSQC$2U=HFMZGMVU+F%M&R#Y+;Q*G%[+"
MN]Y+VP(-)4NG0*1#E5$.24J)4\&! N!)LL8.EB(:-,9,/QT37Y*W8]O4EW5V
M+U[MOK7KS0]GWH#C["U?V\LQH9U[U/JO;%T.WG6E?TXG3,<P,V8 L&!=(S=;
MNZ+LTX+&@Q\H-P_NK/U6K-$K: EVYC7PPF43@&I(L=(,"HI&",*OP8KQ(=",
M*@J+1(,]QI4N'&)J&#5$(\9YIF:H?"S*0[F)'RVQD/.VBOJ!;'UCL;7NX-1/
M5YXCHY:F:IUMD-6L+N$BV.UV3V96'-V$+95[/JNZE16=F5*HZ]700U8*/R!Z
MH&^[@Z^V)7K::A;5=3ML:QHVA=UU_4UKWR,V]K_1C&N+%3R0WIK5MW:'QNK2
M[=:ERASU9-[8#1MW6ZGZ(=^BK'8==6:94VJL-<?77TS=YQC/SSC&<^,X\YQC
MZL_7C];/X<</93]7LX\>/'CQCZO/GQ^MY^?Z_&/R_+[V0M:,T5M$?8.B5O8J
M&Y*+0J=VB[K$JYK$B7MH03JOK'LS6_8=[2(S96MVS3X !,"NR*,(U^.L<)5@
MU8-M$#7,5L ZF:#ARBZ)TI6>OFM NJZB;O%C @YUC(QBNQK>4O5LD2K38BEI
M+*(64TMPA-;R7,3W(;#BL,CXKC<"&VS#CL,MK!XQCQXQC'CZOE]7ZWV?7G\?
M.>,9'5ZC&U]F:LK/6>/K:T[=J#.R^U-7USL,CH;7U*V9MM[6\C3V\+H=C4VI
MW>I7F%,ELDZ2!*$70M3/VID(-)XKHHA/<3"D(,'N/J<7'5U)J%ZIZ-8V*XZ/
ML,45LRGUX%;+61V^9UM?F*?'WK A6,#'ZTRX-A32BYJ=KBI;;JDJQ.2H+E\U
M7%Q@4U+].$BR;PV01'0)[X8A@J(>FPXTIT64Q"FCL$1SDAIQ<&?@>2(0<3(J
MF9.(<Z9%P[[B4^VY[_&/E\L?F?J^6/E\O'R^SY?+Y?@^7&,@4U'0]J@.K7:7
M7FA]"=@=#DMQZT&4K4E.LH@R$+0MXU7K/)SNJYOF)1G$37;VP[2,C:_%[@)%
M1 _9>YX;VS0YT['M$.[EVK;4ZV7<W!S;=0=4]U -9@]@;1LG3'K=L+K;2MF:
M[';(*ZFZ[5I0[=^O-AVY=DT%0;]M:G7\H$V /8KL6LPG]G7Q^X4TC=ZKF]6E
M/93CZDXQ^YC\./&?QX^7ZW#V4_+\RGY?5\L?+];C&>,?F:N##648AL$EQ8ZB
M#$!]V7!9G*9;5,:ARI$:$_)BMR<NHC2'HD5Y]E*'78[*UJ:3[/&/LQ^+'.>'
M&,/&,?5C&.'#AQC#F /56LVE(Q%FKH*PH#%8IT0@X''%T"S<'V\0C Y)&-)3
M!*0\..8BD(N&9D?WB_<O(]M7G/\ #C&'^_X^'#AQC#APX<8PX<.'&,.'#AQC
M#APX<8PX<.'&,.'#AQC#APX<8PX<.'&,.'#AQC#APX<8SA6,YQG&/'G.,XQY
MQYQY\?+SC\./MQ]G(I$]!]@W[M=LO=6Z#.FBU! [,JFS>L]<$46,:>KUA82*
M8N)G8-7,  X?-E*0*[5V\6J!9;%;Y]GK8&W,V6O" PZ@-2N<.,9QC'C'C]7/
M]_.<_C^W/X<_/B(=F(.S2/7;>D#2KTV-MV;J/8<;6CHJ7&'%TWAZJ%&ZU]#D
M)CC,(>9455&0'GSGFH4(FJ)*E.M,-..)7#AQC&>=*8]^:UG;I%N@[-$58EM_
M8Q+3(3<LFRR-GAM-RIT#[DH%M3>)Q.]PW_I%NQ2PXV[37;,-K<L+"(MQ,,L0
MX[P^&,8QCQC&,8^S'RQPXQAPX<.,8</J^KAPXQAPX<.,8<C1]1%CL<K[S4O2
MHN_GZK"D[27<ZYKA5^:.V.[N4N*C2P":4UC;Z5::8%,67!T<K9Q4D4UWK0])
MK]NV)63H&!AAJ2SVL?J_NI5C'X\X\?N_N_5SC.4*^O*%>/.?GG&?'CZ\_N8S
MCS^OQC(QND@WLO$W'NA[<47:T,5]'%&+4[L$J;)4TSM23OO=!JOD-+?2TIX3
MBD0] $]6BY$JA0Q-/]AJO@IT"->J];1XZ3SG&/9^O'CQGYYSCQ\_P^?./K^W
MSSCVTX^M6,9^OQG.,9^?CZ\9\9Q]>/K^W'&,[<.<>TGSX\XQG/RQC/RSG];&
M?&<_5GYX^6?P<YQGS\_]_P#?]3C&'#APXQAPXVU_=-ZJMG[(3=I:G>I&DM)U
M,1=:?MV+:X5E<VJ#9IQ*T7_,&DP1T<O6IU$D"98N1%*2W,FUNP9(=<J/(><B
MH[KGU(.LE]!$2Q,Q<]7%XU=I-T#:_P!L4*PU':5VI.R:X0M5!M6N]:QV#5QO
MT.SB Q_,</5!!6W"R->.A[%6@Q47)AI8Q^G(HNR<;=U,O?:ZQQ8_:O:-#M=?
MZ1.:VHVM3-D&!!EE8V+N47M,#7R&L:8:V!6=:)#PZ!9.P,ZCB+%M$I5IRAHH
M@^B<%$PE;J/<VR6S?+5.9UT*'Z<*;O,=9PEI*F[,+VDO;H3KQ&[&O3C6MYU-
M:@@J9*!-'ZAELE8XMI%V$-%F$AB(AC,(6AFR?48VM3Y^R95?Z[Q[S74G^S^M
M-(P*F>NMOV9<MH=6C@NN6=JU:YJ>O"I&'4['.Q=R@MVDRK98QE?I+$V<*E/6
MGW-<8S4.LE=[.#-]ZACV4QV9N02-EDN7V#L"!L2E:U(]=7NMI,2S4SU(ODV.
MX*VR&[7/,(AC;D&D;UF4D1 MUC,SZT3E39TTG&Y]7=UHWQK#-PD3@$@^*M]S
MI-K%A*_L&HR:M9:>=?%$:Q8ZCM,'7+W6;,,;3%65&&Q+#;F)48D'D$01 :2E
MN,XQAPX<.,8<.'#C&'#APXQAPX<.,8<.'#C&'#APXQAPX<.,8<.'#C&'#APX
MQD5GJ.^J_JGTXM1;=V?>],=C=@KU9%JF$)JFF[_!UO83%UFAH $?C?!&L/:J
M"P\23++!8K,,OI'S8\@(S#G6)441(330OK;]?-X=*G>Z_P!YKM#2Z,*T1L[>
M-DC&]&7]ZL0(NI!QZ1::T$W&D!$U19YT\G7I(6J$X5BBCCDV3%9D9%2VB<(=
M+W;J?4[]6S-.O59KUSJ-B@NC+#5K8%&V.MG1C_CX@<9!&(TP64@/X2GWT2=%
M?8<\8RI&<XQG&*QK772->O:G11J>QJQ^J2Z*]KEBN!XU$529PQX+,J.:FQ#;
M IK$@/(?%/ TP$C5CGG(:HV6%J1F79OI'SM_+]C]'GY_7^#)]T_:M\S;Y_[/
M]M\WYO\ @?\ ]L8</]1.%KJ$&&]PM.V'KK?SQA;T"NTNPM]FJU"UFR-UL\3W
M%<KGJJNL.ZNU_4;#M2IT6\&=JU>E01EKF?$UF;<J2Y&N3J4VGUKNH0.15)(F
M+MZQ52?L&Z4^]VYO4=_!CM=URD:>W]MLALY^$<KT4A=*%*1UKVM5H1:D-%TO
M&ZE8%HRN*)S\8X(!Z7W0BL!:@!#=<Z?''46\/;$#JDFKL3(S;'*9JD9QNXFR
MMKFFMA594&AT,:S0]@$;/0V!-#HPF/6VQM.KD4;D37IH]'+%7FZJ6T& E!&?
M<>[BMV:_Q'TMM#=VAU,_2,*W1R>8LX1V-W8+*Q53<QC0Z_EH19J;&BB6QTV2
M?D,279_JQ=>Z(%..!:[M4[;!02G$XM:M6K]CZH'3S%KBZYM+^O'KA=Z='"BM
MKUW56SJSMH[K.<E-N'4V8V_.'0Y*9S0^41*O:QG/CQX4M/\ \"U)\_N^SYXT
M6Z=#>I&Q-@VG:5TTM7C]ZNE?#UJRFY96UMX(P@2*K&'$,"HMACA(-I^BJ14:
MU.NPX9#N1>GUT32RQZ=5(;8;#N\8PG&?'C&/.<Y_75G*L_CSGS^[QC.>'#AQ
MC#ASC.<8\><XQYSXQYSC'G/V8\_7G];G/&,.'#AQC.JU80E2LX5G"4Y5G"$J
M6K.$XSG.$I3C*E*SX\83C&<JSXQC&<YQCB,V[<D.KR!S":^5D_'MO.>2+4H
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M,C8 Z(I10RX-%QY$I#36_5_IB:+1;O*ZW[RS&M_7OMANYQD0]0[&ED[U V:
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M,Z,L?3CL3/[3>F?(,TR\V+5.[1MYZ?\ =3L,4U2X:'62J-E@M=MC^:N>JUT
M/16#E(,/0Y52L=DAN9.1G75[K_Z/%0DZT@!8.L8CU%UCOK4M=#3MC[*+-7?6
M'8DG(-;_ *SLX&;LT]K?(J_V4@NSVV5M:)>I35L7'L;<V";9BRV\=5NJOI 4
MT-$BB6A4IJ+L706SX%FM6\>P%ZM4>P]63JK'U\%0]@7J]V.U,T#4A=UV34=6
MQCS>N!^)4QEVKOM3I:7QU_0AMOK6DC?RWU&GX^)'A\MX^((\/>"/<=@Z+ZQ/
METIU(3OL=M"U/SV!V_WKX'8@[>>WCY YIX/URM?L1'MG[,ZT[AUOU:NNN^WF
MR^NN_G+)KBTO[M ])Z];[;N!B1JP*<;MVM"!VKT6S']3,V>3*3=A@W*BBZI.
MD1H3NO@/6]L,.,9F[EZ27S2<.H .A^RKP[8-T:]M&0.CN^>[[/IVE[:C.U .
M1'SQ>NDC !W88:;/"SQTTC90;;V(=38LED4AOK)Z2];);,MFNFM25R^;(HN_
MJ:%7<3FQMK:GHS?9%J6YN1RA=>KM;Y6HZB#V29F(G;2K>N:Y2(M]B.3 IJ6U
M#)R/:C'UYT"TO0>N_=^D2>\_4==U[@]:=5]18!B31]ZVK3>O-/:F7<J\6M&
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M9-BG=G[0Q3*=6+I.QK74&IF"0>0XR/0^.3==@W<C(P;M(NP1YKL84%AB@86
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M#T-65J=RI5[#)1U+3*5.74Y8*'4XKHE9*5..72WEM()H9);4Z<*4$]2J4O\
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M$-.5(%]T^A6Y!V34];;.AQH\D5#8!S#\6=5$;%@CS;PWVTFX8EZQ,BBQ"?\
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M<0.([!"&$R!I&DJ$D!06W6"65D()4?*$ D%E4JG],IF* 7@'FH22\<E/!$[
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MKW9F:-@B.I9U]IWVC4'D^V02"3H[3@)!(8NI^H8F/,NP*:7TSX.3'& PWVV
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MM]0K Z8])#S"(Z7NOIS[B[8M3O2QLNZ.U>PNQ$;U!?3]MF\-H578=.T\"KU
MV'0Z'USO-;-:H=UIKRDV(9D@-VZ;KUXBV\]<X5HDPX5DB1Z\1RXPIC+"6?'G
M&,Y\9SG/C'M9QG.?U/G\_P!;'U<XSA/GQGQYSC/UY^><?AQ]N<?/YX^KD ?>
MWLQV>UWV1W+:JCO&TUCKKU4HW7ZWW.'UZQU;O\C6$FT&S)[:A#N9HG>!2K;R
MV!5+IK[-?9U#&ZT7<(=S 6?E5\39=D#(HN0C6S^\?<YW=?86^4Z3LVMC-!=^
M:)U0J>OBMFZ05;JA8J 0N.GZX\'VI$V3LL+V[E[EW4"N]BMVL[!21<5B/)=U
MO"HU1M=>?N+IIC+,'YG/G"<I]KQG'RSC/SQ\OGC&<>?9S^#\'ZG$PB%"NM:W
ML^Z;JV?1\TX"7N5[9L[X%G6=?UEJ(4,:*I@7DV8N-@'%'*</'F2ECV+)>J8N
M6.7A]^MA61KS\JND"[/]Q:_<B78,KVNOYZI,>O7<_3\C=?"M-T]G4$7K)8=X
MN:P=CS9L'7,?;$V^TZ,TFP4JV,;(BMB\0F09,">AR22Y^J1.Y?<2D:?WC=]M
M=@;P7L&Z?3T[];XTC-A!NHFXNK%UN>CZ.Y<*9L+JK<M/SX&U=;4FE5"<*44I
M':'75['[ >,0X9&T#;Q7S$"UL99F-[=U36J<*V'8ME4(#03DND00MV,6\"-J
M9:=LPN% ZZAC;#,GLBITF^'+)7@U-CQY3CMF*' \ ,B9))0VGMW($!PN#,*%
M)L,>-'Q9,T@0G2&8L*%#@LN29DN7)?6AEB-$CLO/R'GEI;8::<=<4E"%*Q48
MI.R]TZFJ7>/?PO>^PSUUV'VG]!X4<A68;JPG7A0O>H3HK&V2FM@8NNH#(AXQ
M4MC6*@#WU*D?1-:B!I(SW-M&?=0X^#67;3M!>MD,]5L;))OW[HW'[Y6CNA<"
M5?J/TUL"ITO%DH_0^(>CQH.!HB3O&F;"K?80DL0#$M$YNGB$%#<4*2FBY+&3
MW4ZZ4_856K5XH5JKMUI=SKP6VU&VU0T.L-:M%6LD!DI7K)7C8J3+&F 1P8^P
M0$%A\B1 )0GFI4-]YEQ*\[+X3G/X/.,^<X_5_!G./M^S.?G]7*=_6F^=F@^N
M-V]\PW83;MLV?6?3+]#KN1M.@OLZG@4:^4IJL;0V9V2H\.N!-8"G@HLSJ^K[
M.9J3 8D+?&'+@26X3<8:"_0%A#T]]P7KLM1]P=G#%V7:-0;MWM>2/5,5%APH
M0,-UGH*8&KJ'8QF$0F3,Y>X#=.MNYED3TI^4X+O .)$BCA\./'RQD@'C]?\
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M/L/MN,OL/ONO,/LNHRVZR\RZM;3K3K:E(<:<0IMQ"E(6E2<YQEQVTOYDG_\
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M(TOI'M]3NXO87:^S>QR;[UFV(+&L:CTHL>,:):W(A'H;<5Z418JP^-(@28)
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MA2JZ*17R*J16*^((H>L]<^SL_O8GT^)%UVL CV3L[0/42+7>%<K$06#Z4#Z
M,L%^T0+M_P .E<:F%.]=95J9NH,FXV4:4NDT'$A,5M# _#&31W/KQH'8UZK6
MS;_I34MWV/3<145*^VS7=1L5QK6!\M1""@%92XB67&I'D,J(0419B$P9_F=$
M2Q+\O<3S85<ZD5_L3I&V[!USJM79?:):R432VPR.K1)G9,XA3-?638QX,,V*
MU6YI2NQQ5#J]C),O$C@R)EAB0)&R%S2#4&36^ZP]CN\5QWMIR%(NU4SVUD=C
M>TBM\::L/<?>]SM\^CA!6]LA-/W_ **_>#&:CZY:PIZHFE7-7[L9V ! D&V
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M7)+!1<24<:4(E]SU*9/!&P*WM1GWW8A(<*3%CSIA.@3I@Z.<B/N$"4X6Y)^
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M[]_1(;_-P/SE'67ZF0?Z;'_L;&>J/L?/UWZI_P!&[G_:FC8@'-;N7\R5E_\
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MJZB5 "5WQJ&CDBE8@5;8ME%BC3,P6(,D@0L#>RCS3RE,Q438PZ(<3/GEB,&
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MCX\TZ<)-QQ0^-F8XRU(*EBTAF./B,^W-GD'6F8S;TI:$YKE;N]1SM11MD=C
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M,NLUC93B\*CJ4I*<)<N>$Y2O*O"LY^>/'RQGB>?E<]_?SYZ8_L0V)_XUX_\
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M=@&U:)N"N$=Q5RR:[KH^K!@H/;!&'1"(8<AYO+=HIRA3T"P2R&'<Y,$Y#S!
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MXXWI?U'HMSONZ%'=DFKS5*Y:(>9%?%WI=ZKC[QYM1,?'IU]=1%G)HLT.SAI
M07[;Z(<V<!(S4Y<7AW]_4BZ1:<%T.L;:#UI#8\%=*+7K73RFP"M?K$NHJG*8
M!Q*WE*96:\Z#/-C)4R"(9C-31:)SA'+R8ZEXNIM8T2YU --N/9-V\*T;7(8A
M&K//QM+#)%)9@C:2;G%'"X988ME42&&3:&[EOU:\Z15X>V:]<0\&?N;NQ80F
M2P$DF"[*6D80RR.7#%>XA[D<9C>&^:IT\V74KAK\@(LT&OKJTG:-I<&.VS9
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MBNZ^;9CN/;*L+TT;-?P4DYK(A^)#93 "SI$A4$6%/S\//3FH[\^:+>:?D/\
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M:/86%H[4.N5R*CL@EL*UF8ZD46J4FS,2K%N*6-K5B(3=>ZSKMS8C3#>UW*>
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M[E:EXUIJ*:$/4+2]UG/S:@B#5"LBER9,8+;I5FAQ4Q9-G3Z;V=_$?_0WM?\
MC;SF-_\ +>L_XVSX]G'PW_I0_C;RC\SY9]C\S^9^KG5!G9C>6\MZ9VHUEO#F
M&LM&=8MY9P[G*G4M91L]/N\/9SY>PWE.'<YSESVL\R'PS0\-VO\ N_N5JWN
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M03:H.K]AJ%;.NKIJN[(MLZQ:].13NLHUG"Y?@P_HR:3D,V]B2**UDM#8E@I
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M@7+90E3\9S/;CMM4,:=]14;H;JL.U)UY9WMZ<.]* 6T)I/M;KFA[2J==[5N
M"5O"=>-ITNO,!+]5Z33,1MJ&]/Z^%A[<9&+>9^GHD$84E77E1]L+RA2],[,6
MI#BGD96=UFI3;RU86X\A6=DYRAYQ>,+<>3G#CBTX4M2E8QGGZ93M[*\/9T_M
M++V%94EW-CUO[["E)PVM>'?OE^WA2FTH;6K"L*6VE*%9RE.$XC\,T3[K_P#
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MSPX<8PYQX^?GY_CSX_%Y\9_=QSGAQC.,^/'SSX^:?Q^UCQC]W/C'ZOU8^?&
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MBMW0\/4/6+/VN%+@2%6 \&R(#_09LJ[**@\!@^!$N#@7 Q'=1PXQB(:1ZU:
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..#C&'#APXQAPX<.,9_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g777688.jpg
<DESCRIPTION>G777688.JPG
<TEXT>
begin 644 g777688.jpg
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M0T17=)>T&B<X0D=E=K+P"D5&6&9S=X+!X>0Y2&.BU_'_Q  > 0$  00# 0$
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MM.@6ARAO%/\ :.(<=(U)&0,(>&H-#)X^(W*WS-PLQE]6S2TG"\$@*$"4<6#
M!K2(8C[27.#$3)'S3LGH,C.R46-;:8F#>(+:$4,7=75H1(4>L"OI:L-CY"1F
MQM80F1&)!*J0@Z$)C4L91PL**Q:FI%:VCF\;'?(8(0D*4A.$ $O?217<0U^N
MD?H3NB9!]J@L)[%5V/@\V:,@U,7G!1M:B6TM@,<*BP4W#PDN&*2H8"U9STFY
M'L8[,1%?GI6T5E!6(/I6*P8VF_9M,0NSHB?BA!)>-*'OA2V91$D @V5C"#Y8
M<J0)CR! ,79+.2B8MFP/-3(PN)DX;58#)AI@(Z<CU>P#BAF#@//DM8@@[>:V
MP6N"1KTQYK5+(5D+!'Z/& J5F0H$7 )))TS9LI 4"FUB+Q%GK[VOFEP6?& I
M^/1B/B),+[1Q9T'BDDS/Q0R>]4KPC-:FI $G60,46-12>B9NV=,TWP!@Z#/@
M2#-5LDZ=O<;6 \C]3G6FM*1]GNHL@6('& 23A,R(\[9*$76LXL4W:LW?[,@H
MP%'1[V6S<WL3*H@P8D4BU$QX,(&# P(>P2D#SU0% =\;GG]PN.8;;G0 :Q3.
MEM2_Z).5(N!SZ]\2#J2?T2!J23:Y))O!PX<.=H\H.'#AQ"#APX<0@X<.'$(.
M'#AQ"#APX<0@X<.'$(.'#AQ"#APX<0@X<.'$(.'#AQ"#APX<0@X<.'$(.'#A
MQ"#APX<0@X<.'$(.'#AQ"#APX<0@X<.'$(.'#AQ"#APX<0@X<.'$(\V-A>(-
MVJJ'Q$N\-*P%2,6DW.]OO#!ZP4;![?DYV/5M4FO8[J';5E3V4-7,/"E9%KH[
MDT":G"8S1H]V,K[JM$%QFRJ;UK65VN\5CO=;D5LJYX39F_7(! _!KO/L"WKF
MICZ[YDS[)17O*1ZAR"<:R,W'T"DF%,EX40+UTU*("]H\&,^3]D\D&';QQ?3=
M'7/H1)[=[<6_,^T5L0>=4$M KT[/YC'8(_#FE):,JP*EZQFYIDQ%96C6@BLF
M4C=00HS=/" <(YD+( NTT?OF"J25Z>>%\YFL7I=;M7<#B3VG"0$:"Q-7L/(5
MAI^%VP_<VC%:]+N=XUM&&+6T3#AU84:K&3/Q[R?&W2LL$1DP6=Y?JH0@.P?C
MZV525P]B(6%IVG+%@E>0SQ!-:TD8*P9W[57L+P_JYC<VEPBQ?:\4CC5QF4OR
M9&,&QL%&O!< ,MFB#2P9\JJ]39-6!>+MVT;]L$^NMQ4'UU8A1]Y,J&/RRMK2
MLXP4UD5D=!#_ '\JHX(#2J!@V;D*&AT?S7=A)/2+1\^DQ+4S&$V@L;EL3SE8
M],/"W[,V7-(W ^P]WV':$B#S,]+?:=JS1I)+%COI)5C81W!V8P$2K:D?41>-
M(5-2XPG*A:XXF/#GG*@XLR2=2=7\,7JAM,9.X<=@NRZD_ANL=LN7NU>T!U67
MQK=Y#))7$4G1][EKL:%NUZZ!RN  )(^61>9@@T[$1[O$:1>CN(17/4'C?]PY
M=F%2F;=<.MC&NUFWA+S2>?%.V+5=S;2O?%I=IQVMF<0'&H&VCZTTJ8RW?FYM
M@V90 FA:K,""7U=I+R%6.?;GQY^U[L-<D-Z_MZ&@6Z&(A:E-W]&RLCFH5>I(
MIXE]8](IL'-C;&B(I@:<3728I/B<N9Q>/AHP(2FXF)JGRP^-V"G9'%.HOAG2
M>R4J)B7;6["$\680!LRB WLC)DFKWY#@3>?UG&!;_P!@(1@B?HZ-/$)I"X0.
M*.9+4(17,C# HPRT5>::O">FWA/VUK:#B&]F[+EFIET)#VBNC=Y7.L_:7O80
MB+"21Q5_#FV+2AMM6:/"#4)<GM*H9-):*8*[FWY$6BNV0A0QKQ6+RB%LW#1$
M;>4VA+#W>?Q+H^+M/NU?IJ&TQ#H'TT'T([6KB$OHY"D2+1[)/E1<%XG"7#YZ
MG (2"DTJ(F9AKIEBEVJ \=R\[_LFGWPKK56L3HZ:S?PT(%-$9%84RVN (6\1
MVL34D O(LS;Q;2('@==R@ NO[2+J 5YK!RHDDP&B26RFF\K;-\.;P\04AB-"
M6]V+M=L=N"9*S.(U-8791-UM.["7W1$_'%E#Y$+<LRDT*.&S<(TDZS+V\<=M
MT03(@0<HZL-7UMX25![E7!U2WNVZAMV7AT@=F-^QDIR5='JZ;[,Z]-N2/P##
MQ<O 6:BC.#DU%MGL/9[[M8VN,;[93RA$G>TO861T XZY+ ((;L1O;=_)55)(
M[$@V#\T]@KTG=5C?#XD/6/1UCDBS-UT%]HN"3Q=JWC:AS?1DL]RT50K^I?OM
MV?O>Z1D5$0;$-A0]B_-2EIKU^+30R%9M>VG:VDM!5CRC/8N)LJG()0F@0"[Y
MXRB=FI)28E)RB;10<S'@MGAVOO&;U_:X"-!VL/)LH<- 2^+NY5$Q\E, )0]$
MR6-N9 '*OU,.1QA8 2+!MR+/U#S(PR88Y7RU)NT5(P1_LS/HD^+$XK&ZCC1(
M\DJ@<( *MCX=Z906D$FEBR)5TPV06()+2J:3&3*INMU=%)!+)*8WQE^<(KN+
M?F<2TZ5?=EW4S/&,K+:\K2"G,DV-B7 2/N!TYN:^=:!\'G'N)*+3*]3W\/ID
M:M)LSTJ)FH3;3X9?2%(#K:*<XE"['O@EQ8!YE$7,2QZ==H;SLPU0P6YGE2R#
M;L7U"3[6@W%<123P$A72C0[5 4E SH0_.K'3E TEBV6;B-31 I%W"SB*R!DY
MC2^BJ+ME^;;Q#&L+ZB=:;_LZ"G9-.+]CFQ)"$5*"(/=?A8."2BR9DZ'MW[HB
MY;,!L4B!780S<O'CTR=<AP:*R>""A%E#>M+K*5$N\VJFN:-K/<D/8C'^\#J&
M-1?=X,"8>N PMPH)V;J;"Q*SMVH+&:[ZCQV[MUNR:H;N5MM]483H(,$K QM(
M=;1P1TX3>N S&D(JV%*.DV9@>FO@>EMJT0WU'R$^/VPV1036'G# ]?15B3>M
MU[LPU)/8JE9B<IA0EF6F.3.<J46E\;Q3;O>I0ET%.1U.N8:@BW,38>/.#VO<
M'51DJ9B!=/7,S\B*@R:=,.S+08,P]+6<6]+2RDN<8PLY0A0"2DYKFPGZ3\2N
M$HDB0N.T]:,O<D?DYS5N [ZNVNMGZV!?46ZTKX;[%IDQ3A+F&VS*VPJ6#IPH
M()C1PF0.%&29<2N!SV>Q/9K:9>'PY[$5F:)U6VGS*I6JDID3&-*FZCCMAW%!
MZTL67/4RF3T,2,U='#\L.I%7WMN*M'X!$VK@F(1SA:" ZV/9!Q23BZDZ\#I(
ML\:D59 RI"'MC.Y!E*6DY9O?:"*>CG1RTFS!E,FNZ6Z>$)8U1DB6NIK&S[>3
MD#O*5NZQ3A_Q>K1I#7;$W'7$+'UX$9P]4"_W=-R ;>,IYR'W%D47CQ,@/4:;
MM'NKMUJX14U75UVG'\(59A&=Q4F4E01WKRR22">8L@6T(.OW:Q8X!)TY^>&3
MU7C0LG&+_K1K;0^V3U:WM9%8519]D-(_.Y.H-!PNMI&LQF>H1Q%,V>YJF9S<
MQ#C[URY8'23,*T%2@W[7T7)JY?P[1Z]J],*$GEN+#Y[91V*D\S.9JA1X;:2G
M1TODPAT7U#CL98B$'.!Z>6@EKNL@+9ZMQZ;AQHVPNHJHG-48&VB#.#UY3D-:
M5\/D F!-8K5,3CK:$BI8Y9/)2,B* =JR2C0^2.Q@YT?9!=&38RX'LER2;E5H
MANGN<<O2:Q<4SC\98PJ. 1J+G4>% 0X:'$L=-]W#Q31F-'*-F;715TLLX5T0
M03U46655VQE13?;-%\69S]F4_P"8_E1WRKZ?>8CC>)\P [-RA^)LDE%7%9]E
M^DM'0?K6U=0M.%736G8C,4^4J8G8T0#KR<M(UTY-9R\7E:)AO\4=>N;_ &CB
M35MF=IF.QV3-;1+LK49NL;C?R:,$NQ/5.J9U6D8(5ZRKBJH!<CEHW37FD&>;
M.)9=YGL3N;WQ"IU%_6KU$B%:GAR@R.1N<+&6Z4L-<W.P5I&814Q:S(N(>Q^-
M6&3K&,/YS'@)/5YJ2"@Y<[06D(@00U(/M7PT>1;LW>KQUA=%3#E?UF&92$,.
M.063CZKHYA)*OCC:'UK(&=.PMJ;KR),VJ[%K%H,608ID(E'&S-RX:(!(^X'C
M$&RZS=)KHBJIIL^+,Y^S*?\ ,?RHXRKZ??Y.WW>2]FNM60'.NN<Q@9Y^CCS_
M +'3^?R]_P VOEGW_5Q[L_4]W(,6L!DL<[W=3XF.D !K1]AUKV32D=6-(4Q0
M(%YS# < + Y>:G2Q5R](C1+$N]9A(DT!C&P\B[>G'94FLHS:,-8,]KKC9/\
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MIM'1)#1LZ3WW:N-F;T@BXU0<::[;(*Y3QHKKKMLGG;&,YYHWXH_KY_TZ4_\
M]I$2_P!J\\Z?B=:Z9[8&O/33/_B[K;WYTUSG\BW^?GSC.>5\^AI^=I_Y/3\'
MF?</\#=.JM$I5276IUE<](RTTMI$JPI+:GFD.%"5*7<A.8@$@$]'3BBJ\)$W
M3JG/R**9+N(E)IZ72XI]Q*EI:<* I20@@%0%R 2!<V/-'M* ]C^O>":>V;TI
M_&NC=YMMMFR(CY:ZZME,YVVSDKY8UQCW[;9]V,>_/-S_ !2_7/\ Z?*:_P"T
MN'?[8YXF0NB?PIU_6T_R(,?\GI];UO[WGUG1/SS_ %M/Y\_\GI]/ZGE:]P$4
MMQS7$$^ E*1I)RQOJ2>=SHN!V,4)X4YT)2>Y,KJ2/[2[LR_9\^I[<WMD_%+]
M<_\ I\IK_M+AW^V.68=:I-&YO4("1PR0!9;'W9*2(-3D:)LS8ARNR,N&SQ%N
M1&K.6BRK1QINW<IIK;;H+:[)*XUWQG'/YM7H:?G:?^3T_!Y[MO SQC7PVJBQ
MKC&N/CW>&?+&,8Q[[-,YS[L>6.8EX8.#22P3A>5JTM59J?<>K,K(%E^79:0E
M#LG//EP*;6I14E4L$A-K$+).H$7%A;&TSB*HNR#TBS+)1)NS7&-O+<)+;LNW
MD(4A( /'%5QKWO0=+6/4J_G2G^)M_)S,Q])7!EAG*>^,854SG.=-L8QCU"N/
M?G./M\^^90+^2;3]4I^\J<UG+Q((RC4$<YVQ?\,3APX<\80<.'#B$+$1^:&=
M_5$_X*@W%N6[+ !%M7K4R\>);$:,Z_U]?Q0KA^/39G@]@%+K&-@ UOOY.6Q$
M9M2Q-=X\=8RR43-,,)>CLV=>;($?FAG?U1/^"H-R(5U>'%0W8>\;ANJYX56%
MH/K%ZXP"@8@-L2JH[-'%8[PTU>!DA+@)8\N[VW4D2MOL=5Q3)F'4:K0]JYR6
M=*/DL#(##_R53]-U/KDQ,5GY20]$T_J8U>F>^5I]A9LU'5)U:<EJX'H]=5YO
M84BO*#QE[%]+ZI6M+W5PT@RD>(EI)F$PNS1B;W5D29[2 L/?M1.J2>-%L=OK
M%X@)^\]:*,S[KG*J:@7:5L:WZ]3Y:PX180>5E0T:DTZ3B<O'Q[08<@$I.P&'
MRB61]!T.- ':$;-!GLC&R'4.+-?76;PSJ1HF8.+.F,?KFX;99,.OH^%VD?JH
M"SG4%1H?K5677UMK'9(]>GS+!(ZX@9B:)HL'['00M+WHC_=#=JH6?=;K?T9L
MJI0?4V!V/=$+G-<=,FYI]5P>&U09@QZ43-] YC5H.4V";.6=.F:[:-P2PIJ@
MWCT<"!TG\D,,CK@H@U"H!G<]8= [?R'JB'A_6!WKZ>57,I37EB=D*BA\XA.N
M_P :XH<F(YF= KZQP7,<#R([.VSA$LK$3(V5-PV-=RSJ-N/;K9DJ*0<NT=D0
M[>]774[$5BSO^I'T^/PUK8(6*L)T!?%R<-?Q9S.AT@9MVCM;5=B3A#-Y-!GH
MJ9<$HBS=29@@X"-UGVBF*=+TB=A%IYM/M4MBG< EVMR.Q%<;;I;/^D3CISI"
MLOL'=-E=VV%\3_22Y;Z[YUT^*NH=/3;VYB/D*\,^41<77E>OKY"%*BAYBB)X
M5$LZ;0$V*6LBB^K$7ZRCG(^P=I^_9#(-(DH< F[V.OHB:D0O9$I!QTO^*I?&
M@]8= [?R'JA$ZIMVIZYUR+6,S:YZ]C@]&/P:595(R)GJJK'++5DB4!,M6B.5
MGKUA+<PZ6* UF;=?#YO&CKM/&&HIZLC]M^TO7)Y84-JAE=M9/;$L.-B)?!XD
MREX=X6E4<D(D@?CI0(FV<JHOT)& $&#T=317RY/@PY<P'0>C1CYTW@*P\.6X
M5)$RF\K[ UU))/&:ZZR5A"$!5*S6 MX^"Z\QV_XV1-LIE#[[86M&9I825\OW
M_P 9:_G,3<Q=L&6A[I*7Q&2'&#CB">%D[B]EUY/)3V,L.R4(S,NO]H2MO)C=
MK,E939% UF#KP652C0*YV%3)##RT2AY_?>3UK,96)R*,B5)0=3E+HB.6'0.W
M\AZH1."S>Y/5>F9II7-JW_54!G2C <2UB<HF P4>RT--C#H!MD<NIA?5>2IQ
M\XG%F>VNKR3N@Y)B ;DGK)PWT^F_<CJF[,5  :]B*=<&;]$##U-#4)]'E75C
MACCE5@"(Q5--[M[1:GBC=R&!;XRG[:.-70,7AV8:N&*:VL[IJA8UH*V5F<HB
ME%KHZKVYN,S$TWRFVO65U(W;:/;DLFFRBFDG6D*BC<ANWSK&UD5%D6!)1RIM
MK'(#X9\JCL;C5=LKX K5RZTI=&U&;FGE=YI(D:'[46+VBA^(!,-;)T0KY4J2
MGVT//*O@$P^ ("\S&':QV6E'CO"PZ!V_D/5"'NZ\23J1K<9"I1ET5D:2B->7
M+/[3F@ZP8RM':J3IJ:57 BH:7[:NME$GI>3V?H!'N&BBS5.1QLS%E=E)%C0=
MHUH+VNK.T+4A=>UP09S@%/*5EMT@+&CA=@1BSH9#K*CU7EP.NJ7F[]L-9 =6
M1?)[X2W%.Q!(22;MB2.Z"=;I_P (662474<8(]E!K&,=>*X,5]3B\3J(I!9]
MZK?L_1'9&,%)_8T-MP)(R*H?6BQ,),:0)Q7[TV^+/;,'DX]*DT6>LP>L_1E#
MKS/8]8&MAO).090B]H_(&CY*:EW!R1WI?0*[2DEVE5B6/8DR<9$:@6D943/G
M3A$\OE:2.23!==05A8= [?R'JAV[=O\ 6?\ PX<.+#H';^0]4(.'#AQ8= [?
MR'JA!PX<.+#H';^0]4(.'#AQ8= [?R'JA!PX<.+#H';^0]4(.'#AQ8= [?R'
MJA!PX<.+#H';^0]4(.'#AQ8= [?R'JA!PX<.+#H';^0]4(.'#AQ8= [?R'JA
M!PX<.+#H';^0]4(.'#AQ8= [?R'JA!S5YM^5*1?<EY^];<VCFKS;\J4B^Y+S
M]ZVY058#N74=/F,WU"_P$5E.\(2/GDKUZ(XAGY (_=$__& IPX0S\@$?NB?_
M (P%.'%)\%4ST?)?NS4*CX0GO/)KKUQ"6UNK?1:RIM:=@62XB;B75U(2]NV^
M46MUT#WK=W,>JRW7M_()\U:29FVA<=)=>AZ#MJA)D1X#1P!&V:R3T/A&IYOK
M;2O_  XNNDCA]N$;3J&MR$5E:WQ6D<T[#B X9*5F.K%*TW[.3VD\T;BGY%QU
MJK:HW342KZY;(-5G/T6^5I,J9?5]]O.@G9FR;I[[$*]K?8M6W?=E':5M=RSG
M\1C:SRJ*EZFUV?K>9[L7Y=-T5V)W1%+1ZP$H\NBP(Z1^[G$P>_[SQ"A-'\H3
MX?G;U>VZB/)YTIE"/6<8E)ZPT!]/6;D,(=^%5TMZV*I8A<J>FA1/0I<U53^(
M[9T&.7;5&,X+ZZIQDT.)OI"*.+=>Q]/=?KW@$+G5A6"0A$3ADHCMPQ2VZ]MW
M>K$42RD;,Q>+2;>P0A-F-+#%0DW?IQYP_?.V&KLHP*A54R:(QXEI);J%U=*F
MA\>-RJ5.Y[(&L:D"+AU>,G1L25RF*UBZJ=C;:BZ,@;F35D.J>8$H&7GZ3=0D
M4AZ)%)RINH@J_1C%>W6>WZDH.GZ+JZFXAVCK&IBE:12FQKZO(B?GM*MX[5,X
MBDQN^PHG8]_U%2E^%WF2SN.U[7(H-6D6@9B;,I.N--"(2@-WBA&:#MR,W-&(
M[U^K>QB)3K/!^@R<>C%KF*G;LXXB,ZU]GZT<.+8(C)*_1UL*OA\UR[8(5(_D
M$,8%C38</'%XPF@@*0BWF7=)>L5GG&,J=Q'; MR$A,7E,4B$OD("L+5C%5KK
M_)S'+8@,<+M899H: N-EVT?8R<8_3;,=<QY_E]'TM0^AMT.ZR++[.WD V)OB
M$D[ R.7/BI\\2<V/GM$(P"O"/6;L[?JISZ&S00RBP[XGR--Y'X^SKVLVL89!
M4*]BJ8V25=PUG7<#AL#8.G+]I#HP"C2)![A+X<2P%&MA^Y0ALAHFFJ1**H*$
M""^--<KO72ZVV/2WSS<N(1 XMX<W70U$3$7(K7"\($Y'4TC96 ^O:U2MI1C>
MAY8ZF]-AHC89F2DI)'8U7DE?D"@,"Q=X9.'I @]-X+/WKAVIF(3T4K>!6H-N
M,-:'9=U-D1L)$R)R=["V&>'6".KUL>:15E8@HD_6:RQF/2DI??=B]QHQ=O72
MA-RV4)J+O%9L\.(15UVSL;XKVXH*]CY?>C%H^X]?\.]1G/KE">/0RGELM_:^
MK\_2]/W^E\V/+D9_EIS]CF?OIC^8\9?=_P#-S6_]C8Q^^E^1!YBNK3LRBI3R
M$NV2F9="1D;-@%&PN4DG[R8^D?!EA'#T[P?80FYFG\;,3%"D'77.53J,ZU-
MJ.5$PE";]"4@"^@&EGNE=/X_\KF?=HKGWE<>_P DM\^7N8?5\O+[7S_4YU,7
MCYXQGXL?/_ZV_P#X#B63_M__ ,BW[PIS%Z_-C]+'[G,Y<#[2)ZBU1R:'&K15
M<B3<HLGD<JJUFR@'4G4@G7GYK:U_"6I-/H^*J Q3I?D[3N'0\M/&O.YG.Z<^
MC-F><<4.]0D6!"=+VN3#]^7'_P"S'[;?_P !QC1U/6>BD))MG<5ERHX:? ]?
M1>8TPQ6V0]9Z_/J,[95_MO1]5CT/F]+;D/>3%IK\H0[_ *^8_P"^YYDVHRK$
MK+AQA!0OC$)S9EJ[TA1(LI2DZE(/-?[HUS1SGR?YB,S\2=/KDI^Q=/\ 7<UJ
M9170=%) ^^';K?!ABZGJLH:Z>GY^CIY>GA3;T?+TO/S]'/S>7E[_ #PW^:98
MOY195]R%OWQ+D.P\Z7V05D@NM@Z#F*T@[.VO28]#S'R&(2>OT_N-O\;'X/#U
M^G]QM_C8_!YU>'+SR)Z/>?QCPB$]]>&>T[56(ZM]2YG<&W?!0<:R 2@;>1:)
MXC#=9KA[[24DXK;?+W#G.^4/@FN&_H8UPHKC;SPF/ZB"Q_\ K+/_ /LF:_TY
MY=E7_P"5I+_K[_\ ]]/FZ\F6.$G&M,9;I\C6BQ)R2$RTLSR"EN<4RR AM'&/
M23CJ\J4@9EK4H\Y43K%O3&#,-SC[TW,TU+LQ,N*>><,S.I*W'%9EJ*43*4"Y
M)T2E(UT M%#.W@JL0K9^1QV.?.LI#7R7JLU8U1QGX4AEOZ7IXFRGEG3UGIXQ
MZ/X[R]'SQY^?-+_J0K+/_I^>?]F[7^E_/0(>_(0K_P!3W_\ ?TXE>2,IPGXY
M=2M:ZXI2@H)OW/I0T"4D:)D0!SGU^2U.O N%@$CN6FVNG*Y_^[?YT3K;IV_?
M%,O]2%9?]/SS_LW:_P!+^7Z=#26.GW62&T*DCFP=(R>G9G$I54UC6[W,OE+Z
M09;9$)Z&-4/9^77P3"N""OPG&F%LZ(YVRGA2\8\?_(AM^K<?OV_(+%F)*UBR
MFM4W$$Z:A)-3C4XA@R\K+99AII]I#G&2C$NZ;-ONIRE90<]RDE*2FOI6&J)2
M9E4S3Y(2[ZF5,J6'YER[:EMK4G*\\XD74V@W"01:P-B1$UOQ5RGV"Z?YP[?[
M(YOU7]B=YC/8W&<Q'4?[6<ND<O<&LN?@_J1SUWZ7P?(U#UGI?!_5^7K=/+TO
M2\\^7HY@)QS=>OS9X']T"/\  );F,)VA4IF3FG6Y7*XW+/+0KCI@Y5H;)2JQ
M=(-BD&Q!!UN""1$^4I )MS [3^,6Y8SYXQGZ<>?#G&OS8_2Q^YSGF.X\H.'#
MAQ"%B(_-#._JB?\ !4&XSN+$1^:&=_5$_P""H-QG<@,/_)5/TW4^N$3%9^4D
M/1-/ZF#FK3.<0NN8Z]EU@2Z,0:*#5&*)&33&0"(Q'V"Q1^V%#4GIHX\8#&JA
M H]9C6.B[I/=V_=MF;?"CA=)/?:>(_L5UMH[MG4\@HWL76\?MBIY2[C[\_"9
M-J^R)).XL?'2< NML,>CGVFXXX*8/D_4/$M5<H[-G.JS1=PW5GXAX=^,XSCS
MQ[\9]_T_/[_J>[YN1_<WTT;71;E.YC;G9S5-!5K>S@]@HCA TTL:47A&48X@
M/^!Y58N!6]*N7:I-5TY1=ZR!NBFS0V'*J.WRU:MF+9NS9-T&C1H@BV:M6R6B
M#=NW;I:(H(((IXU311123T2223UUT33TUTUQC77&.0RNOK+9\MM24VW2EUA:
MKD%E4<*Z_62RF%5IVD*<1.-2.>26'2Z$)-YM G4;L.*N[0GC=!4Z[ET(.-2X
M_!V'N%@;95PA'3H_Q!>MUSXI^-:S^.1>W[8KRJYK\DSLB](EHP:MBGPEW ("
M3D2(9I&U)<X@9GV^("J/6!N2 F+PV("JLD'&&[2L7MWUMJ68G*^L6WXA%)K&
MH SM$[&";E[[8&0(F5=@ LC<M&K!SOJTD4D8N(O&$=,[OY-*L(QB/M"1]RU'
M+02A/AR35K.'<-*V>F$ZB02Y:(G4#J3XGC2%ERC7KGU@IJH*[*:WB)EHXE&X
M^^DD+4?S4$0@KR8D7\.99BDLB$<D3]L]85I>&="IR*L@'&+ D4#&2*+].!5?
M)LWTZ?E8,:Z;6W9-P1!Z7FC>Q@]C2P/)CT_U8EFC.:Q:5"60Y=\ FC(XX&D@
MR$.^8^(1TQKV)PJ<3?L-7L6C-@,942C9$V[)L-]V4'-H1:9.#(]85@I%-(M+
MG;.%G\2UB"W%3=ZQA;S5*4O6HA7ZOKN[3M+5'8%F#C0F?$X0[M $UA0LS[*)
MR*9TUE7>R8>R?NAKQ!L6B39J0<F,[M7":";!?U6%_+TL52]B/#P[!16'2JI.
MO["23,KV9I2R*HNRW-DX?)XDV+V=>Y:R7I8LEV O<M;L$2 ,IM)E7<Y:%>RL
MFGD=;.!Y..C[,$0>7;R3MGPLYO:!J=CL=DQ8.J))-.V-BA(7FF,D90/E_;($
MU'R!P?G/RF-$#@>#$U9(ZB8H1%8NL[%238=(GY)\&&F,(1+"T?$7ZB5&'N<M
M)[5;O%*$&&BUB!XQ'97)3;9I%YJ#KJ7?%UD,"*)35>$3:2!(Q/$(>Z.;P4V0
M0&R_V([V]5C(.^^/72')"=+>M"NZS)2:Q[5@L68.I8N;U?#ZPL_>KG\FD#MN
M 8IP=F@>= !4NWEF@P%!)@>:P@M)G1?"2KJ)5E>&-95ERBWCAKM%E\SGT%[8
MP*+H2"NY3(R4:&]EIU7EEA5B+A]<WL#9&J#]8QB)B@->1:L8])JZ0<(%AS>?
MN59UG+2GPRY:5TL?2,=B6T5UO\-V)KOL%HK43.2^WZB[!=@9]?;P/6"I.;HY
MK>PHDO:,_A V:E$YU'# .0MRYJOEY#&8T]'H1-^M^WG6ZW;,E5/5Q;D5E=D0
MMU.F$CBP[<GH\9$:OEJ$$LH:BY>CF@PF2K^7NV ":CQ#]^]BY F)3-H,M"PU
M1TF^P'B0]5:! =B%2=DA)9/NMU9SBQYE5L76?/Y8\Q! 88T:C0O=H+>CGDA%
MI2B([RH:P7(DH*,E(8]+QPD0[1<J?=0])&]3SZI)JUG^I-&JRO>@BF)Q%O@>
MQK3N;>L>N5)%4CN>>*-UJY1 )QE1XL@^6F&5\F5?86VFP]5"VGX8ABSL6[%7
M5_:#:FE[_MQ/*TB.E4"E)5 ;?[D027PBPY%)[ ;2IDZL"#QC-BV.<A$(0!Q
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M.&8AX?4ON%J!QTZEE</R3;0^\9LI77^4]+#;NUV8-QHV#URNLW:V-*UO0B,
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M6/'S=KDKKVAD]R'R@\*1<98AHZ6#H"W@,PR'2"1QG)M:,2$T(?=[KMT4Z_\
M5Z9R6:U, ?"'AL81CP88X5$;B8/%2\DWEQ2+Q30>#&$_9+P]ELYSO*"LI+-6
M8X6&8E&H0<T')H0O2'B/58V3>OQ=3=B93'"4W=UC4TPC%<AB$4OZR!]B?)@^
MAM3F'$U9::O4I*W-N6IJRTJWB)J)1:63R/R,M"XX4.(:::\5NA@B8Q5Q6_81
M9)O"93/K/41KP$CBA@4!O''7FPD+=1(3EBY8'H39&KA G'(4C.39F-LGTPA;
M*4QMHJ0QO#[PW:,=:F6S277N#$8E;R>UI'0-R289'*&G9*=YLDE+Z6"))[,H
MN9>2Y8@XUP93E T:!-R.#AAPV"R,W&G^01\.+K?I$91#W#:?$FTXJN2U3-31
M>?F2LGEHZ:VN7NV:2H^??ZKO7\[E=D'BIXO)=LZ[9T<Z"V#)B*9L6;9"%()\
M5NK6KV5C[)IF\JZ6B)SN!N9>^Q8G-@8JMNG5K8I^8V89*Q*6O<M&LNF#P$#A
M<,&LS4U/2 S@4&$EF;!Z93Z=E>)J*@#B''Y#6%CUE&8[++? =@8+:$)9:VY%
M6\(ZY*7G#7$4;PV>22$$&DKT(QW&)*G)R\48,-Y$TDQ:(NHK*GD??V/#[ZZN
M']KN3 N6R%C<0>_(]*01J8E' AD%[*6 #M6TV$9U:ZLB4?P0L,'B6@G3,GE_
M%BI(EL"=M$%&:+'%(>'G3FX/=F<F]^2B6N)),9>]M@U<\GTMIW)9?53.F,%-
M)R#T"OA.T8@(T<-B;*/MQ P6[;N2CIB2?')(J90B25$W1'K^K819D9#R $++
M/3H[49)/BXX>H.H\:>@WN[8S"I),X+)A+ARQ4<"9-")C*8L:8*HNQ9MUILIJ
MDX.(OK_U\@O7*(FXI"5CY)663F569-9-*2#4C(IA/IHY;N)'*#&PL:#!-7A'
MX&R2V9Q\ #$(Z-=-D1NCA1TX</3B$'#APXA!PX<.(0<.'#B$'-7FWY4I%]R7
MG[UMS:.:O-ORI2+[DO/WK;D?5O!=1\QF^H7%93O"$CYY*]>B.(9^0"/W1/\
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MS3TNB55+X<$N$-+4X%#NI4',Q*TI(-UD6%Q8 WUB 'Q;D?V/G/O00_F_)=U
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MZM,1>4OPF'&"F^XK9?+[#?X3E/+)/#?.WJL;J^7IY\8GGCZ<?KXY[5_!>_\
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M )TM]/ZOG'MDM]<GW[*6_#Y=#G_Y/_XAV<YS[)H_WYS_ .E[?^AO./\ P?\
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MR7G[UMR/JW@NH^8S?4+BLIWA"1\\E>O1'$,_(!'[HG_XP%.'"&?D C]T3_\
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M_P HES\NVM2%%>9"BDV3<7!L=;]K'=>Z93!]9G99B;81+%F8;2ZV53"4JR+
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M4V!L-I'DO+7ARLW\6):/UIA?WM+_ .W.'XL2T?K3"_O:7_VYRZOBS5?V&/\
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MXRP<I>CJIOKMKIGS4\_/;7;&?+R]WGY\DK^*U"?80;^_0O\ FW*[@?Y))_\
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MY4Q0B;@;MC0LK? L0>T*XG<;*[6.D2F\3M"L2<7BSJK08:1RMH=5S,42FZ[
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M?O6W-HYJ\V_*E(ON2\_>MN1]6\%U'S&;ZA<5E.\(2/GDKUZ(XAGY (_=$_\
MQ@*<.$,_(!'[HG_XP%.'%)\%4ST?)?NS4*CX0GO/)KKUQ&^=]SZJ@5JO:M>
MK3D"D:,PF-65/(=7!Z3UI44DLA,0X@X"RY6.]+V$5.,9%&2ZZ#$:9TC$?D\=
MDDS6C<>,LR:FU2SMC0,34)-/E)C,I+ +/A=.RT#!3P6:2"#V!/B;P/&P,Z"
MBCHC$'+MXP?:J)'T&*Z>C-TIA!3+=;&BDD76.Y65KV>?J*]!M<5QV!L6O+2N
M!G\1,F+2#2:!Q6N($81J.9J2!&- A5GP.K8K%I)I+H5*7D7V4D1Z*N=R!EFV
M!Q1&^%I)4I3%BSZV8 U$U9)!J5:IQ2G\1F0'H/OV&SV).:7,<0E3O:=3A,_Z
M(2.FV" 80S<$)M."8E_); *HC9"*.+$J[[6=>K-CX0Y&[;@23@Q4$8O=S%C<
MPC(><1FJI;% \T%3&9P]Z8P=B836.G!C]\3--6HYBFYUW7>X3VU5WRHOLUUP
M-CXF6"W_ $F7%3Z4)PF"DAEKP$@PFDS7;CWB,2B;QI(5F\CDRS,N+=I  RCT
MKNV),%]&>4GK796DBQ_"(M8+6S79I9S*V_DOJ!U$(_7T:@#8$?L)/Y%:&@CN
M,.ALCL^.U,5:OI-UUBJI+27LDCMFUU)Y)6D]L!##..'&GU"_"FGUUF+$MFSB
M3*L5K9O&]2$@KAH!G%7B'U36+).O9G,F:PBG[N%:,IC*"_7Y$ID/:DAFJ+T?
M)1$FF00;.H_[+V0B]N%W/3]D&Y/&J\M6MIY(H2O\%F8&&3J+2DU$G/P]^+^#
MR<4"+/WX!?)(44'X1+-VBGPX:_:9UPX9N$TUFAW$ZS[R*]XV]N2#@5NM$@A<
M4NTU*3;.)Q"!R>?A$I!&H^4FDD5%Q54NY'N6NKQBR+.5A9%T@'(X;%]MF.B3
MZW]'M: G5?S1O+@I%2(UUVHA)=(5$=0KR2$>QW9Z/]B&TB=D,D'6=W46R)(A
M7>KY%\L;*FG9_5=EZQRS<QA >%!*ZY+S1]!^TDWF8F03'K[)1X.\8]&9"0U;
MU&$ML1)]BE@U:&J2QDI=,"%M/98M8D=DH><$C0A=O+#QQ&72=ZY0B?+CN;U^
M0ML!3B<O>/S\C(QB/L9**C4B*UDE,9U$=; @4$>VB/'.(*TFLY@NVLNBD>4-
MY=%P;@:Y2VT4.Q] K*C&<9QC./?C.//&?IQGE0G73H/V"I::=<6$TM.F+AI[
MK97M:5]78$U#;9 %87M!:U=04S8$3B[.T"%9.;4ESYPX>ZV#. 4NDL-C!%_"
M(41"#')9T=MZQ[L8Q[OFQ\WNQ_@^U]'$(@!V-C,;+61N[*1\*2=?%\,EER_&
M,W;C*>FS_.B>5ET=U/0T]/?T=/2]'7TL^6,>>?-#?$:$_8?&/O&-_F_&AVDM
M:#0^U% T@++,R&L:!.\HIC"+O'J'&Y'"6_KFS=5+\=ZK?SU]+TM?+\=C'GCD
M=/E^JK[(77WC,_S/EAS[U/$[-!QR4#@?<"PM36<*"K$*!UO?GOK&Z.!Z-C=[
M".'7I&FXG=DW*5*+E7)66JBI9;*FTE"F5-(+2FR-4E!*2+VTO# 0@L)RIC&8
M?&/+.JGGC((;G&<>JWQY9\VWS9\_?SY^3^!_83$_\WQ?\UYHJ78"J=-_2S(7
M7HZZ*[;?[A&?=KJEOG.<8PS]^<8QY^7SY^;'O\N=7\4?4'V2//\ -\W_ #+F
M5.#A#TQ3)]5,2XZTFH97%204I <Y-+FRRSWN?*4FQURD'FM&%^&J5K$C7J2W
M7I>HRLPNCA;"*LW,M/*8Y;-)"FQ-@++7&!8NGO<X7M"K,3Y/X']A,3_S?%_S
M7C>B H6) MV0H<Q&L]'#Q31HP:(-&VBBJ^=E=]4$--$]=U-OQRFV-?/?;W[9
MSGD7?Q1]0?9(\_S?-_S+CR@]GPD_'&I,456<,U7+Y+17<:00SE1!QE-7'JUD
M-%,8UW]V,YUQC;Y]?/'OY>T_+U%+ Y0S.!!<3;C4/9<UE6_3%KVOO&L89*D*
MT04D\]DV)M]VS4??#6]#3^YU_P 7'\G%I<FNN*MG.<:XQG %7.,XQC&<9^%-
M,>?ZV<_K\V/XZQK]'J?L-W_JN+RV94!?5K-&C9YMNNN#6T3UV:N4]<YPX;;Y
M\]]TL:ZXQKIMGSSGY_+'U>1TFTZ)N5);6!RE@DY%:#C$&YTT^_\ RCK8]!]1
MBM_;?;SS[_JY^ICZ?TN<>GM]/^C'\G.,[)9SG^O)^_.?[O[?]Y]7R^IY_4^G
M'./-/\^3_P#\_=\_]Y]KZGG]3Z<<RB+6&FMAL\G^GJW:>%E="O?VV#U1MHG&
M,LM<YQC.?6J^_./U/,EY8^C'ZV.*UW:,(BBN0YPQNU()ZZ.=DDQQ%UKA%UKZ
M:&WKF[51+.=]=<YSKC;.VGS;8QG/.M\NE8?9 M]YC'\RYQR"=<_I$2<RM"^^
M0M+#BDJ23<*20D@@Z$$>6''LI[U3S25#0I4X@$$<X()N#N,-A;?=%N[51WV2
M4T9.LZJ)YSIOKG*?EG.NVOEMC.<9SCW9^;.<<U+VJ3^N#W]E+?A\U)6[ZT7;
MO$TCZVV^6+K.,>QR^,>6J?I;9SG9GC&,8UQG/V_FQ[^:A\L->?7Q7[U%/YIS
MV:ILZ <TC,WN.>6<O;FVHYO]>B.BIADGO7FR.;1Q-K_<?)#<]JD_K@]_92WX
M?+=^I+5L^HR-.7K=%VYW+RW7==REHNMMJF?<ZZ:[*J:[;[8TUQC73&=LXUUQ
MY8\L<HL^6&O/KXK]ZBG\TY<+U$NNMTJ'C&FYMSZ7MB79_&ARFV/+,@=>7EGX
M+CS^C/T9^U[^6GCB0G4T=HHDYE*C/L@%,NZDVXF8)%P@&VER-VZ.S3J5J(0X
M%G+>R5 FUQK8&]KV^_?$X?90SZWLOV*C^!S+@1S!$NR429-4U--U,Z*)MTM-
M]<Y05QG.NVNN,XSG&<XSY9]^,YQ\V>)_Y;ZU^O;K[S%/YMS9H;;$$/R82'%%
MG#@@^662:H[BR"&JF^C1POMC*RR&J>GDDEOMY[[8QG./1QGSSC',2*E)]*5*
M7+S80E)*BIMT)"0+DJ)%@D"Q).EK1465T'U'ML'JB17#A\_#E''$'#APXA"Q
M$?FAG?U1/^"H-QG<6(C\T,[^J)_P5!N,[D!A_P"2J?INI]<(F*S\I(>B:?U,
M'#APY/Q#P<.'#B$'#SQY^7U>'(K_ (G"4?BR/Q5'XHV\?B=\@7R+_B6OC"U_
M$_?&#XY?&CY8_BU\']?\I/P'_>W[6]+UWLC^L?"_@O\ 8/$(E/G.,8SG.<8Q
MC&<YSGZ,8\\_K8]_(H5GW=ZT6^>KB-P>=F')&X0)J350I):OMN A[-"1X0WD
M!AY )%/X'&([,?@4?=)2#=J *OGBH#"IMNV6%MW#I*5JF,[:;8QC&<YUVQC&
M?=C.<ZYQC&?M9SGW^_'NYYV1OAG]NHI0W4 %#;DL\A:<*ZO713\G"V/:L46K
M_K;/IYU;-Q2,S"HWD&BX:2BS >=L6=/C9S'BLVDT-KFPI46!HNG.%##="/1/
MG?&,9SGTO+'G_P"9OG/NQY_-C7S_ -'O^;'OYKX"5!I*B57$[D=DPIXW&B&7
MX,Z%VU+1YYLP*:M4S0T>H18:.=-L,C0[1V%+(XPZ$D'S7;5;/G;G/1KM(= &
MC-?]<=ZIA+Z6&75:=6&USUA9$:J^3[TC'8ABSY!&Y4;#UZDSEEF"EC2LNJ.T
M(U=M8-V*]M1!F:LRTYW&PT?>\-;6?"P%N0.YPXR;V]=D-[)[=9H(,MN717:)
MW%:?8 8H,L&H'"&-WM@'9>#/B(BRCD:=%+BA,7!-(_/8L!J*U['F(5"/39%[
MVJF9%96'C\N0=.83*-X/)'3H6=$!&$STECN#[1)&2&18^/$Y-B5M,AL A)1^
M4V7>"5=&NS4X&7?MOTL>_/O]W][M]/E[L>7GG_!^G\W**-^C-Q/K![-GY[4
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MR7G[UMR/JW@NH^8S?4+BLIWA"1\\E>O1'$,_(!'[HG_XP%.'"&?D C]T3_\
M& IPXI/@JF>CY+]V:A4?"$]YY-=>N*AK=[,WQ"^[QL:[L20H=>HK>'6*G_@U
M6/.N\H Q0M<C.LQRU?\ 8JG+#&1?LNYE=AR>R&#V#VIU]FLJBL7B9Z%FRD%>
M(PNTV9F'U6>(MVV.9Z@U7)[%#[3]CW$%%NSLUVB,+98F'3BY)1,A?7@6LR3$
MX 15:2K&W(%]+HVD+)JO.KM@^3U!8D7W4N1LVRNB\7[*0 ?::M%MNS_P6-#(
M-(Y)#@)&Q8RUEQ P&A(G2Q58Z]<0+69EUS@>$BR\HCRDM*.2(R,MB;QTL@LT
MYW&NM4#%#',_A=2@0YPC"JX%Y-0>-89D'VQ638@4203R$6TW2:F)G,%(Z.SI
MAF->RJ2+M-&JITJH[D(HXK>\,7O9879RU+TCEH28V5$6.%$]K>K(D_3,NJ96
M.=:I=,I96XZ#""DGA,01MAO&6D8K>Q2UAAG4M:+.KW:B_C#L,:!&J=S^,8QC
MRQC&,8^;&,>6,?X,<6<$;5-+@5;6?7XF&%0BU=#]*KF(,$-TT:5?,AT<.,1\
M/(IL$'0F(R <+BK_ "&'99#GB0H'NNRSN,98;LOTL?;_ ,7;^3YOM_-\_P!&
M?)"/KASC&<9SG'O]WTXSC[7NSG&,9_P>?T_-S4A$^A,@E$PA(.5Q\Q+Z_P!H
M_I.(R,*LWQR(J2L7N;C2<C&-E5'8=0Z'3V*BDGZ2"CX=Z+U#7=MOHILA&W<.
M:\O+8NVE R$.) '0F)D&8DPJ+JD6NA\C'8^]#C3AUH)V5P^6$B2,A!,2!#1'
M+5J\+CFRJNJSM'3;8>(10WXAG_E%K_\ L'$?WTWR#?+;NX%<Q23W$J5,,W2[
MS,4CK;.Z)%RVT]4@H4RGKZI+.-//'K-O/;Y]O/W_ #8Y%SY&(#];7_WY??A<
MP]6:9,.U6H.)4T$KFGE %2KV*]+V21>V_P"_H^J'!-PE4"F<&N"*?,,513\G
MAVG2[JFI>74V5MLI2HH4J<0HIOS$H22-@TO#3/\ :+?]7<_]W4YJVOS8_2Q^
MYR>^E+P#.=L9'/\ RV36USY&7WS;);XSC^V^KC/ES%XHRN<8QCV82]V/+\G'
MW_[\V$X$9IJCT&KL306I;M9XU)9 6D)Y#)H-RM2#>X/,"+6UN;1J?\+"O26*
ML98;G*:B8;:E\+IE7!-H;:7QG=:I.W2&G7P4Y7$ZE0-[Z6L3!WD^J"_,S%_=
M0_\ PAGF'^0RN?K62^_C[DR:8J6$-("/008O]4M")G.-=BKI3.,J/<[[?CMO
MQV<>?G[L_-\V.9'Q-B.GHIZ%*3,VY2V-&T'G;</_ !=UO](UEI]/???*$%N_
M%D]\I0%LR!L2=;D;+<^L+3FI3W\I4G^Y#C]W3DS/DOAOZ">_?)S_ "\6%U0&
M,"*HGA)BT=:.V<?650V5?.%4\;_"6J>?33SG&-]<ZJ;8\LY^?RS]3EER.):>
M_.R;*$36=Z:EVD9FVP,SCJ$)N>--A=6IL; 'GTO+N4:<0VXXHLY4-K6JRUDV
M2G,; MC6U[:C_&U5_#G&5O+/EZI/W9S^>?Z?ZY[^'KO_ .TE[O\ [S_6>_\
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M/WK;FT<U>;?E2D7W)>?O6W(^K>"ZCYC-]0N*RG>$)'SR5Z]$<0S\@$?NB?\
MXP%.'"&?D C]T3_\8"G#BD^"J9Z/DOW9J%1\(3WGDUUZXKZF5$=C ]M7Z,KV
M$T+.:P[5V[45L2:P;=(O#+RI/B'!*=K>4QMS2ZL4>,;;T]ATTSDM5O=9_$6X
M":2I;<VS:,XLV(2&'HGP]>SRT[;EGC*MXPTC]FQ623>5-+BGLR,=J2PCL1O:
M0JZ; "'8NS9PN=0.N?AL'"L-G4F*NM)>1@S"1BJT@,,;.YX2'L9V",7);0RI
MX+4#VG>MUE5Y5UNNK#G)B)3Z4F)?!JULZ5F*]?;M-8( #P""6Q%WC36;N%%I
M_(V!^.-%HFVU#GR4:S_=3N%7UI]B8C*(AUSEXVI+(H&FX"$BF;0BTAG]C]M7
ML=$TFF=D<C,G0$,BT7)RP7\IQ9,&?(.1K JZBHG!)0:'<R$4<06EO0[NS5E>
M)%W*\(C0BM^N"-7S:6U)/K2?3.Q:\!]>NO,92K]V!AM<';2?L6LMINQHLX>1
M4QHPA("U][(J6MF4D;RUB8P-7=(.S5W^T;!IER&IRDSG8JZGE:Q".3=^N$J0
M85(=:VT7[ 4'(;*JE\_^"!&%6V;'H 1K>-UXHQ%F$!];DL5E+C2JL\[,\0+L
M!6 U"#G%^I[RTE.SU>48_E<;>WE)X=&P<VKNZYB\(RBJF 9M:8XZ+D%+E(:'
M<"CA^*RG+Y8Z@1%Y!' K*U"C))*9C4D#E,U(Q$O)I "2*DB<#$3 !$GN'BZZ
MK%<*&G^V\R'(;CLM/7-9#G#]-WAQZ6B:64D]4(@GU!Z86'UZLZ/S@@O&&NAV
MO>T@ZY7(>1G2;V?3^P>U0^V*0/FVCMJU0/ZP:M",XCS-R[7;JPM&0.(=&T_B
MZY])M#T+X<7<2%%+Q7E$AZU=C@]R69UAF=@Z+1*75 >N1:!1ZSQ5L2RP&<DE
M]W00G*"):30;86$ED:ED#UC,9U91J*1G:'UT##^@;AQ"*ONK/4*TZSGG3ZU+
M1;09_9E3]#IKU=O*>,3SN532;RW,UH,U"%MIF3C8B032)LF]?V 5;N9$HP=A
M2$FQH@(RN7)K)6@\.'$(KH[-,W:]GJ*(MEU=/BX$U]--+??7SQN1\\>>NN<>
M>//'N^WR/?LTA^@7?['5_ Y+>_OS0-_N&(_]Y[Q)\L>?EDKG)E16H7>6; #]
MK?\ ?Z]T;>X,J[K.%:"TEILANFRJ0257-FDZFQM"W3&D/2S_ &"[_M%/^;J_
MG>W]YSJ^S"7Z >?L9;\#C8;_ /"X_4J?O>_/KF2\ #B*=.I'?7GB;G34RTN#
MS>0>^,1\+TVN<K=,6I"4%%*"+)N;_P!<F57U.^WW7A2^S"7Z >?L9;\#DI*J
MWT9PQF@[WT:K8?$]LHN-M45<:[NLYUVRFIG7;&-L>_7.<>6<>_'GCBUYN K_
M (@C^J6_?-N715V!495,NM1;2'D.9D@$W2E8M8Z6.;W1B^4G%R+I>2A+A*2B
MRB4BQ*5$Z7/ZO-OYX;_PUG^BVW^72_#XHK[=M=J;L775RWVVS&UL8QJLGG.<
M_#&?NQC&WGGG>XJ+T_,@L+_V<7_[TTY#4R@,M5*GNB8<);G91P H38E#[:@#
M;6Q(UBN=Q ^ZTXT9=H!QM;9(6LD!:2DD:<XN2/(.G2L7;?3SS_7$_GS_ ,II
M]/ZKG'IZ?GB?^4T_"YI.V,>>?=CY\_4Q]/./+'T8_6QS/01< WY]W^L6WQAZ
M!V['L->Z6<-]'N^N[A#7;U:>?+99+7/EG7W9\L[XSY9\N8SX4U_13;]D(_A\
M7$JQCVPI[L?\6;?4Q_<[<USRQ]&/UL<DFI(*;0HN'OD@_HC2^SGBE6^0M0RC
MGWQ*"NG+;,P&8PY;YSE$EC&,+I9SG/LYU[L8QOG.?\')*^N2_/4_\?7^7D"Z
MLQCX]!_=C_@BGU/_ %4\Y+?RQ]&/UL<MZKRH1-(&<F["3S ?^XX.GH'OBME5
ME;9.@LLC:?U4GI'3&^^N2_/4_P#'U_EY+^HI9%1D#%LR4E CW:;LMLHU>EF+
M5QIJJ07W3VV167T4UU4TSC;3.=<8VU]^OGCW\@'Y8^C'ZV.=5?&/3Q[L?VN/
MJ8^G/(*:IB)UL-*=4@!8<NE()) *;:GF[XGU"*@D@$Z&VZVWRF+4/CY!OLRB
MWW^&?SGF\5M+XF1G$>9#Y/'WSQPY<ZH-&9=@Y<K;:CGF^VJ2*2^ZBFVNFF^^
M<:ZYSC37;;/NQG/*<?+'T8_6QR0757&/Q05:>['Y*%?J?_9HWR%G\.LL2,X\
M)EQ1:E9AP)*$@$H:6H D&]B1K'0K)!%AJ+=O?V&MZ_#G&OS8_2Q^YSGF*8Z0
M<.'#B$+$1^:&=_5$_P""H-QG<6(C\T,[^J)_P5!N,[D!A_Y*I^FZGUPB8K/R
MDAZ)I_4P<.'#D_$/!PX<U@M-8>!+C !N51L0<->A['#%#PD>6*^M6RW3P-&O
M'B#U_E1QC*&F&B"WIK8REKYJ8SKQ"-GX<X]+7S\O/'G]'GCS]WS^[Y_=]7Z.
M'GCW>_'O^;WX]_Z7T_/C]?B$:39I(B&KBP# ?,DP6%0F5DA>8;'$)A+L$6($
M@Z8YBT2=9PWE,CPZ22R#CB^<(FRGP48KG"3K?/*HZG.]W%YQ5")<O=;L =+
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M(NP]+'O^KY?/Y8SGR^U[L9]_VOG\LXSY>_AC/G[\?Z<9QG];/EG'*9.ZE/\
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MUZP:.W;!,DAAJ038N7"*BS/1^VQ\'>Z-MTM':']9<ZJI_C>=?>+1M1TX?;@
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MZ)/Q,%(?89^WTC_VMQ#=GJ$Z4Q.A+/-]A(KJWIUM&7&)PEB03KX41&[N&V4
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MTDWK\V/TL?N<YX?-PYAJ*V#APX<0A8B/S0SOZHG_  5!N,[BQ$?FAG?U1/\
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@0<.'#B$'#APXA!PX<.(0<.'#B$'#APXA!PX<.(1__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
